# World Premier International Research Center Initiative (WPI) Activities Report of the WPI Academy Center (FY 2017 – FY 2019)

Host Institution	Osaka University	Host Institution Head	NISHIO Shojiro
Research Center	Immunology Frontier Research Center		
Center Director	TAKEDA Kiyoshi	Administrative Director	

Common Instructions:

\* Unless otherwise specified, prepare this report based on the current (31 March 2020) situation of your Center.

\* Use yen (¥) when writing monetary amounts in the report. If an exchange rate is used to calculate the yen amount, give the rate.
 \* Prepare this report within 10 pages (excluding the appendices, and including "Summary of State of WPI Academy Center Progress" (within 2 pages)).

### Summary of WPI Academy Center's Activities (write within 2 pages)

Established as a WPI center in 2007, the Immunology Frontier Research Center (IFReC) of Osaka University has produced excellent results by conducting research activities aimed toward a "comprehensive understanding of the immune system" through the integration of immunology, imaging, and informatics. Although WPI grant support for IFReC was terminated at the end of FY 2016, in recognition of IFReC's distinguished research capabilities demonstrated by its outstanding research achievements, <u>IFReC</u> received major funding since FY2017 from pharmaceutical companies within a new framework for industry-academia collaboration. This funding has provided IFReC with the financial base for its operations. IFReC has maintained the same scale of operations as when IFReC was funded by WPI and continues to carry out activities pursuant to the WPI philosophy of world-leading scientific research, interdisciplinary research, internationalization, and organizational reform.

Dr. AKIRA Shizuo, the former IFReC Director, established an operational foundation for IFReC through the above comprehensive collaborations with pharmaceutical companies. Then, in July 2019, the directorship of the center changed from Dr. AKIRA to Dr. TAKEDA Kiyoshi. Dr. TAKEDA subsequently set a goal of contributing to society through IFReC's basic research results based on the industry-academia collaboration framework. He set policies for activities for the next five years: promotion of human immunology, nurture of the next generation of researchers, and internationalization of the center. Specific activities are described below.

## World-leading scientific research

With more than 1,700 published papers to date reaching an average of 61.5 citations and an h-index of 132, IFReC has accumulated an extremely high level of research achievements in the last three years. The percentage of top 1% and top 10% papers is 5.1% and 25.5%, respectively, which demonstrate the high international level of research that IFReC maintains.

## Securing the operational foundation through industry-academia collaboration

In April 2017, IFReC began comprehensive cooperation agreements with both Chugai Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. and received grants totaling more than 10 billion yen over a 10-year period. Through these partnerships, IFReC has secured a financial base for its operations to replace the previous WPI grant. In return for the funding, IFReC discloses its research results to the companies. This allows the partner companies to conduct preferred joint research and utilize patents. As a result, the funding has become available for use in almost the same way as the public funding from the WPI. Furthermore, IFReC researchers are guaranteed the freedom to conduct basic research according to their own interests as before.

In these collaborations, practically all of IFReC's research results are promptly disclosed to the partner companies, which assess whether the results are worth pursuing. This has led to the commencement of many joint research projects, which are funded separately under the normal joint research agreements. Each of the partner companies brings their own unique technology for drug discovery to the collaboration so that the discovery of innovative new drugs based on the basic research results of IFReC is expected. **Promotion of human immunology** 

Recent rapid developments in measurement and analysis technologies, such as single cell analysis, have enabled the measurement of small amounts of human-derived samples, and resulted in human immunology research becoming a global trend. <u>IFReC strongly promotes basic research in human</u> <u>immunology by taking advantage of the availability of human samples through its collaboration with Osaka</u> <u>University Hospital. IFReC established the Human Immunology Laboratory, hired two PIs (associate</u> <u>professors), and started systematic support for utilizing the advanced technologies led by the two PIs.</u>

### Nurture of the next generation of researchers

IFReC has enhanced its research competitiveness by <u>appointing two full-time PIs and eight adjunct PIs</u> in FY2017-2019, and now has a total of 34 research groups.

A few PIs who have made significant contributions as core members of IFReC reached the age of official retirement. <u>Those PIs who are able to secure sufficient external research funding and who are capable of leading the world through their research ability are allowed to continue research activities at IFReC after the retirement age.</u> IFReC clarified the conditions for employment and its compensation package to provide a stable research environment. Furthermore, the PIs at retirement age are required to actively contribute as mentors to nurture researchers for the next generation and to pass on the tradition of immunology research at Osaka University.

<u>IFReC has supported young researchers with programs to promote their international circulation</u> such as the Program for International Circulation for Young Talented Researchers, the Advanced Postdoc Program, and the Winter School. Furthermore, <u>IFReC set up a grant program in FY2018 to support the</u> <u>next generation of PIs (50 years of age and under) who are expected to be the core researchers of IFReC</u> <u>in the future.</u> In the program, IFReC has supported five PIs with a research grant to allow them to produce their representative research achievements and provided them with evaluation and advice from senior PIs. **Promotion of international circulation of researchers and cooperation with overseas research institutions** 

It is important for IFReC to recruit international talent and to promote research collaboration with overseas researchers and institutions in order to enhance its research competitiveness by stimulating research and ensuring diversity.

IFReC has created opportunities for international research exchange. <u>IFReC organized eight international</u> <u>symposia in the last three years</u> as opportunities to disseminate its latest research results and introduce the hottest research results from abroad to researchers in Japan. IFReC also organized the Winter School, which is highly regarded for their effectiveness in training young talented researchers from all over the world.

<u>IFReC established the Advanced Postdoc Program to promote the international circulation of young</u> <u>talented researchers.</u> The program provides an international-level salary, which is up to 1.3 times that of the standard pay for a postdoc in Japan, and an annual research grant of 3 million JPY over three years. To date a total of 11 Advanced Postdocs were employed. <u>IFReC has also provided financial travel support</u> to nine young IFReC researchers to allow them to participate in overseas research activities.

IFReC has developed a cooperative relationship with <u>ImmunoSensation</u>, a <u>Cluster of Excellence of the</u> <u>University of Bonn</u>, and <u>University College London (UCL)</u>, one of the Global Knowledge Partners of Osaka University.

#### Support from host institution

Osaka University has fully supported the new IFReC in its operations in the manner described below; <u>Osaka University established the International Advanced Research Institute (IARI) in FY 2017</u> with the university president as its director, and has allowed IFReC to be managed by the leadership of the IFReC Director as an independent department within IARI. <u>Six tenure posts were provided</u>.

In the comprehensive collaboration agreement with Chugai Pharmaceutical Co., Ltd., the entire budget for indirect costs that was allocated to the head office was allocated back to IFReC, and <u>the entire amount</u> received (1 billion yen per year) was made available to IFReC.

Osaka University actively supports the promotion of IFReC's international cooperation through original funding programs. <u>In particular, Osaka University took the lead in promoting collaboration with UCL</u>, a Global Knowledge Partner of Osaka University.

\* Describe clearly and concisely the progress being made by the Center from the viewpoints below.

- In addressing the below-listed 1-8 viewpoints, place emphasis on the following:
   (1) Whether research standards and operation of the Center is maintaining a "world premier" status.
  - Whether the Center participate and cooperate to the activities to advance the overall development of the WPI Program and to (2) promulgate its achievements.

## 1. Overall Image of Your Center

- Describe the Center's current identity and overall image.
- List the Principal Investigators in Appendix 2, diagram the Center's management system in Appendix 3-1, enter the number of center personnel in Appendix 3-1a, and enter center funding in Appendix 3-2.

Established as a WPI center in 2007, the Immunology Frontier Research Center (IFReC) of Osaka University has produced excellent results by conducting research activities aimed toward a "comprehensive understanding of the immune system" through the integration of immunology, imaging, and informatics. In 2015, IFReC was also highly evaluated by the WPI Program Committee for attaining World Premier Status. Although WPI grant support for IFReC was terminated at the end of FY2016, in recognition of IFReC's distinguished research capabilities demonstrated by its outstanding research achievements, IFReC received major funding since FY2017 from pharmaceutical companies within a new framework for industryacademia collaboration. This funding has provided IFReC with the financial base for its operations. IFReC has maintained the same scale of operations as when IFReC was funded by the WPI and continues to carry out activities pursuant to the WPI philosophy. In addition, as one of the centers of the WPI Academy, IFReC endeavors to accelerate and expand the international circulation of young talented researchers.

**Maintaining a high level of research** With more than 1,700 published papers to date reaching an average of 61.5 citations and an h-index of 132, IFReC has accumulated an extremely high level of research achievements. The percentage of top 1% and top 10% papers is 5.1% and 25.5%, respectively, which demonstrates the high international level of research (Web of Science and InCites as of March 30, 2020). There were also four hot papers (top 0.1% of cited papers) in 2018-2019, which is more than 10 times the average.

Change of director and new policies In July 2019, Dr. TAKEDA Kiyoshi succeeded Dr. AKIRA Shizuo as the center director. Dr. TAKEDA set a goal of contributing to society through IFReC's basic research results based on the industry-academia collaboration framework established at IFReC. He has set the following policies for the next five years: (1) promotion of human immunology, (2) nurture of the next generation of researchers, and (3) internationalization of the center.

Establishing industry-academia partnerships In April 2017, IFReC began comprehensive cooperation agreements with both Chugai Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. and received grants totaling more than 10 billion yen over a 10-year period. Through these partnerships, IFReC has secured the necessary funding to replace the previous WPI grant, thereby giving IFReC researchers the freedom to pursue basic research. In return for the grants provided, IFReC discloses its latest results in basic research, which allows the partner companies to effectively use the research results and establishes a system for seamless collaboration with the partner companies. As a result, many joint research projects were started and the results of the basic research are being actively used.

**Promotion of human immunology** Recent rapid developments in measurement and analysis technologies, such as single cell analysis, have enabled the measurement of small amounts of human samples, and resulted in human immunology research becoming a global trend. IFReC strongly promotes basic research in human immunology by taking advantage of the availability of human samples in collaboration with Osaka University Hospital. IFReC has made the latest measurement equipment available as common-use facilities and started to establish a support system and support programs.

**Nurture of the next generation of researchers** IFReC has enhanced its research competitiveness by appointing two full-time PIs and eight adjunct PIs in FY2017-2019, and now has a total of 34 research groups. As a few core members of IFReC have reached the age of official retirement in the past few years, a generational change of executive board members was made by the new director. IFReC supports the international circulation of young researchers and young PIs to promote their development into core researchers of IFReC through various support programs. Even after the retirement age, PIs are allowed to keep their positions and continue with their research activities as long as they can lead the world through their research and contribute as mentors to nurture the next generation of researchers.

**Cooperation with leading overseas research institutions** In order to ensure diversity in research and to complement our technology and know-how, such as informatics in human immunology, it is necessary to enhance cooperation with leading overseas research institutions. IFReC has promoted

collaboration with ImmunoSensation at the University of Bonn in Germany and with University College London (UCL) in the UK, which is a Global Knowledge Partner of Osaka University, by concluding academic exchange agreements and holding continual joint symposia.

## 2. Advancing Research of the Highest Global Level

Describe what's been accomplished in the Center's research objectives and plans. In Appendix 1, list the papers underscoring those research achievement and list the Center's research papers published in 2017-2019 in a manner prescribed in Appendix A.

Approximately 450 refereed articles have been published by IFReC researchers from 2017 to 2019. Although there was no significant change in the number of papers each year, there was an improvement in the quality of the papers. The number of papers in high-impact journals such as Nature, Cell, Science, and their sister journals, Journal of Experimental Medicine and Journal of Clinical Investigation, was 20 and 17 in 2017 and 2018, respectively, and was 30 in 2019 (Web of Science<sup>™</sup> as of March 11, 2020). During the period of WPI funding (FY2007-FY2016), IFReC researchers published an average of 13% to 14% of their articles in high-impact journals. This percentage reached about 20% in 2019 for the first time since 2008. It is thought that the quality of IFReC's research papers has improved over that during the period of WPI funding.

At present, not much time has elapsed since the papers were published so the number of citations is provided for reference only. However, here we compare IFReC with the La Jolla Institute for Immunology (LJI) of the USA, which is one of the world's leading immunology institutes, and whose scale of research is close to that of IFReC. The average number of citations for all articles was "IFReC: 10.8, LJI: 14.1", the average number of citations for immunology was "IFReC: 10.8, LJI: 13.2", the h-index for all articles was "IFReC: 30, LJI: 37", the h-index for immunology papers was "IFReC: 19, LJI: 24", the top 1% of all papers was "IFReC: 5.0, LJI: 6.5", and the top 1% of immunology papers was "IFReC: 8.3, LJI: 5.5". Overall, LJI was slightly superior to IFReC in both average citations and h-index, but IFReC was superior in the top 1% of papers in immunology. Comparing IFReC with the Institute of Medical Science at the University of Tokyo, which is one of the top institutes in Japan, IFReC was superior in all criteria that indicate a paper's auality.

It should be clear from the above that IFReC is the top immunology research institute in Japan, and has been producing results comparable to the world's leading immunology research institutes. In terms of internationalization, IFReC's internationally co-authored papers accounted for 41-42% during the period, which was less than 54% for LJI, but was unrivaled in Japan.

**Research achievements** As new PIs join IFReC, the research themes in IFReC continue to diversify: (1) By using big data and with many collaborators, Dr. OKADA Yukinori and his group classified human leukocytes (Ref. 7 in Appendix 1-1) and analyzed the type of constitution that makes one susceptible to stroke (Ref. 13 in Appendix 1-1).

(2) Dr. YAMASHITA Toshihide discovered the role of B lymphocytes in the development of the central nervous system (Ref. 6 in Appendix 1-1).

(3) Dr. AKIRA Shizuo showed a mechanism of how ribonuclease Regnase-1, discovered by the group, is phosphorylated by IL-17 and stabilizes the mRNA (Ref. 17 in Appendix 1-1).

(4) Dr. TAKAKURA Nobuyuki found that the activities of hematopoietic stem/progenitor cell are regulated by Regnase-1 (Ref. 15 in Appendix 1-1).

(5) Dr. TAKEDA Kiyoshi (IFReC Director) analyzed the effects of substances produced by gut microbiota and their mechanism on intestinal immune responses (Ref. 12 in Appendix 1-1).

(6) Dr. KUMANOGOH Atsushi obtained important findings in semaphorin reaction (Ref. 10 in Appendix 1-1) and in elucidating the principles of blood cancer and Car-T cell therapy (Refs. 2 and 11 in Appendix 1-1).

(7) Dr. SAKAGUCHI Shimon further investigated the mechanism of immune regulation by regulatory T cells, which he discovered (Refs. 9 and 14 in Appendix 1-1).

(8) Dr. ISHII Masaru observed living osteoclasts and discovered the osteoclasts progenitor that causes autoimmune diseases using original bioimaging technology (Ref. 19 in Appendix 1-1).

(9) In the field of infectious diseases, some important papers were published on the mechanism of pathogen recognition and immune responses against malaria or toxoplasma (Refs. 1, 3, 4, and 18 in Appendix 1-1). A number of important papers related to immune reactions during inflammation and infection were produced by IFReC researchers (Refs. 5, 8, 16, and 20 in Appendix 1-1).

**Invited Lectures** Over the past three years, Dr. SAKAGUCHI Shimon and Dr. KISHIMOTO Tadamitsu received a number of international awards, and they were invited to give many commemorative lectures. Other senior researchers including Dr. TAKEDA Kiyoshi (IFReC Director) and Dr. AKIRA Shizuo (former IFReC Director) were often invited to established gatherings such as the International Union of Immunological Societies or Keystone Symposia (Appendix 1-2).

**Awards** In this period, <u>Dr. SAKAGUCHI Shimon received a large number of awards. In addition to prestigious national and international awards, he was named a Person of Cultural Merit in 2017 and a recipient of the Order of Culture in 2019. Dr. KISHIMOTO Tadamitsu received the King Faisal International <u>Award and the Keio International Medical Award.</u> Other researchers were presented awards mainly in Japan, such as the highly esteemed Japan Academy Prize to Dr. NAGASAWA Takashi and the Medal with Purple Ribbon to Dr. KINOSHITA Taroh. The prestigious Japanese Society for Immunology (JSI) presented the JSI Award to Dr. YAMASAKI Sho (2018) and Dr. ISHII Ken (2019). In addition, Dr. Cevayir COBAN and Dr. KINOSHITA Taroh were awarded in 2017 the JSI Prize for Women Immunologists and the JSI Human Immunology Research Award, respectively. Michelle Sue Jann LEE, a brilliant graduate student, was awarded the JSPS Ikushi Prize 2018. She was the only winner at Osaka University and the only overseas recipient in all fields (Appendix 1-3).</u>

## 3. Facilitating Interdisciplinary Research Activities

• Describe the content of measures taken by the Center to facilitate interdisciplinary research activities. For example, measures that create an environment that will facilitate doing joint research by researchers in differing fields.

• Describe the contents and results of interdisciplinary research activities yielded by the measures described above.

IFReC has promoted interdisciplinary integration from the WPI era and continues to organize IFReC Colloquia in order to enhance the exchange of information among researchers. The Live Immuno-Imaging Facility, which IFReC operates as one of its prominent facilities, significantly contributes to interdisciplinary research. The bioimaging and bioinformatics techniques have been widely adopted among the researchers at IFReC and are now part of IFReC's research methodology. In 2019, IFReC appointed two young PIs to promote human immunology. In their labs, mass cytometry and a next-generation sequencer were introduced for research on single human cells. Active joint research activities with other laboratories is expected to result in new knowledge in the field of human immunology. The technologies that have advanced over the past three years and the achievements from their use are mentioned below.

(1) Using MRI, Dr. Cevayir COBAN and her colleagues found that <u>malaria infection causes strong activation</u> of immunity, and invasion of plasmodium by-products into the bone marrow significantly reduces bone <u>homeostasis</u> (Lee et al. Sci Immunol 2017). The image in the article appeared on the cover of the journal. (2) Dr. ISHII Masaru and his group reported novel non-labeling multiphoton excitation microscopy imaging of fresh human colorectal mucosa (Matsui et al. Sci Report 2017). The group showed <u>bone-forming mature</u> osteoblasts and bone-resorptive mature osteoclasts functions are regulated via direct cell-cell contact between these cell types (Furuya et al. Nat Commun 2018). They discovered the osteoclasts in pannus originate exclusively from circulating bone marrow-derived cells and not from locally resident macrophages (Hasegawa et al. Nat Immunol 2019).

(3) Dr. Nicholas SMITH and his group developed a label-free multimodal microscopy platform that allows the non-invasive study on immune cells without any labeling. In combination with machine learning technology (Deep Learning), they applied this system in <u>the analysis of fine cellular processes such as macrophage cells activation upon exposure to lipopolysaccharide (LPS).</u> (Pavillon et al. PNAS 2018).

(4) Primarily by the use of positron emission tomography (PET) technology, Dr. Jun Hatazawa and his group proposed <u>an astatine isotope as a potentially new radiation source for use in cancer treatments</u> (Ikeda et al. Appl Rad Isotop 2018).

(5) Dr. OKADA Yukinori and his group developed a novel in silico screening method (MIGWAS) and revealed that <u>microRNAs are involved in the development of human diseases</u>, such as rheumatoid arthritis, by acting in a tissue-specific manner. (Sakanue et al. Nucl Acid Res 2018). Furthermore, the research group discovered <u>an increase in the number of species belonging to Prevotella and a decrease in the genes-related redox reactions in the patients of rheumatoid arthritis (Kishikawa et al. Annal Rheumat Dis 2019). The international research groups including Dr. OKADA Yukinori conducted <u>a multiancestry genome-wide-association meta-analysis on 521,612 individuals and discovered 22 new stroke risk loci, bringing the total to 32</u> (Malik et al. Nat Gen 2018).</u>

(6) Dr. Daron STANDLEY and his group made significant contributions to collaborative research with many research groups. <u>A paper published by the group on MAFFT (multiple sequence alignment program) (Katoh & Standley Mol Biol Evol 2013) has the highest number of citations since the establishment of IFReC, and</u>

an improved version of the MAFFT paper was published (Nakamura et al. Bioinformatics 2018).

## 4. Maintaining an International Research Environment

 Describe what's been accomplished in the efforts to raise the Center's recognition as a genuine globally visible research institute, along with innovative efforts proactively being taken, including the following points, for example:

- Efforts being developed to maintain an international research environment based on the analysis of number and state of worldleading, frontline researchers; exchanges with overseas entities
- Proactive efforts to raise the level of the Center's international recognition
- Efforts to make the Center into one that attracts excellent researchers from around the world (such as creating of an environment in which researchers can concentrate on their research, providing startup research funding, supporting efforts that will foster young researchers and contribute to advancing their career paths, and arranging support system for the research activities of overseas researchers.)

- Consolidation of the administrative structures to support implementing the efforts described above

 In Appendix 3-1, describe the state of cooperation with overseas satellites, and list the main international research meetings held by the Center.

It is important for IFReC to accept international researchers and to promote research collaboration with overseas researchers and institutions in order to enhance its research competitiveness by stimulating research and ensuring diversity. IFReC has created opportunities for international exchange at international symposia and Winter Schools, strengthened relationships with leading overseas research institutions to promote international joint research, and promoted the international circulation of young talented researchers. In particular, in order to promote this circulation of young researchers, it is necessary to actively recruit young researchers and to create many successful cases where young researchers at IFReC produce excellent results and are promoted and transferred to other institutions. This makes it important for IFReC to attract excellent researchers. IFReC continues to improve its international research environment and support system established during the WPI era in order to create many success stories.

**Collaboration with leading overseas research institutions** <u>ImmunoSensation, a Cluster of</u> <u>Excellence of the University of Bonn (Germany)</u>, was established by the German Research Excellence Initiative program in 2012 and is rapidly increasing its research competitiveness. In FY2018, IFReC and the University of Bonn concluded an academic exchange agreement and held their first joint symposium in Bonn, Germany. The researchers were invited to International Symposia and the Winter School hosted by IFReC to promote academic exchange. IFReC has developed a cooperative relationship in the research field of acquired immunity with <u>University College London (UCL)</u>, one of the Global Knowledge Partners of <u>Osaka University</u>. In FY2019, IFReC invited 10 speakers from UCL and hosted their first joint symposium in Osaka, Japan.

**International symposia** IFReC organized <u>eight international symposia including two symposia held</u> <u>abroad in the last three years</u> as opportunities to disseminate the latest research results of IFReC and introduce the hottest research results from abroad to researchers in Japan.

**Winter School on Advanced Immunology** The Winter School on Advanced Immunology has been held jointly with the Singapore Immunology Network each year since FY2011. In FY2019, there were 233 applications from Ph.D. students and early postdocs, of which 53 were selected through rigorous screening. The Winter School has succeeded in globally fostering young researchers and providing them with an opportunity to network with other talented researchers. Furthermore, the Winter School has been a place for recruiting young researchers to IFReC and its participants were offered opportunities to join IFReC as advanced postdocs. Among the past Winter School participants, those who became PIs at their affiliated institutions were invited as lecturers to IFReC International Symposia. They were the role models for the international circulation of talent and became familiar goals for the young researchers.

**Advanced Postdoc Program** IFReC established the Advanced Postdoc Program in FY2017 to recruit excellent young international researchers. The program provided an international-level salary, which is up to 1.3 times that of an ordinary postdoc in Japan, and an annual research grant of 3 million JPY over 3 years. <u>In total, 11 Advanced Postdocs were employed</u>. The progressive research activities of the Advanced Postdocs have been highly regarded and are expected to produce excellent results.

**Program for International Circulation for Young Talented Researchers** IFReC provides financial travel support to young IFReC researchers for them to participate in overseas research activities. Under the program, nine researchers took advantage of the support. The young researchers later posted activity reports on IFReC's internal website to share their experiences.

**Support for international researchers** The Research Planning and Management Office (RPMO) manages the activities described above, and also <u>provides researchers from overseas with various forms</u> <u>of support for research and in their daily life.</u> For example, the RPMO members holding PhDs work with researchers to assist them in applying for external funding programs. Not only do the members provide the necessary language translation, but they also help improve the applications by writing them from a

scientific viewpoint. Knowledge of Japanese laws and regulations is required to conduct experiments with genetically modified organisms, experimental animals, pathogens, and human samples. In order to ensure that researchers from abroad are able to conduct their research seamlessly, the RPMO members who are knowledgeable and experienced in the field assist them with the various procedures and conduct an annual orientation program in English to educate them in this regard. Furthermore, IFReC provides weekly Japanese language classes for about 40 international researchers.

## 5. Making Organizational Reforms and their Ripple Effects

- Describe distinctive effort in managing research operation and administrative organization, such as the strong leadership that the director is giving on the Center's operation, strong performance by the administrative director who provides the center director with strong administrative and managerial support, and division of roles and authority between the Center and its host institution.
- Describe the ripple effects that activities to disseminate experience and know-how accumulated by the Center, such as the followings, have/had on the host institution (or other research institutes, if any):
- System reforms made through the Center's leading activities to its research operation and administrative organization
- Experience and know-how accumulated by the Center as it have worked to establish itself as top world-level research institutes.
   Other than the above, give examples, if any, of cooperative activities by the Center and the whole WPI Program or other WPI centers, to disseminate experience and know-how accumulated by the WPI program and/or the WPI centers.

**Center management through the strong leadership of the center's director** The IFReC directorship changed from Dr. AKIRA Shizuo to Dr. TAKEDA Kiyoshi in July 2019. Both directors provided strong leadership as <u>Dr. AKIRA established an operational foundation for IFReC through comprehensive collaboration agreements with companies</u> with the strong support of the former administrative director, Dr. SAKAGUCHI Nobuo, and <u>Dr. TAKEDA in turn promoted human immunology.</u> Dr. TAKEDA upgraded equipment with the center director's discretionary funds and established a support system.

(1) Senior PIs A few PIs including Dr. AKIRA Shizuo (in FY2018) and Dr. SAKAGUCHI Shimon (in FY2016) who have made significant contributions reached the age of official retirement. <u>Those PIs who are able to secure sufficient external research funding and who are capable of leading the world through their research are allowed to continue research activities at IFReC after the retirement age.</u> IFReC clarified the conditions for employment and its compensation package to provide a stable research environment. Furthermore, the PIs at retirement age are required to actively contribute to nurturing the next generation of researchers and to pass on the tradition of immunology research at Osaka University.

(2) Researchers of the next generation IFReC supports young researchers mainly through the Program for International Circulation of Young Talented Researchers, Advanced Postdoc Program, Winter School, and other programs by promoting the international circulation of their talents. The Grant Program for Next Generation PI was set up in FY2018 to support the PIs under 50 years of age who are expected to be the core members of IFReC in the future. The program aims to support the PIs to produce their representative research results that will give them an advantage in obtaining future competitive funding. To date, IFReC supports five PIs with research grant and provides them with evaluation and advice by senior PIs.

(3) **Research management personnel** In order to maintain and improve the international research environment, it is essential to nurture research management personnel. At IFReC, two PhD-level staff members were hired in the RPMO and trained on-the-job to enhance PR and outreach activities that promote the international circulation of talented researchers and to enhance industry-academia management centering on the comprehensive collaboration agreements.

## **Dissemination of achievements**

The experience and know-how accumulated at IFReC were disseminated as follows:

(1) New industry-academia collaboration Large-scale industry-academia collaboration agreements for promoting basic research between IFReC and Chugai Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. have attracted much attention. Having shared that experience within the university, Osaka University has begun a similar agreement with Daikin Industries, Ltd. that provides a total of 5.6 billion yen in funding over a 10-year period starting July 2017.

In FY2018, Osaka University and its partner companies (Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Daikin Industries, Ltd.) were awarded the first Japan Open Innovation Awards Minister's Prize by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) that recognizes leading and highly original initiatives that are expected to serve as shining examples of open innovation in Japan.

This comprehensive collaboration has led to the active implementation within Osaka University of joint research with private companies. As a result, according to a report by MEXT entitled "Status of Industry-Academia Collaboration of Universities in FY2018", <u>Osaka University is ranked first among universities in</u> Japan in terms of both the amount of research funding received from private companies and the amount of large joint research funding of over 10 million yen from private companies.

The experience was also shared with external institutions at the 10th Osaka University Joint Research Chair Symposium (December 7, 2016) and at the 2nd Research University Consortium Symposium (October 25, 2018, Tokyo). It was also published as commentary articles in journals "Ensho-to-Meneki" (Vo1.24, No. 6, 2016) and "Seisan-Gijyutsu" (Vol. 70, No. 1, 2018).

(2) PR and outreach activities IFReC has been actively engaged in international PR and outreach activities to date, and has accumulated considerable know-how. To share our know-how, IFReC issued press releases and held events in collaboration with the PR offices of the Graduate School of Medicine and the Research Institute of Microbial Diseases (RIMD) of Osaka University.

(3) Support for international researchers The documents translated by IFReC into English regarding procedures related to research are provided to the university. IFReC made an educational training seminar in English in the legal aspects of research available to all researchers in Osaka University. The efforts made by IFReC are thus being utilized by all international researchers within Osaka University.

## 6. Effort to Enhance and Amplify the Visibility and Brand of the Overall WPI Program

• Describe how the Center's outreach activities have contributed to enhancing and amplifying the visibility and brand of the WPI program. Describe the successful cases of the Center's outreach activities in Appendix 4, and enter the number of activities in Appendix 4a.

• Other than the above, describe, if any, the activities and their concrete contents that have contributed to the enhancement and amplification of the visibility and brand of the WPI program (such as holding a large international research meeting, collaborative activities with multiple WPI centers). If you have already provided this information, please indicate where in the report.

In order to further enhance the brand strength that IFReC has established, it was important to select methods for effectively communicating with strategically selected targets. Since FY2017, <u>IFReC has strengthened its PR and outreach efforts targeting young researchers in Japan and abroad to accelerate and expand the international circulation of talented researchers.</u> IFReC has also actively promoted outreach activities to the general public to increase public awareness and to garner support for IFReC's activities as a WPI Academy center.

**Acceleration and expansion of international circulation of talented researchers** Efforts to improve the visibility of the center for young researchers in Japan and abroad were made mainly through the Advanced Postdoc Program and other international student support programs set up by IFReC. IFReC conducted PR activities by utilizing the network of IFReC alumni, by posting job advertisements on the websites of leading academic journals, and by exhibiting a booth at Nature Careers Live, a global job fair intended for young overseas researchers, and at the Annual Meeting of the American Association for the Advancement of Science (AAAS). At the booths, IFReC researchers discussed science and explained IFReC's world-class research environment. Administrative staff were also available to discuss the living environment in Japan and answer a wide range of questions from visitors. <u>This resulted in an increase in the number of Advanced Postdoc applications from 78 (FY2017) to 166 (FY2019).</u> IFReC continues to hold the Winter School for young researchers. Through similar PR and outreach efforts, <u>IFReC was able to attract 233 applications from 21 countries around the world and select 53 participants for the Winter School in FY2019. This increase in the number of applications is an indication the ongoing activities to date combined with a new multifaceted approach have been effective in improving the visibility of IFReC among the targeted international immunologists of the next generation.</u>

**Outreach to general public** PR and outreach activities aimed at raising the level of public awareness in Japan were enhanced. In addition to the annual report, IFReC started the publication of a new PR magazine, Imuneco, in FY2018, which is more accessible to the general public. In FY2019, IFReC held 34 events. Among them, eleven Science Cafés (5.5 times increase from the previous year) attracted approximately 540 visitors (1.7 times increase from the previous year). IFReC was able to gain understanding and support for its research activities from the public who attended the events. Such activities targeting the general public were conducive to fundraising activities.

Press releases were issued and events were held in collaboration with PR offices of the Graduate School of Medicine and RIMD of Osaka University. A total of 339 articles about IFReC were published in newspapers and media in the three years from 2017 to 2019. The number of Facebook Likes increased 1.38 times from April 2018 to March 2020.

**Branding WPI** The AAAS Annual Meeting is a valuable opportunity to make direct contact with international science journalists. IFReC participated in the meeting and conducted PR activities about the initiatives undertaken by IFReC as a WPI center and the research results of IFReC thus far. <u>IFReC continues</u> to participate in the AAAS Annual Meeting, where it has been working as a WPI center, and continues activities to enhance its international brand on behalf of the WPI. IFReC also co-hosted an event with iCeMS of Kyoto University to improve visibility in Japan as a WPI center.

## 7. Effort to Secure the Center's Future Development over the Mid- to Long-term

Address each of the following items that have been done to secure mid- to long-term center development:

 Contents of the measures taken by the host institution to support maintaining the activities of the Center (such as securing financial and personnel resources, coordination among host institution to bring together in-house researchers, in-kind provision and/or facilities afforded in terms of usage of building, lab space and other equipment, new management reform carried out after the funding period ends).

Actions and measures taken to sustain the Center as a world premier international research center.

**Appropriate operation of comprehensive collaboration and ensuring stable operation of IFReC** In April 2017, IFReC began 10-year comprehensive collaboration agreements with Chugai Pharmaceutical Co., Ltd. and with Otsuka Pharmaceutical Co., Ltd. comprising a total funding of more than 10 billion yen. Thus, through these agreements IFReC secured a financial base for its operations in lieu of WPI support. In exchange for the funding provided, IFReC discloses its latest research results to its partner companies. As a result, the partner companies are given priority for conducting joint research and patent use. Under the agreements, the funding provided by the partner companies can be used in almost the same way as the public WPI funding in that IFReC can spend the funding with a high degree of freedom on activities leading to research results. Since no specific research theme was set as in a typical joint research agreement, IFReC researchers are guaranteed the freedom to conduct their curiosity-driven basic research as in the past.

To date, there have been limited opportunities in Japan for academic research results to actually attract the attention of companies. However, in these comprehensive collaborations, practically all of IFReC's research results are disclosed to its partner companies, which assess whether they are worth pursuing. This functions as a practical system for seamlessly developing basic research results into applied research and has led to increased opportunities to conduct joint research with partner companies. Joint research based on the disclosed results is funded separately under the normal joint research agreement procedures. Each company's research space in IFReC has been set up as joint research chairs (established in April 2017 for Chugai Pharmaceutical Co., Ltd. and established in February 2020 for Otsuka Pharmaceutical Co., Ltd.). Since each of the partner companies has its own unique technology for drug discovery, the discovery of innovative new drugs based on the results of IFReC is expected. On the other hand, because it is impossible for the partner companies to conduct applied research on all the research results created by IFReC, IFReC also promotes collaboration with other companies. In order to manage the increasingly sophisticated and complex industry-academia collaboration, including the management of such comprehensive collaborations, IFReC recruits and trains research management personnel in the RPMO through MEXT's Program for Promoting the Enhancement of Research Universities.

**Effort to promote human immunology** The new director, Dr. TAKEDA Kiyoshi, set up policies to promote human immunology research in addition to interdisciplinary research, which were approved by the WPI Program Committee. IFReC is able to conduct these types of research due to its access to human samples through the PIs affiliated concurrently with Osaka University Hospital. In addition, recent remarkable technological innovations have made it possible to analyze single cells and improved computing capability has enabled the analysis of big data, thereby clearing the way for progress in human immunology research. In order to upgrade the equipment available for common use, in FY2019 IFReC purchased single cell analyzers (Chromium by 10xGenomics and Rhapsody by BD) and a next-generation sequencer (NovaSeq6000). In addition, IFReC established the Human Immunology Laboratory and hired two PIs (associate professors) to provide systematic research support. By covering the cost of expensive analysis techniques, IFReC makes these expensive state-of-the-art technologies available to IFReC researchers.

**Recruitment and nurture of the next generation of researchers** IFReC provides support to researchers at different stages in their careers. IFReC has fostered young researchers through the Advanced Postdoc Program, the Program for International Circulation of Young Talented Researchers, and the Winter School, and has supported young PIs with research funding through the Grant Program for Next Generation PI to promote their development into core researchers at IFReC. Furthermore, IFReC recognizes PIs who have the ability to continue to lead the world in research even after their retirement age, and encourages them to actively contribute to nurturing the next generation of researchers as mentors.

**Evaluation and support by host institution** As the host institution, <u>Osaka University established the</u> International Advanced Research Institute (IARI) in FY2017 with the university president as its director, and has allowed the IFReC director to manage IFReC as a department within IARI under his leadership. Osaka University holds IFReC in high regard with respect to the following points. (1) IFReC has many world-class researchers and continues to produce world-class research results, thereby contributing significantly to the improvement of academic standards at Osaka University; (2) IFReC contributes significantly to the internationalization of the university as it has a high proportion of international researchers and actively promotes the international circulation of young researchers and the exchange of research with overseas research institutions; and (3) IFReC contributes significantly to <u>industry-academia</u> <u>collaboration at Osaka University</u> as it promotes new forms of collaboration, mainly through large-scale comprehensive cooperation agreements, and obtains a large amount of external funding from companies, thereby establishing and maintaining an independent management system. As the host institution, Osaka University has provided the following support to IFReC.

Human resources support Six tenured posts (two professors, two associate professors, and two assistant professors) were provided and bilingual administrative staff were assigned preferentially to IFReC.
 Financial support In the comprehensive collaboration agreement with Chugai Pharmaceutical Co., Ltd., the entire budget for all indirect costs that was allocated to the head office was allocated back to IFReC, and the entire amount received (1 billion yen per year) was made available to IFReC.

(3) Support for international cooperation Osaka University supports the promotion of IFReC's international cooperation. In particular, <u>Osaka University took the lead in promoting collaboration with UCL</u>, <u>a Global Knowledge Partner of Osaka University</u>. Immunology is one of the fields that UCL requested for collaboration with Osaka University, which has created opportunities for promoting interaction. Accordingly, the aforementioned joint symposium was held with the support of Osaka University, and a Strategic Partnership Agreement between the universities was signed in October 2019. In addition, Osaka University promotes international joint research through funding.

(4) **Support for industry-academia collaboration** With the start of the comprehensive collaboration, a close collaborative relationship has been established within Osaka University. The number of collaborative research projects derived from this comprehensive collaboration and the amount of grants received from them have also increased. Therefore, the department in charge of industry-academia collaboration has provided sufficient support to help IFReC with its increasingly complex management.

## 8. Others

 Describe the Center's efforts over the past 3 years in making it a place that expands and accelerates the international circulation of the world's best brains. Give about 5 example of their success cases and describe their concrete contents and effect in narrative.
 In addition to the above1-7, note any of the Center's notable efforts and activities.

**Results to accelerate and expand international circulation for young researchers as a WPI Academy center** The specific results are as follows.

(1) Advanced Postdocs To date, IFReC has recruited 11 outstanding young researchers. In FY 2019, 166 applications were received and 3 were hired.

(2) Collaboration with ImmunoSensation, University of Bonn In response to a request by the Rector of the university on his visit to IFReC, a partnership was established and an academic exchange agreement was signed. A joint symposium was held in Bonn in 2018. The next one will be held in Osaka.

(3) Collaboration with UCL A collaborative relationship was established in the field of immunology under the leadership of Osaka University. A joint symposium was held in Osaka. The next symposium will be held in London in 2020.

(4) Winter School of Advanced Immunology The school is highly regarded for successfully recruiting outstanding young researchers selected from many applications from all over the world. The school also contributed to the recruitment of young researchers to IFReC.

(5) PR and outreach activities to accelerate international circulation of young researchers Recruitment activities were carried out overseas. This led to an increase in applications to the Winter School and Advanced Postdoc Program and increased the visibility of IFReC to young researchers.

**Operational system in the absence of an administrative director** Dr. SAKAGUCHI Nobuo, the former administrative director, stepped down in July 2019. Until a new administrative director is appointed, Director Takeda also serves as the administrative director with the assistance from two associate professors in the RPMO. A new administrative director will be selected and appointed in 2020.

**Decrease in research competence due to outflow of fixed-term staff** In IFReC, there are a very limited number of tenured positions for researchers and administrative/technical staff, most of whom are employed in fixed-term. Following the revised Labor Contract Act Law enacted in 2013, Osaka University cannot employ fixed-term researchers for more than 10 years and other fixed-term employees for more than five years. In recruiting professor-level researchers, it is difficult to offer tenured positions at present so only fixed-term positions can be offered, making it extremely difficult to recruit them in practice.

Currently, only associate professor-level researchers can be recruited as new PIs on the assumption that they will be transferred within 10 years, <u>thereby reducing the potential for IFReC's development</u>. In addition, there is a strong concern that research level and operational efficiency have been reduced due to the inevitable outflow of experienced technical and administrative staff over the past few years.

# Appendix 1 List of Center's Major Research Achievements

### 1. List of Major Refereed Papers

- List up to 20 papers representative of the Center's research activities during the period between FY 2017 and FY 2019, and give brief descriptions (within 5 to 10 lines) of them.
- \*For each, write the author name(s); year of publication; journal name, volume, page(s), and article title. Any listing order may be used as long as format is the same. If a paper has many authors, underline those affiliated with the Center. \*If a paper has many authors (say, more than 10), all of their names do not need to be listed.

1. Plasmodium products persist in the bone marrow and promote chronic bone loss.

Michelle S. J. Lee, Kenta Maruyama, Yukiko Fujita, Aki Konishi, Patrick M. Lelliott, Sawako Itagaki, Toshihiro Horii, et al. Science Immunology 2:12, eaam8093 (2017).

Cevayir Coban's group and others have revealed that malaria infection induces robust immune activation and invasion of parasite by-products into the bone marrow leading to harmful outcomes on bone homeostasis. The research group additionally showed that supplementation of alfacalcidol, a vitamin D3 analog, reverses the adverse outcomes of malaria infection on bone. Their results highlight the risk of bone loss in malaria-infected patients and the potential benefits of coupling bone therapy with anti-malarial treatment.

The activated conformation of integrin  $\beta$ 7 is a novel multiple myeloma–specific target for CAR 2. T cell therapy.

Naoki Hosen, Yukiko Matsunaga, et al. Nature Medicine 23:1436-1443 (2017).

Naoki Hosen, Athushi Kumanogoh and their research group showed that the active conformer of an integrin can serve as a specific therapeutic target for multiple myeloma (MM). They identified MMG49 as an MM specific mAb specifically recognizing a subset of integrin  $\beta$ 7 molecules. MMG49 CAR T cell therapy is promising for MM, and a receptor protein with a rare but physiologically relevant conformation can serve as a cancer immunotherapy target.

3. Immune evasion of Plasmodium falciparum by RIFIN via inhibitory receptors.

Fumiji Saito, Kouyuki Hirayasu, Takeshi Satoh, et al. Nature 552:101-105 (2017).

Hisashi Arase and others revealed a novel molecular mechanism that P. falciparum suppresses host's immune response and causes severe malaria. The research group found that proteins called RIFIN expressed on P falciparum-infected erythrocytes bind to a host inhibitory receptor LILRB1. Furthermore, RIFIN suppresses the immune response to malaria, resulting in severe complications of malaria. This result is expected to greatly contribute to the development of therapeutic drug and vaccine against malaria.

4. Intracellular metabolite  $\beta$ -glucosylceramide is an endogenous Mincle ligand possessing immunostimulatory activity.

Masahiro Nagata, Yoshihiro Izumi, Eri Ishikawa, Ryoko Kiyotake, Rieko Doi, Satoru Iwai, Zakaria Omahdi, Toshiyuki Yamaji, Tomofumi Miyamoto, Takeshi Bamba, and Sho Yamasaki. PNAS 114(16):E3285-E3294 (2017).

Group A Streptococcus (GAS) causes invasive streptococcal infections in humans, resulting high mortality. Thus, GAS is also known as "killer bacteria" or "flesh-eating bacteria". Sho Yamasaki and his research group reported that the C-type lectin receptor macrophage inducible Ctype lectin (Mincle) recognizes GAS and initiates anti-bacterial immunity. Their findings indicate that Mincle plays a central role in protective immunity against acute GAS infection.

Regulation of inflammatory responses by dynamic subcellular localization of RNA-binding 5 protein Arid5a.

Mitsuru Higa, Masahiro Oka, Yoshitaka Fujihara, Kazuya Masuda, Yoshihiro Yoneda, and Tadamitsu Kishimoto. PNAS 115 (6):E1214-E1220 (2018).

Tadamitsu Kishimoto, and the research group revealed the regulatory mechanism of subcellular localization of Arid5a in response to inflammation. They showed 1) Arid5a translocates to the cytoplasm from the nucleus in response to inflammation, 2) bimax, which inhibit cNLS-dependent nuclear import via highaffinity interactions with NLS-binding sites of importin-a, inhibits the nuclear import of Arid5a, 3) CRM1 inhibitor, Leptomycin B, inhibits the nuclear export of Arid5a after LPS stimulation.

6. B-1a lymphocytes promote oligodendrogenesis during brain development.

Shogo Tanabe & Toshihide Yamashita. Nature Neuroscience 21:506-516 (2018).

Toshihide Yamashita and his research group showed the most abundant infiltrating lymphocytes in the developing brain are B cells. They identified the subtypes of lymphocytes that are present in neonatal mouse brains and investigated their functions. They found that B-1a cells, a subtype of B cells, were abundant in the neonatal mouse brain and infiltrated into the brain in a CXCL13–CXCR5-dependent manner.

7. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes.

Rainer Malik, Ganesh Chauhan, Matthew Traylor, Muralidharan Sargurupremraj, <u>Yukinori</u> <u>Okada</u>, et al. Nature Genetics 50:524-537 (2018).

Stroke has multiple etiologies, but the underlying genes and pathways are largely unknown. The international research groups including Yoshinori Okada conducted a multiancestry genome-wide-association meta-analysis in 521,612 individuals (67,162 cases and 454,450 controls) and discovered 22 new stroke risk loci, bringing the total to 32.

8. T Follicular Helper Cell-Germinal Center B Cell Interaction Strength Regulates Entry into Plasma Cell or Recycling Germinal Center Cell Fate.

Wataru Ise, Kentaro Fujii, et al. Immunity 48(4):702-715 (2018).

Wataru Ise, Tomohiro Kurosaki and the research group discovered how high affinity antibodies, which are essential for host protection from pathogens, are generated. This study analyzed germinal center B cells carefully and identified plasma cell precursors among germinal center B cells. The findings in this study are expected to contribute to the development of novel vaccine that targets efficient production of antibody against various virus.

9. Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis.

Keiji Hirota, Motomu Hashimoto, et al. Immunity 48(6):1220-1232 (2018).

Using a model of spontaneous autoimmune arthritis, Keiji Hirota and Shimon Sakaguchi's group identified in an animal model of rheumatoid arthritis an inflammatory cellular cascade instigated by an arthritogenic T helper subset and enhanced by GM-CSFproducing synovial-resident innate lymphoid cells.

10. Semaphorin 6D reverse signaling controls macrophage lipid metabolism and anti-inflammatory polarization.

Sujin Kang, Yoshimitsu Nakanishi, Yoshiyuki Kioi, et al. Nature Immunology 19:561–570 (2018). Polarization of macrophages into pro-inflammatory or anti-inflammatory states has distinct metabolic requirements, with mechanistic target of rapamycin (mTOR) kinase signaling playing a critical role. Sujin Kang, Athushi Kumanogoh, and their research group showed that an mTOR–Semaphorin 6D (Sema6D)-Peroxisome proliferator receptor γ (PPARγ) axis plays critical roles in macrophage polarization. Their findings highlight crucial roles for Sema6D reverse signaling in macrophage polarization, coupling immunity, and metabolism via PPARγ.

11. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.

Pakawat Chongsathidkiet, Christina Jackson, <u>Shohei Koyama</u>, et al. Nature Medicine 24:1459-1468 (2018).

Shohei Koyama (Kumanogoh group) and the researchers of Harvard University, Duke University, and the John Hopkins University revealed that in a patient with a brain tumor, the tumor prevents the migration of T lymphocytes from the bone marrow. This T cell sequestration is accompanied by tumor-imposed loss of S1P1 from the T cell surface and is

reversible upon precluding S1P1 internalization. In murine models of glioblastoma, hindering S1P1 internalization and reversing sequestration licenses T cell- activating therapies that were previously ineffective.

12. GPR31-dependent dendrite protrusion of intestinal CX3CR1+ cells by bacterial metabolites. <u>Naoki Morita</u>, <u>Eiji Umemoto</u>, et al. Nature 566:110-114 (2019).

Naoki Morita, Eiji Umemoto, and Kiyoshi Takeda's group revealed the role of bacterial metabolites lactate and pyruvate in intestinal immune response. These metabolites produced by gut microbiota stimulate intestinal macrophages through the receptor GPR31, allowing macrophages to protrude trans-epithelial dendrites and take up pathogenic bacteria efficiently in the intestine. Accordingly, lactate and pyruvate cause enhanced immune responses to pathogenic bacteria and increased resistance to the infection.

13. Genetic and phenotypic landscape of the major histocompatibility complex region in the Japanese population.

Jun Hirata, Kazuyoshi Hosomichi, Saori Sakaue, Masahiro Kanai, Hirofumi Nakaoka, Kazuyoshi Ishigaki, Ken Suzuki, Masato Akiyama, Toshihiro Kishikawa, Kotaro Ogawa, Tatsuo Masuda, Kenichi Yamamoto, Makoto Hirata, Koichi Matsuda, Yukihide Momozawa, Ituro Inoue, Michiaki Kubo, Yoichiro Kamatani, and <u>Yukinori Okada</u>. Nature Genetics 51:470-480 (2019).

To perform detailed fine-mapping of the major-histocompatibility-complex region, Yukinori Okada and the research group conducted next-generation sequencing -based typing of the 33 human leukocyte antigen genes in 1,120 individuals of Japanese ancestry. They showed that the Japanese HLC type consists of 11 patterns, and its individual difference involves in more than 50 phenotypes including diseases.

14. Satb1 regulates the effector program of encephalitogenic tissue Th17 cells in chronic inflammation.

Keiko Yasuda, <u>Yohko Kitagawa</u>, <u>Ryoji Kawakami</u>, Yoshitaka Isaka, Hitomi Watanabe, Gen Kondoh, Terumi Kohwi-Shigematsu, <u>Shimon Sakaguchi</u>, and <u>Keiji Hirota</u>. Nature Communications 10:549 (2019).

Keiko Yasuda, Keiji Hirota, Shimon Sakaguchi and their research group demonstrate that Satb1 (special AT-rich sequence-binding protein-1) differentially regulates gene expression profiles in non-pathogenic and pathogenic Th17 cells and promotes the pathogenic effector program of encephalitogenic Th17 cells by regulating GM-CSF via Bhlhe40 and inhibiting PD-1 expression.

15. Regnase-1-mediated posttranscriptional regulation is essential for hematopoietic stem and progenitor cell homeostasis.

Hiroyasu Kidoya, Fumitaka Muramatsu, Teppei Shimamura, Weizhen Jia, <u>Takashi Satoh</u>, Yumiko Hayashi, Hisamichi Naito, Yuya Kunisaki, Fumio Arai, Masahide Seki, Yutaka Suzuki, Tsuyoshi Osawa, <u>Shizuo Akira</u>, and <u>Nobuyuki Takakura</u>. Nature Communications 10:1072 (2019).

Regnase-1, a member of the CCCH zinc finger protein family has RNAse activity, and mediates post-transcriptional regulatory activity through degradation of target mRNAs. Nobuyuki Takakura and his research group showed that Regnase-1 regulates self-renewal of HSPCs (hematopoietic stem and progenitor cells) through modulating the stability of Gata2 and Tal1 mRNA.

16. The COMMD3/8 complex determines GRK6 specificity for chemoattractant receptors.

<u>Akiko Nakai, Jun Fujimoto</u>, Haruhiko Miyata, Ralf Stumm, Masashi Narazaki, Stefan Schulz, Yoshihiro Baba, <u>Atsushi Kumanogoh</u>, <u>Kazuhiro Suzuki</u>. J Exp Med 216 (7):1630–1647 (2019).

Akiko Nakai, Kazuhiro Suzuki and the research group identified a protein complex consisting of copper metabolism MURR1 domain-containing (COMMD) 3 and COMMD8 (COMMD3/8 complex) as an adaptor that selectively recruits a specific GRK (G protein-coupled receptors kinase) to chemoattractant receptors and promotes lymphocyte migration. The COMMD 3/8 complex plays a crucial role in humoral immune responses and can be a drug target for the treatment of inflammatory diseases.

17. Phosphorylation-dependent Regnase-1 release from endoplasmic reticulum is critical in IL-17 response.

<u>Hiroki Tanaka</u>, Yasunobu Arima , Daisuke Kamimura, Yuki Tanaka, Noriyuki Takahashi, Takuya Uehata, Kazuhiko Maeda, <u>Takashi Satoh</u>, <u>Masaaki Murakami</u>, and <u>Shizuo Akira</u>. J Exp Med 216 (6):1431–1449 (2019).

Regnase-1 is an endoribonuclease involved in mRNA degradation of inflammation-associated genes. Hiroki Tanaka, Shizuo Akira, and their research group demonstrated that interleukin (IL)-17 induces phosphorylation of Regnase-1 in an Act1-TBK1/IKKi–dependent manner, especially in nonhematopoietic cells. By the stimulation with interleukin 17, Regnase-1 is phosphorylated and translocated to the cytoplasm. As a result, the mRNA targeted by Regnase-1 is stabilized and translated.

18. CXCR4 regulates Plasmodium development in mouse and human hepatocytes.

Hironori Bando, Ariel Pradipta, Shiroh Iwanaga, Toru Okamoto, <u>Daisuke Okuzaki</u>, <u>Shun Tanaka</u>, Joel Vega Rodríguez, <u>Youngae Lee</u>, <u>Ji Su Ma</u>, <u>Naoya Sakaguchi</u>, <u>Miwa Sasai</u>, Yoshiharu Matsuura, Masao Yuda, Marcelo Jacobs-Lorena, and <u>Masahiro Yamamoto</u>. J Exp Med 216 (6):1431–1449 (2019).

The research group of Masahiro Yamamoto showed that enhanced CXCR4 expression increases calcium ion concentration in hepatocytes, and malaria parasites differentiate into erythroid phase. Blocking CXCR4 expression by genetic or pharmacological intervention profoundly inhibited the liver stage development of the P. berghei rodent malaria parasite and the human P. falciparum parasite also. CXCR4 inhibitors that have been used are expected to be new preventive agents for malaria.

19. Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1.

Tetsuo Hasegawa, <u>Junichi Kikuta</u>, Takao Sudo, Yoshinobu Matsuura, Takahiro Matsui, Szandor Simmons, Kosuke Ebina, Makoto Hirao, <u>Daisuke Okuzaki</u>, Yuichi Yoshida, Atsushi Hirao, Vladimir V. Kalinichenko, Kunihiro Yamaoka, Tsutomu Takeuchi, and <u>Masaru Ishii</u>. Nature Immunology 20:1631–1643 (2019).

Junichi Kikuta, Masaru Ishii and their research group discovered the osteoclasts in pannus originate exclusively from circulating bone marrow-derived cells. They identify murine CX3CR1hiLy6CintF4/80+I-A+/I-E+ macrophages (named [AtoMs]) as the osteoclast precursor (OP)-containing population in the inflamed synovium, comprising a subset distinct from conventional OPs in homeostatic bone remodelling. Tamoxifen-inducible Foxm1 deletion suppressed the capacity of AtoMs to differentiate into osteoclasts in vitro and in vivo.

20. Cross-talks of glycosylphosphatidylinositol biosynthesis with glycosphingolipid biosynthesis and ER-associated degradation.

<u>Yicheng Wang</u>, Yusuke Maeda, Yi-Shi Liu, <u>Yoko Takada</u>, Akinori Ninomiya, <u>Tetsuya Hirata</u>, Morihisa Fujita, <u>Yoshiko Murakami</u>, and <u>Taroh Kinoshita</u>. Nature Communications 11:860 (2020).

The structure of the core backbone of Glycosylphosphatidylinositol (GPI) is conserved whereas the structural variation of GPI anchors is introduced by side-chain modifications. In some mammalian GPI-APs, the N-acetylgalactosamine side-chain linked to the first mannose is further modified with galactose by an unknown galactosyltransferase (GPI-Gal-T). The research group of Taroh Kinoshita found that B3GALT4, known as GM1 synthase, is GPI-Gal-T. They also demonstrated the requirement of lactosylceramide for efficient galactosylation of GPI side chain.

2. Major Invited Lectures, Plenary Addresses (etc.) \*List up to 10 main presentations made between FY 2017 and FY 2019 in order from most recent. \*For each, write the date(s), lecturer/presenter's name, presentation title and conference name.

Date(s)	Lecturer/Presenter's name	Presentation title	Conference name
March 14. 2020	SAKAGUCHI Shimon	Discovery of regulatory T cell and its clinical Application	Memorial Lecture for Paul Elrich and Ludwig Darmstaedter Prize, Germany
March 9. 2020	SAKAGUCHI Shimon	Discovery of regulatory T cell	Memorial Symposium for Order of Culture, Japan
March 2, 2020	KUROSAKI Tomohiro	B Cell Renaissance: Epigenetics, Regulation and Immunotherapy	Keystone Symposia, Canada
December 19, 2019	KISHIMOTO Tadamitsu	IL-6: From Molecule to Medicine	Memorial Lecture for Keio Medical Prize, Japan
October 20, 2019	TAKEDA Kiyoshi	Regulation of intestinal homeostasis by epithelia and immunity	International Union of Immunological Societies, China
September 11, 2019	SAKAGUCHI Shimon	Discovery of regulatory T cell and its molecular basis for clinical application	Memorial Lecture for the German Immunology Prize
July 30, 2019	SAKAGUCHI Shimon	Regulatory T cell: From Molecule to Medicine	Memorial Lecture for Honorary Doctorate from University of Birmingham, UK
April 9, 2019	AKIRA Shizuo	RNA degradation controls inflammation	NIH WALS Lecture Series, USA
March 11, 2019	AKIRA Shizuo	The control of inflammatory and immune responses by the endoribonuclease Regnase-1	Keystone Symposia, USA
April 4, 2017	KISHIMOTO Tadamitsu	IL-6: From Molecule to Medicine	Memorial Lecture for King Faisal International Prize, Saudi Arabia

**3. Major Awards** \*List main awards received between FY 2017 and FY 2019 in order from the most recent.
 \*For each, write the date issued, recipient's name and the name of award. In case of multiple recipients, underline those affiliated with the Center.

eteedter Drize
etaadtar Driza
staedter Prize
Scientific Minds ers)
munology) Award
on Award
ze
ize
iversity of
nd Prize
munology) Award
n
Scientific Minds ers)
earch Award
ologists
apan
ence.
Prize for Medicine

# Appendix 2 FY 2019 List of Principal Investigators

NOTE:

\*Underline names of principal investigators who belong to an overseas research institution.

\*Indicate newly added researchers in FY 2019 (2019.4.1-2020.3.31) in the "Notes" column.

		<principal at="" end<="" investigators="" th="" the=""><th>of FY 2019&gt;</th><th></th><th></th><th>Principal Investigators</th><th>Total: 34</th></principal>	of FY 2019>			Principal Investigators	Total: 34
Name	Age	Affiliation (Position title, department, organization)	Academic degree, Specialty	Effort (%)*	Starting date of participation	Status of participation (Describe in concrete terms)	Note
Center director TAKEDA Kiyoshi	53	Director and Professor, WPI Immunology Frontier Research Center, and, Graduate School of Medicine, Osaka University	MD, PhD (Immunology)	100	01/11/2007	usually stays at the center	
AKIRA Shizuo	66	Professor, WPI Immunology Frontier Research Center, Osaka University	MD, PhD (Immunology)	15	01/10/2007	usually stays at the center	
KUROSAKI Tomohiro	64	Deputy Director and Professor, WPI Immunology Frontier Research Center, Osaka University		80	03/12/2007	usually stays at the center	
ARASE Hisashi	54	Deputy Director and Professor, WPI Immunology Frontier Research Center, Osaka University	MD, PhD (Immunology)	40	01/10/2007	usually stays at the center	
KUMANOGOH Atsushi	53	Professor, Graduate School of Medicine, WPI Immunology Frontier Research Center, Osaka University	MD, PhD (Immunology)	25	01/10/2007	usually stays at guraduate school of medicine	
ISHII Ken J.	51	Professor The Institute of Medical Science, The University of Tokyo Professor, WPI Immunology Frontier Research Center, Osaka University	MD, PhD (Immunology, Vaccine Science)	5	01/11/2007	join to meetings every two months, workshops several times a year, and symposiums occasionally.	

Cevayir COBAN	46	Professor, The Institute of Medical Science, The University of Tokyo, WPI Immunology Frontier Research Center, Osaka University	(Clinical	20	01/04/2008	stays at the center once (1 week) a month, joint IFReC Management meetings, at skype meeting three times a week.	Cross appointmen t started on 2019/06/01
SUZUKI Kazuhiro	44	Professor, WPI Immunology Frontier	MD, PhD (Immune cell dynamics)	90	01/04/2011	usually stays at the center	
YAMAMOTO Masahiro	41	Professor, Research Institute for Microbial Diseases, WPI Immunology Frontier Research Center,Osaka University		45	01/04/2012	usually stays at the center	
<u>Benjamin</u> John SEYMOUR	47	NICT Invited Executive Researcher and Wellcome Trust Intermediate Clinical Fellow (Cambridge University)	PhD (Neurological Science)	10	01/04/2014	He visits IFReC several times/year to attend symposia, etc. to contribute to research at IFReC. He regularly communicates with us by emails.	
HATAZAWA Jun	66	Professor, Research Center for Nuclear Physics, WPI Immunology Frontier Research Center, Osaka University	MD, PhD (Nuclear Medicine)	5	16/01/2009	stays at the center once a month, usually stays at Research Center for Nuclear Physics Osaka University, RCNP	research for new radionucli de developm ent for medical use
KIKUCHI Kazuya	54	Lengingering WUL Immunology Frontier	PhD (Chemical Biology)	10	01/08/2009	usually stays at the center	<b>u</b> 30
ISHII Masaru	46	Professor, Graduate School of Frontier Biosciences, WPI Immunology Frontier Research Center,Osaka University	MD, PhD (Bioimaging)	10	01/12/2008	usually stays at the center	
Nicholas Isaac SMITH	44	Associate Professor, WPI Immunology Frontier Research Center, Osaka University	PhD Engineering/ Applied Physics)	100	01/06/2009	usually stays at the center, except when teaching or during conference travel	

Daron M.STANDLEY	51	Professor, Research Institute for Microbial Diseases, WPI Immunology Frontier Research Center, Osaka University	PhD (Bioinformatics)	15	01/10/2008	usually stays at the center
NAGATA Shigekazu	70	Professor, WPI Immunology Frontier Research Center, Osaka University	PhD (Molecular/Cell Biology)	80	01/04/2015	usually stays at the center
KINOSHITA Taroh	68	Institute for Microbial Diseases, WPI	PhD (Immunology, Biochemistry)	70	01/10/2007	usually stays at the center
SAKAGUCHI Shimon	69	Professor, WPI Immunology Frontier Research Center, Osaka University	MD, PhD (Immunology)	70	01/04/2011	usually stays at the center
SAITO Takashi	69	Team leader, RIKEN, Research Center for Integrative Medical Sciences, Professor, WPI Immunology Frontier Research Center, Osaka University		10	01/04/2008	join to meetings every two months, workshops several times a year, and symposiums occasionally.
KIKUTANI Hitoshi	69	Professor, WPI Immunology Frontier Research Center, Osaka University	MD, PhD (Immunology)	100	01/10/2007	usually stays at the center
KISHIMOTO Tadamitsu	80	Professor, WPI Immunology Frontier Research Center, Osaka University	MD, PhD (Immunology)	80	01/10/2007	usually stays at the center
Fritz MELCHERS	83	Max Planck Fellow	PhD (Immunology)	10	01/10/2007	He visits IFReC several times/year to attend symposia, etc. to contribute to research at IFReC. He regularly communicates with us by emails.

YANAGIDA Toshio	73	Professor, Graduate School of Frontier Biosciences, WPI Immunology Frontier Research Center, Osaka University		10	01/10/2007	join seminars, symposium, and meetings (several times a year at IFReC)/ interdisciplinary research promotion at NICT CiNet
OKADA Yukinori	38	Professor, Graduate School of Medicine, WPI Immunology Frontier Research Center, Osaka University	MD, PhD (Bioinformatics)	5	01/04/2017	conducts research 2 or 3 times a week at the center
YAMASHITA Toshihide	55		MD, PhD (Neurological Science)	10	01/04/2017	conducts research 2 or 3 times a week at the center
NAGASAWA Takashi	58	Professor, Graduate School of Frontier Biosciences, WPI Immunology Frontier Research Center, Osaka University	MD, PhD (Immunology)	36	01/04/2017	Conducts research relating to the Center and participates several times a month (includes visits) in exchanging information with the Center's researchers.
YAMASAKI Sho	50	Deputy Director and Professor, WPI Immunology Frontier Research Center, and Research Institute for Microbial Diseases, Osaka University	PhD	80	01/04/2017	usually stays at the center
OKADA Masato	61	Professor, Research Institute for Microbial Diseases, WPI Immunology Frontier Research Center, Osaka University	PhD(Science)	15	01/08/2018	stays at the center once a week
HARA Eiji	55	Professor, Research Institute for Microbial Diseases, WPI Immunology Frontier Research Center, Osaka University		5	01/08/2018	usually stays beside the center
TAKAKURA Nobuyuki	57	Professor, Research Institute for Microbial Diseases, WPI Immunology Frontier Research Center, Osaka University	MD,PhD(Vascular and Stem Cell Biology)	15	01/08/2018	usually stays beside the center

FUJIMOTO Manabu		Professor, Graduate School of Medicine, WPI Immunology Frontier Research Center, Osaka University		15	01/04/2019	usually stays at guraduate school of medicine	New
MORO Kazuyo	43	Professor, Graduate School of Medicine, WPI Immunology Frontier Research Center, Osaka University	MD.PhD. (Immunology)		01/08/2019	usually stays at guraduate school of medicine	New
James Badger WING	39	Center, Osaka University Associate Professor, WPI Immunology Frontier Research Center, Osaka University		100	01/11/2019	usually stays at the center	New
OKUZAKI Daisuke	47	Associate Professor, WPI Immunology Frontier Research Center, Osaka University	PhD. (Human Immunology)	50	01/11/2019	usually stays at the center	New

\*Percentage of time that the principal investigator devotes to his/her work for the Academy center vis-à-vis his/her total working hours.

Osaka University -1

Immunology Frontier Research Center

## Principal Investigators resigned since FY 2017

Next Affiliation (Position title, department, organization)	Period of participation

Osaka University -2

Immunology Frontier Research Center

## Appendix 3-1 Record of Center Activities (FY 2017-FY 2019)

## 1. Researchers and Center Staffs, Satellites, Partner Institutions

1-1. Researchers and Center Staffs Participated in the Center's Activities

- Enter the number of researchers and center staffs affiliated with the Center in the table in Appendix 3-1a.

#### **Special mention**

- Describe the Center's concrete plans for the future and already-established schedules for employing researchers, particularly principal investigators.
- As background to how the Center is working on the global circulation of world's best brains, give good examples, if any, of how career paths are being established for the Center's researchers; that is, from which top-world research institutions do researchers come to the Center and to which research institutions do the Center's researchers go, and how long are their stays at those institutions
- In Appendix 3-1b, describe the positions that postdoctoral researchers acquire upon leaving the Center.

#### 1-2. Satellites and Partner Institutions

- List the satellite and partner institutions, both domestic and overseas, in the table below.
- Indicate newly added and deleted institutions in the "Notes" column.

#### <Satellite institutions>

Institution name	Principal Investigator(s), if any	Notes

#### < Partner institutions>

Institution name	Principal Investigator(s), if any	Notes

## 2. Status of Collaboration with Overseas Satellites

#### 2-1. Coauthored Papers

- List the refereed papers published between FY 2017 and FY 2019 that were coauthored between the Center's researcher(s) in domestic institution(s) (include satellite institutions) and overseas satellite institution(s). List them by overseas satellite institution in the below blocks
- Transcribe data in same format as in Appendix 1. Italicize the names of authors affiliated with overseas satellite institutions.

Overseas Satellite 1 1) 2) 3)	Name (Total: OO papers)
Overseas Satellite 2 1) 2) 3)	Name (Total: OO papers)

#### 2-2. Status of Researcher Exchanges

- Using the below tables, indicate the number of researcher exchanges between the Center (include domestic satellite institutions) and overseas satellite institutions during the period of FY 2017-FY 2019. Enter by institution and fiscal year.

- Write the number of principal investigator visits in the upper space and the number of other researcher visits in the lower space.

## Overseas Satellite 1:

### <To overseas satellite>

	FY 2017	FY 2018	FY 2019	Total
Principal investigators				
Other researchers				
Total				

## <From overseas satellite>

	FY 2017	FY 2018	FY 2019	Total
Principal investigators				
Other researchers				
Total				

## **Overseas Satellite 2:**

<To overseas satellite>

	FY 2017	FY 2018	FY 2019	Total
Principal investigators				
Other researchers				
Total				

#### <From overseas satellite>

	FY 2017	FY 2018	FY 2019	Total
Principal investigators				
Other researchers				
Total				

# 3. Holding and Participating in International Research Meetings

3-1. Holding international Research Meetings
 Indicate the number of international research conferences or symposiums held between FY 2017 and FY 2019, and give up to five examples of the most representative ones using the table below.

FY 2017: 2 meetings	FY 2018: 4 meetings	FY 2019: 2 meetings
Major examples (meeting titles, pl	Number of participants	
Cluster Science Days 2018 and the 10th international symposium of IFReC Venusberg Campus of the University Hospital Bonn, Bonn, Germany November 5-6, 2018		From domestic institutions: 9 From overseas institutions: 200
Next Gen Immunology in Health a Grand Cube Osaka, Osaka, Japan February 7-8, 2019	From domestic institutions: 180 From overseas institutions: 10	

The 1st UCL-OU Joint Symposium on Immunology Taniguchi Memorial Hall, Osaka, Japan June 27-28, 2019	From domestic institutions: 148 From overseas institutions: 10
The 9th Winter School on Advanced Immunology The Awaji Yumebutai International Conference Center, Hyogo, Japan January 20-24, 2020	From domestic institutions: 12 From overseas institutions: 59
The 11th International Symposium of IFReC Grand Cube Osaka, Osaka, Japan January 24, 2020	From domestic institutions: 92 From overseas institutions: 89

### 3-2. Participating in International Research Meetings

Give up to five examples of the most representative case in which the Center, not individual researchers, participated in international research meetings to enhance the visibility and brand of the Center or of the overall WPI Program

Meeting titles, places, dates held and number of participants	Form of participation (e.g. operating a booth)	Number of participants from the Center
N/A		

## 4. List of the Cooperative Research Agreements with Overseas Institutions

Indicate the number of agreements concluded with overseas institutions still in effect as of the end of FY 2019 (March 31, 2020). Give five examples of the most representative agreements.

Number of effective agreements (as of March 31, 2019): 1

Five examples of the most representative agreements:

1. Name of the Agreement:

AGREEMENT ON ACADEMIC EXCHANGE BETWEEN IMMUNOLOGY FRONTIER RESEARCH CENTER, RESEARCH INSTITUTE FOR MICROBIAL DISEASES, AND GRADUATE SCHOOL OF FRONTIER BIOSCIENCES OF OSAKA UNIVERSITY, AND THE RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITY OF BONN FOR ITS IMMUNOSENSATION CLUSTER OF EXCELLENCE

Dates of the Agreement: Nov.5, 2018

Counterpart in the Agreement: University of Bonn

Summary of the Agreement:

The Immunology Frontier Research Center, the Research Institute for Microbial Diseases, and the Graduate School of Frontier Biosciences of Osaka University have entered into an agreement with the University of Bonn for the purposes of academic exchange, such as collaborative research and

the exchange of personnel.

- 2. Name of the Agreement: Dates of the Agreement: Counterpart in the Agreement: Summary of the Agreement:
- 3. Name of the Agreement: Dates of the Agreement: Counterpart in the Agreement: Summary of the Agreement:
- 4. Name of the Agreement: Dates of the Agreement: Counterpart in the Agreement: Summary of the Agreement:
- 5. Name of the Agreement: Dates of the Agreement: Counterpart in the Agreement: Summary of the Agreement:

5. Postdoctoral Positions through Open International Solicitations - In the columns "number of applications" and "number of selections," put the total number (upper) and the number and percentage of overseas researchers in the < > brackets (lower).


- In Appendix 3b, describe the status of e	mployment of postdoctoral researchers.
--	--

Fiscal year	Number of applications	Number of selections
FY 2016	2	2
11 2010	〈 2, 100%〉	〈 2, 100%〉
FY 2017	78	3
112017	〈 78, 100%〉	〈 3, 100%〉
FY 2018	176	9
112010	〈 176, 100%〉	〈 9, 100%〉
FY 2019	169	7
112017	〈 169, 100%〉	〈 7, 100%〉

## 6. Diagram of Management System


#### 6-1.

- Diagram the Center's management system within the Center in an easily understood manner.
   If any changes have been made in the Center's management system vis-à-vis that stated in the application for WPI Academy center certification, describe them. Especially describe any important changes made in such as the center director, administrative director, head of host institution, and officer(s) in charge at the host institution (e.g., executive vice president for research).




## 6-2.

- Make a diagram of the organizational chart to show Center's position within the host institution.



## 7. Campus Map

- Draw a simple map of the campus showing where the main office and principal investigator(s) are located.





		FY2016		FY2017	,	FY2018		FY2019	)
		Number of persons	%						
Researchers		126		108		116		123	
	Overseas researchers	37	29.4%	27	25.0%	27	23.3%	37	30.1%
	Female researchers	19	15.1%	22	20.4%	21	18.1%	25	20.3%
	Principal investigators (PIs)	27		27		30		34	
	Overseas PIs	5	18.5%	4	14.8%	4	13.3%	5	14.7%
	Female PIs	1	3.7%	1	3.7%	1	3.3%	2	5.9%
	Other researchers	68		63		65		58	
	Overseas researchers	10	14.7%	11	17.5%	13	20.0%	14	24.1%
	Female researchers	13	19.1%	14	22.2%	12	18.5%	13	22.4%
	Postdocs	31		18		21		31	
	Overseas Postdocs	22	71.0%	12	66.7%	10	47.6%	18	58.1%
	Female Postdocs	5	16.1%	7	38.9%	8	38.1%	10	32.3%
R	esearch support staffs	125		121		112		122	
	Administrative staffs	26		27		27		32	
	TOTAL	277		256		255		277	

## Appendix3-1a Number of Center Personnel FY2016-FY2019

Number of persons who were/have been paid using the host institution's operating budget (excluding indirect funding) among the above persons.

	FY2016	FY2017	FY2018	FY2019
Principal investigators (PIs)				
Other researchers				
Postdocs				
Research support staffs				
Administrative staffs				

% Make consistent with the number of persons reported in Appendix 3-2.

Changes vis-à-vis the Center's application for academy center certification

 $\times$  If changes have been made vis-à-vis the Center's application for academy center certification, describe the main changes and the reasons for them.

Appendix 3-1b

# Appendix 3-1b Career Path of WPI Postdocs

Enter the information below during the period from the start of the center through the end of FY 2019.

- For each person, fill in the spaces to the right. More spaces may be added.

- Leave "Position as of April 2020" blank if unknown.

## Japanese Postdocs

Employment period	Position before employed at Position title, organization	Country where the	Next position after WP Position title, organization	Country where the	Position as of April 2 Position title, organization	Country where th
	Position title, organization	organization is located	Position title, organization	organization is located		organization is loca
2008.4.1- 2009.9.30	Graduate School of Medicine, Kyoto University, Postdoctoral Researcher	Japan	Institute for Frontier Medical Sciences, Kyoto University,JSPS Postdoctoral Fellowship	Japan	Division of Infectious Diseases, Imperial College London, Research Associate	UK
2008.10.16- 2009.10.15	Graduate School of Frontier Biosciences, Osaka University,Specially Appointed Researcher	Japan	Graduate School of Medicine, Osaka University,Specially Appointed Researcher	Japan	Specially Appointed Associate Professor(full-tme), Institute for Radiation Sciences, Osaka University	Japan
2008.4.1- 2011.3.31	The department of internal medicine, Kyoto Hospital Medical doctor	Japan	Graduate School of Medicine, Kyoto University,Assistant Professor	Japan	Graduate School of Medicine, Kyoto University, Assistant Professor	Japan
2009.10.16- 2011.3.31	Graduate School of Medicine, Osaka University,Specially Appointed Researcher	Japan	KAN Research Institute Inc., Researcher	Japan	N/A	N/A
2008.4.1- 2011.3.31	Institute for Frontier Medical Sciences, Kyoto University, Part- time Lecturer	Japan	Immunology Frontier Research Center, Osaka University,Specially Appointed Assistant Professor (Full-time)	Japan	Representative executive, Regcell Co., Ltd.	Japan
2010.4.1- 2011.3.31	Graduate School of Engineering, Kyoto University,Graduate Student	Japan	Immunology Frontier Research Center, Osaka University, Specially Appointed Assistant Professor (Full-time)	Japan	Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Assistant Professor	Japan
2010.6.1- 2011.6.30	Research Institute for Microbial Diseases, Osaka University,Specially Appointed Researcher	Japan	Immunology Frontier Research Center, Osaka University,Specially Appointed Technical Staff	Japan	N/A	N/A
2010.9.1- 2011.6.30	Osaka University Hospital,Medical doctor	Japan	Eli Lilly Japan K.K., Clinical Research Physician	Japan	Eli Lilly Japan K.K., Clinical Development Doctor	Japan
2011.4.1- 2011.9.30	Institute for Protein Research, Osaka University,JSPS Postdoctoral Fellowship	Japan	Department of Chemical & Biomolecular Engineering, Johns Hopkins University,Post-Doctoral Research Fellow	USA	Graduate School of Engineering, Tokyo University, Lecturer	Japan
2009.4.1- 2012.3.31	Graduate School of Medicine, Osaka University, JSPS Postdoctoral Research Fellow	Japan	Immunology Frontier Research Center, Osaka University, Specially Appointed Assistant Professor (Full-time)	Japan	Department of Pathology, University of Michigan, Research Fellow	U.S.A
2010.4.1- 2012.3.31	Graduate School of Medicine, Kyoto University, JSPS Postdoctoral Research Fellow	Japan	Immunology Frontier Research Center, Osaka University, Specially Appointed Assistant Professor (Full-time)	Japan	Department of Immunology, Graduate School of Medicine & WPI Nano Life Science Institute, Kanazawa University, Project Associate Professor	Japan
2011.4.1- 2012.3.31	Graduate School of Frontier Biosciences, Osaka University,Graduate Student	Japan	Graduate School of Medicine, Osaka University, Specially Appointed Researcher	Japan	Department of Microbiology and Immunology, Graduate School of Medicine, Tohoku University, Assistant Professor	Japan
2010.4.1- 2012.6.15	School of Medicine, University of California San Diego,Postdoctoral researcher	USA	Institute for Virus Research, Kyoto University, Assistant Professor	Japan	Department of Medical Chemistry Graduate School of Medicine, Kyoto University, Assistant Professor	Japan
2011.4.1- 2012.7.31	Institute for Frontier Medical Science, Kyoto University, Postdoctoral researcher	Japan	National Hospital Organization Osaka Minami Medical,Medical Staff	Japan	National Hospital Organization Osaka Minami Medical,Medical Staff	Japan
2010.4.1- 2012.10.15	Graduate School of Life Science, Hokkaido University,Graduate Student	Japan	The Institute of Medical Science, The University of Tokyo, Assistant Professor	Japan	Lecturer, Graduate School of Pharmaceutical Sciences, Osaka University	Japan
2010.4.1- 2012.12.31	Takeda Pharmaceutical Company Limited Medical writer	Japan	Astellas Pharma Inc.,Researcher	Japan	Astellas Pharma Inc., Section Chief	Japan
2009.4.1- 2013.3.31	Murakami Medical Hospital Asahi University, Internal medicine doctor	Japan	Immunology Frontier Research Center, Osaka University, Specially Appointed Assistant Professor (Full-time)	Japan	Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Lecturer	Japan
2009.4.1- 2013.3.31	Research Institute for Microbial Diseases, Osaka University,Specially Appointed Researcher	Japan	Immunology Frontier Research Center, Osaka University,Specially Appointed Technical Staff	Japan	N/A	N/A

2010.4.1- 2013.3.31	Graduate School of Medicine, Osaka University,Graduate Student	Japan	Immunology Frontier Research Center, Osaka University, Specially Appointed Assistant	Japan	Associate Professor, Immunology Frontier Research Center, Osaka University	Japan
2010.4.1- 2013.3.31	Graduate School of Science, Nagoya University,Assistant Professor	Japan	Professor (Full-time) Immunology Frontier Research Center, Osaka University, Specially Appointed Assistant Professor (Full-time)	Japan	Specially Appointed Associate Professor(full-time), Immunology Frontier Research Center, Osaka University	Japan
2011.4.1- 2013.3.31	School of Medicine, Iwate Medical University, Postdoctoral researcher	Japan	Immunology Frontier Research Center, Osaka University, Specially Appointed Assistant Professor (Full-time)	Japan	Center for Translational Neuromedicine, University of Copenhagen, Associate Professor	Danmark
2012.4.1- 2013.3.31	Graduate School of Frontier Biosciences, Osaka University,Graduate student	Japan	Graduate School of Medicine, Osaka University,JSPS Postdoctoral Fellowship	Japan	Assistant Professor, Graduate School of Medicine, Osaka University	Japan
2010.4.1- 2013.3.31	Graduate School of Frontier Biosciences, Osaka University,Specially Appointed Researcher	Japan	Graduate School of Frontier Biosciences, Osaka University,Specially Appointed Researcher	Japan	N/A	N/A
2012.4.1- 2013.3.31	L'Oreal Paris Japan Researcher	Japan	Institute for Academic Initiative, Osaka University,Specially Appointed Assistant Professor (Full-time)	Japan	TAKARA BELMONT CORPORATION	Japan
2010.4.1- 2013.4.15	Research Institute for Microbial Diseases, Osaka University,Specially Appointed Technical Staff	Japan	Immunology Frontier Research Center, Osaka University,Specially Appointed Technical Staff	Japan	N/A	N/A
2010.1.1- 2013.4.30	Paul O' Gorman Leukaemia Research Centre, Division of Cancer Sciences and Molecular Pathology, Section of Enperimental Haematology, University of Glasgow, Gartnavel General Hospital	UK	Babraham Institute, Researcher	UK	The Francis Crick Institute, Senior Research Scientist	UK
2010.4.1- 2013.5.15	Frontier Research Center for Applied Atomic Sciences, Ibaraki UniversityPart-time researcher	Japan	NARA Institute of Science and Technology,Part-time researcher	Japan	Nara Institute of Science and Technology Graduate School of Science and Technology Division of Biological Science, Assistant Professor	Japan
2010.6.1- 2013.6.30	Research Institute of Molecular Pathology,Postdoctoral researcher	Austria	National Institute for Basic Biology,Researcher	Japan	Institute for Genome Research,Tokushima University, Assistant Professor	Japan
2011.4.1- 2013.11.30	RIKEN Research Center for Allergy and Immunology,Junior Research Associate	Japan	Immunology Frontier Research Center, Osaka University,Endowed Chair Associate Professor	Japan	Department of Physiological Regulation Mechanisms, Institute of Advanced Medicine, Wakayama Medical University, Lecturer	Japan
2013.4.1- 2014.3.31	Research Institute for Microbial Diseases, Osaka University,Specially Appointed Researcher	Japan	Graduate School of Medicine, Osaka University, Specially Appointed Researcher	Japan	Specially Appointed Researcher(full-time), Immunology Frontier Research Center, Osaka University	Japan
2013.4.1- 2014.6.30	Graduate School of Medicine, Kyoto University, Graduate Student	Japan	Institute for Frontier Medical Sciences, Kyoto University,Specially Appointed Researcher	Japan	Japanese Red Cross Wakayama Medical Center, Clinical Departments of Hematology, Deputy Director	Japan
2012.4.1- 2014.8.31	Graduate School of Frontier Biosciences, Osaka University, Graduate Student	Japan	AbbVie GK	Japan	Bristol-Myers Squibb, Medical Project Manager	Japan
2013.4.1- 2014.8.31	Graduate School of Medicine, Nagoya University, Graduate Student	Japan	Graduate School of Frontier Biosciences, Osaka University, Assistant Professor	Japan	Graduate School of Frontier Biosciences, Osaka University, Assistant Professor	Japan
2012.4.1- 2015.5.31	Graduate School of Pharmaceutical Sciences, Osaka University, Graduate Student	Japan	Kanazawa University, Researcher	Japan	Department of Immunology, Graduate School of Medicine & WPI Nano Life Science Institute, Kanazawa University, Project Assistant Professor	Japan
2011.8.1- 2015.7.31	Research Associate, Department of Cell Biology, Johns Hopkins University	USA	RIKEN Center for Life Science Technologies, Engineer	Japan	N/A	N/A
2012.11.16- 2015.11.30	Postdoctoral fellow, University of Pennsylvania school of medicine, Dept. of Cell & Developmental Biology	USA	Kanazawa University, Assistant Professor	Japan	Department of Immunology, Graduate School of Medicine & WPI Nano Life Science Institute, Kanazawa University, Assistant Professor	Japan
2016.4.1- 2016.9.30	Specially Appointed Researcher(Full-Time), Research Institute for Microbial Deseases, Osaka University	Japan	Researcher, National Institute of Biomedical Innovation, Health and Nutrition	Japan	Researcher, National Institute of Biomedical Innovation, Health and Nutrition	Japan

2013.1.1- 2016.9.30	Research Fellow, Mechanobiology Institute, National University of Singapore	Singapore	Assistant Professor, Tokyo Medical University	Japan	Lecturer, Tokyo Medical University	Japan
2016.4.1- 2018.3.31	PhD student, Graduate School of Medicine, Kyoto University	Japan	Researcher, Kyoto University	Japan	Department of Anatomy and Cell Biology , Graduate School of Medicine, Kyoto University, Reseacher	Japan
2015.7.1- 2018.6.30	Technical Staff, Immunology Frontier Research Center, Osaka University	Japan	N/A	N/A	N/A	N/A
2018.6.16- 2018.9.30	PhD student, Graduate School of Medical Sciences, Kyusyu University	Japan	Specially Appointed Researcher(Full-Time), Research Institute for Microbial Deseases, Osaka University	Japan	N/A	N/A
2015.4.1- 2019.3.15	Researcher, Graduate School of Medicine, Kyoto University	Japan	Lifematics. Inc	Japan	Lifematics. Inc	Japan
2018.10.1- 2019.3.31	Specially Appointed Researcher(Full-Time), Research Institute for Microbial Deseases, Osaka University	Japan	Specially Appointed Researcher(Full-Time), Research Institute for Microbial Deseases, Osaka University	Japan	Specially Appointed Researcher(Full-Time), Research Institute for Microbial Deseases, Osaka University	Japan
2016.4.1- 2019.4.30	PhD student, Graduate School of Medicine, Kyoto University	Japan	Specially Appointed Researcher(Full-Time), Graduate School of Medicine, Osaka University	Japan	Specially Appointed Researcher(Full-Time), Graduate School of Medicine, Osaka University	Japan
2018.4.1- 2019.7.31	Student, Kumamoto University/Part-time, Immunology Frontier Research Center, Osaka University	Japan	Researcher, Graduate School of Health Sciences, Kumamoto University	Japan	Researcher, Graduate School of Health Sciences, Kumamoto University	Japan
2018.2.16- 2020.2.29	Specially Appointed Researcher(Full-Time), Research Institute for Microbial Deseases, Osaka University	Japan	Assistant Professor, Research Institute for Microbial Deseases, Osaka University	Japan	Assistant Professor, Research Institute for Microbial Deseases, Osaka University	Japan
2019.4.1- 2020.3.31	Specially Appointed Researcher(Full-Time), Research Institute for Microbial Deseases, Osaka University	Japan	Researcher, JSPS Postdoctoral Fellowships for Research	Japan	Researcher, JSPS Postdoctoral Fellowships for Research	Japan
2020.2.1- 2020.3.31	Technical Assistant, Research Institute for Microbial Deseases, Osaka University	Japan	N/A	N/A	N/A	N/A

## **Overseas Postdocs**

	Position before employed at	: WPI center	Next position after WP	I center	Position as of April 2	2020*	
Employment period	Position title, organization	Country where the organization is located	Position title, organization	Country where the organization is located	Position title, organization	Country where the organization is located	Nationality

2008.3.1- 2008.8.15	Research Institute for Microbial Diseases, Osaka University,Specially Appointed Researcher	Japan	Department of Microbiology, Yogi vemana University,Associate Professor	India	Department of Microbiology, Yogi vemana University,Associate Professor	India	India
2008.1.1- 2010.2.28	Graduate school of Medicine, Osaka University, Part-time Technical Staff	Japan	(Pohang University of Science and Technology: POSTECH),Research Assistant Professor	Korea	N/A	N/A	Korea
2008.8.1- 2010.7.15	Blood Research Institute, Blood Center of Wisconsin, Pre-doctoral Fellow	USA	St Jude Children's Research Hospital, (USA)Postdoctoral Fellow	USA	MAYO Clinic, Center for Immunology and Immune Therapies, Assistant Professor of Immunology	USA	China
2009.5.16- 2010.7.19	Become Japan Corporation,Principal Software Engineer	Japan	DeNA Co. Ltd., Engineers	Japan	N/A	N/A	USA
2008.3.1- 2010.8.30	Graduate School of Engineering, Osaka University, JSPS Postdoctoral Fellowship	Japan	Graduate School of Engineering, Osaka University, JSPS Postdoctoral Fellowship for Foreign Researcher	Japan	The Division of Electron Microscopic Research, Korea Basic Science Institute	Korea	Korea
2008.4.1- 2010.8.30	Graduate School of Medicine Osaka University, Part-time Technical Staff	Japan	RIKEN, Postdoctoral Researcher	Japan	DAIKIN INDUSTRIES, Ltd.	Japan	Korea
2009.11.1- 2010.9.30	Graduate School of Frontier Biosciences, Osaka University, JSPS Postdoctoral Fellowship for Foreign Researchers	Japan	Immunology Frontier Research Center, Osaka University,Specially Appointed Assistant Professor (Full-time)	Japan	N/A	N/A	UK
2008.11.1- 2011.3.31	National Institute of Public Health, Researcher	Korea	Childbirth		Dong-Eui University, Department of Life Science and Biotechnology	Korea	Korea
2008.4.1- 2011.3.31	Graduate School of Medicine, Osaka University, Graduate Student	Japan	Immunology Frontier Research Center, Osaka University,Specially Appointed Assistant Professor (Full-time), (Japan)	Japan	Key Laboratory of Pu-erh Tea Science, Ministry of Education, Yunnan Agricultural University	China	China
2008.4.1- 2011.3.31	Research Institute for Microbial Diseases, Osaka University,JST Researcher	Japan	Immunology Frontier Research Center, Osaka University, Specially Appointed Assistant Professor (Full-time), (Japan)	Japan	PSI CRO AG, Clinical Research Associate	Swiss	UK
2010.6.16- 2011.3.31	University of Hyogo, JST researcher	Japan	Xiamen University, Research Fellow	China	N/A	N/A	China

2010.10.1- 2011.8.8	Graduate School of Computer Science and Systems Engineering, Kyushu Institute of Technology,Graduate Student	Japan	Department of Chemistry, University of Ottawa,Postdoctoral Research Fellow	USA	the Commonwealth Scientific and Industrial Research Organisation, Materials Science and Engineering, Post-Doc	Australia	Cuba
2010.8.16- 2011.9.30	Graduate School of Natural Science and Technology, Okayama University, Teaching Assistant	Japan	N/A	N/A	Associate Professor, Al Hussein Bin Talal University	Jordan	Jordan
2009.4.1- 2011.10.31	Laboratory of Allergy and clinical Immunology, Department of Life Science, (Pohang University of Science and Technology: POSTECH), Postdoctoral Fellow	Korea	(Pohang University of Science and Technology: POSTECH),Postdoctoral Research Fellow	Korea	Aeonmedix, Inc	Korea	Korea
2010.12.1- 2011.10.31	University of Ulsan, Postdoctoral Fellow	Korea	N/A	N/A	N/A	N/A	Korea
2009.5.16- 2011.11.15	Center for High Performance Computing, University of Utah,Visiting Fellow	USA	National Institute of Biological Resources (NIBR),Researcher	Korea	National Institute of Biological Resources (NIBR),Researcher	Korea	Korea
2008.10.1- 2012.3.31	The Institute of Medical Science, the University of Tokyo, Postdoctoral Fellow	Japan	Epidemiology and Public Health, Facultad de Medicina Veterinaria, Ibague Colombia, Universidad del Tolima, Assistant Professor	Columbia	RIKEN Center for Integrative Medical Sciences Laboratory for Cell Signaling, Research Associate	Japan	Columbia
2010.1.1- 2012.3.31	Department of Preventive Veterinary Medicine, Molecular Immunology and Pathogenic Microorganism, Jilin University,Graduate Student	China	Jilin University, Changchu,Associate Professor	China	Associate professor, National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University	China	China
2010.4.1- 2012.7.31	Research Institute for Microbial Diseases, Osaka University,Specially Appointed Researcher	Japan	N/A	N/A	H&R Block Australia, Tax Consultant	Australia	Sri Lanka
2009.10.1- 2012.7.31	The Institute of Medical Science, the University of Tokyo,Visiting Researcher	Japan	Immunology Frontier Research Center, Osaka University, Specially Appointed Assistant Professor (Full-time)	Japan	Lecturer, Institute for Frontier Life and Medical Sciences, Institute for Liberal Arts and Sciences, Kyoto University	Japan	Belgium
2011.9.1- 2012.9.15	Miller School of Medicine, Diabetes Research Institute,Postdoctoral Fellow	USA	Immunology Frontier Research Center, Osaka University,JSPS Postdoctoral Research Fellow for Foreign Researchers	Japan	N/A	N/A	Nigeria
2012.8.1- 2013.3.31	Guangzhou Institute of Advanced Technology, Chinese Academy of Sciences (GIAT), Principal Investigator	China	N/A	N/A	N/A	N/A	China
2009.4.1- 2013.3.31	Research Institute for Microbial Diseases, Osaka University,JST Postdoctoral Researcher	Japan	N/A	N/A	N/A	N/A	China
2009.4.1- 2013.3.31	Hanoi University of Science,Lecturer	Vietnam	Immunology Frontier Research Center, Osaka University, Specially Appointed Assistant Professor (Full-time)	Japan	Vietnam Academy of Science and Technology, Institute of Biotechnology, Deputy Director	Vietnam	Vietnam
2010.4.1- 2013.3.31	Platform Computing Beijing Branch, Senior 2nd-line Technical Support Engineer and Team leader	China	IBM Investment Company Limited, Technical Support Professional	China	N/A	N/A	China
2009.4.1- 2013.3.31	Department of Clinical Pharmacology, Niigata University of Pharmacy and Applied Life Sciences, Postdoctoral Fellow	Japan	Graduate School of Medicine, Osaka University, JSPS Postdoctoral Fellowship for Foreign Researchers	Japan	International Medical University, Department of Pharmaceutical Chemistry School of Pharmacy, Lecturer	Malaysia	India
2010.9.1- 2013.3.31	Max Planck Institute for Infection Biology, Department of Lymphocyte Development,Postdoctoral Fellow, (Germany)	Germany	Immunology Frontier Research Center, Osaka University, Specially Appointed Assistant Professor (Full-time)	Japan	Junior Research Group Leader, CharitéUniversity Medicine Berlin	Germany	Germany
2009.4.1- 2013.3.31	Institute of Pharmacology, Center of Biomedical Medicine and Pharmacology, Medical University of Vienna, Graduate Student	Austria	N/A	N/A	Safety Scientist, Otsuka Pharmaceutical	Japan	Austria
2011.9.1- 2013.6.30	College of Life Science, East China Normal University, Graduate Student	China	N/A	N/A	N/A	N/A	China
2010.8.16- 2013.8.15	Immunology Division, Indian Institute of Toxicology Research, Scientist	India	N/A	N/A	N/A	N/A	India
2010.3.1- 2013.8.15	Stem Cell and Development Biology, Genome Institute of Singapore, Pre-doctoral Fellow	Singapore	Guangzhou Institutes of Biomedicine and Health,Researcher	China	Southern University of Science and Technology,Regulatory Genomics and Human Disease Laboratory, Associate Professor	China	UK

2010.7.16- 2013.9.30	Centre of Biological Resources, Teaching Hospital of Nancy/INSERM U724, Cellular and Molecular Pathologies of Nutrition, School of Medicine, University Henri Poincare, Nancy,Research Assistant	France	RIKEN Center for Life Science Technologies, Researcher	Japan	The University of Tokyo, Institute of Industrial Science, Research Scientist	Japan	France
2012.7.1- 2013.11.15	Department of Chemistry, University of California, Irvine, Postdoctoral Researcher	USA	Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, JSPS Postdoctoral Fellowship for Foreign Researchers	Japan	Assistant Professor at Northwestern Polytechnical University	China	China
2010.7.1- 2013.12.31	Graduate School of Frontier Biosciences, Osaka University,Specially Appointed Researcher	Japan	N/A	N/A	Department of Immunology, Graduate School of Medicine, Osaka City University	Japan	China
2011.4.1- 2014.3.31	Applied Molecular Biology Lab, School of Life Science, Jawaharlal Nehru University,Graduate Student	India	Hokkaido University, Researcher	Japan	Chief Research Advisor, WERP	India	India
2010.4.1- 2014.3.31	Immunology Frontier Research Center, Osaka University,Temp staff (Technician)	Japan	N/A	N/A	Software engineer at Factset	Japan	France
2011.4.1- 2014.3.31	School of Life Sciences, Jawaharlal Nehru University	India	N/A	N/A	Chief Research Advisor, WERP	India	India
2010.4.1- 2014.3.31	Immunology Frontier Research Center, Osaka University, Temp staff (Technician)	Japan	N/A	N/A	Software engineer at Factset	Japan	France
2011.9.1- 2014.4.30	Kyushu University,JSPS Postdoctoral Research Fellow for Foreign Researchers	Japan	N/A	N/A	Associate Professor at Faculty of Science, Mahidol University	Thailand	Thailan
2008.2.1- 2014.5.15	N/A	N/A	Institute for Genetic Medicine, Hokkaido University, Postdoctoral fellow	Japan	N/A	N/A	China
2013.4.1- 2014.6.15	Graduate School of Medicine, Osaka University, Graduate Student	Japan	School of Medicine, University of Pennsylvania Postdoc researcher	USA	N/A	N/A	Korea
2013.1.1- 2014.9.30	Graduate School of Frontier Sciences, The University of Tokyo, Specially Appointed Researcher	Japan	Institute for Virus Research, Kyoto University, Specially Appointed Researcher	Japan	Bioinformatics Scientist, StemRIM, Inc. & COMIT Osaka University	Japan	Indones
2014.4.1- 2014.9.30	Graduate School of Medicine, Osaka University, Assistant Professor	Japan	Graduate School of Medicine, Division of Health Sciences, Osaka University, Assistant Professor	Japan	Graduate School of Medicine, Division of Health Sciences, Osaka University, Assistant Professor	Japan	Taiwar
2014.10.1- 2014.11.15	Immunology Frontier Research Center, Osaka University, JSPS Postdoctoral Research Fellow for Foreign Researchers	Japan	Dana Farber Cancer Institute, Harvard University Instructor/Research Fellow	USA	N/A	N/A	Nigeria
2011.1.1- 2014.12.31	Postdoctral fellow, Department of Dermatology, Seoul National University College of Medicine	Korea	Research Institute for Microbial Diseases, Osaka University,Specially Appointed Researcher	Japan	Research Institute for Microbial Diseases, Osaka University,Specially Appointed Assistant Professor	Japan	Korea
2011.4.16- 2015.1.15	Immunology Frontier Research Center, Osaka University, Research Fellow	Japan	Ewha Womans University Mokdong Hospital, Research Professor/Clinical Assistant Professor	Korea	N/A	N/A	Korea
2011.4.1- 2015.3.31	Postdoctoral Researcher, Department of Microbiology and Immunology National Cheng Kung University	Taiwan	Immunology Frontier Research Center, Osaka University,JSPS Postdoctoral Research Fellow for Foreign Researchers	Japan	Endowed Chair Associate Professor, Immunology Frontier Research Center, Osaka University	Japan	Taiwar
2012.1.16- 2015.3.31	Graduate School of Life and Environmental Sciences, University of Tsukuba, Graduate Student	Japan	Researcher, Riken	Japan	Researcher, Riken	Japan	Tunisia
2014.5.1- 2015.4.30	Research Institute for Microbial Diseases, Osaka University,Specially Appointed Researcher	Japan	Research Institute for Microbial Diseases, Osaka University,JSPS Postdoctoral Research Fellow for Foreign Researchers	Japan	Specially Appointed Researcher(Full-Time), Research Institute for Microbial Deseases, Osaka University	Japan	China
2014.12.16- 2015.7.31	Graduate student, University of Texas Medical Branch	USA	N/A	N/A	N/A	N/A	Taiwai
2015.2.1- 2015.7.31	Ph.D. Student, Middle East Technical University (METU)	Turkey	N/A	N/A	Postdoctoral fellow, Division of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Malm ö, Sweden.	Sweden	Turke
2015.4.1- 2015.10.31	Institute for Virus Research, Kyoto University, Technical Staff	Japan	LINE Fukuoka Software, Engineer	Japan	N/A	N/A	Swiss
2014.11.16- 2015.11.15	Immunology Frontier Research Center, Osaka University,JSPS Postdoctoral Research Fellow for Foreign Researchers	Japan	Novartis, Researcher	Slovenia	Lab Head Quality Control/Analytical science&technology, Bioanalytics at Lek Pharmaceuticals d.d.	Slovenia	Sloveni
2013.1.16- 2015.12.31	n/a		Institute for Virus Research, Kyoto University, Specially Appointed Assistant Professor	Japan	Assistant Professor, Research Institute for Microbial Deseases, Osaka University	Japan	China

	Graduate School of Biomedical						
2015.4.1- 2015.12.31	Science, Tokyo Medical and Dental University, Graduate Student	Japan	National Institutes of Health Postdoctoral, fellow	USA	N/A	N/A	Egypt
2012.7.1- 2016.6.30	Research Associate,Division of Bacteriology, National Institute of Cholera and Enteric Diseases	India	University of Washington School of Medicine、Postdoctoral researcher	USA	Boston Children's Hospital, Postdoctral Research Fellow	USA	India
2014.9.1- 2016.6.30	Cancer Biology and Inflammatory Disorder Division, Indian Institute of Chemical Biology	India	TATA MEDICAL CENTER、PI	India	TATA MEDICAL CENTER、 PI	India	India
2014.4.1- 2016.9.30	Researcher, Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation	Japan	N/A	N/A	Kyoto University, Student	Japan	China
2012.11.1- 2016.10.31	Research Associate, DNA Fingerpringing Unit, National Bureau of Animal Genetic Resources	India	N/A	N/A	N/A	N/A	India
2016.6.1- 2016.10.31	Lecturer of Clinical and Chemical Pathology/Faculty of Medicine, Fayoum University	Egypt	N/A	N/A	N/A	N/A	Egypt
2015.4.16- 2016.11.30	Research Associate/Department of Brain Behaviour and Mental Health, Neuroscience and Psychiatry Unit, School of Health Sciences, University of Manchester	UK	Elekta Limited、Senior Physicist- MR	UK	N/A	N/A	Australia/L K
2014.4.1- 2017.3.15	Specially Appointed Researcher, Immunology Frontier Research Center, Osaka University	Japan	N/A	N/A	School of Medicine, Cardiff University, Research Associate	UK	UK
2014.4.1- 2017.3.31	PhD student, Graduate School of Comprehensive Human Sciences, University of Tsukuba/Tsukuba Branch, RIKEN	Japan	Washington University、 Research Associate	USA	Washington University、 Research Associate	USA	Bangladesł
2014.10.1- 2017.3.31	Attending physician, Rheumatoid Immune Medicine,Department of Rheumatology, First Hospital of Jilin University, Jilin Province	China	Attending physician, Rheumatoid Immune Medicine,Department of Rheumatology, First Hospital of Jilin University	China	N/A	N/A	China
2015.10.1- 2017.3.31	Researcher, JSPS Postdoctoral Fellowships for Research in Japan/Immunology Frontier Research Center, Osaka University	Japan	Researcher, JSPS Postdoctoral Fellowships for Research in Japan	Japan	Specially Appointed Researcher(full-time), Immunology Frontier Research Center, Osaka University	Japan	Australia
2015.4.1- 2017.3.31	PhD Student, Universitat Pompeu Fabra, Barcelona	Spain	LPM, Formation as Psychotherapist	Germany	LPM, Formation as Psychotherapist	Germany	Germany/J pan
2013.9.1- 2017.3.31	Tutor/Postdoc, Department of Physics and Astronomy, University of Canterbury	New Zealand	Karolinska Institutet、 Bioinfomatician	Sweden	Scania, Data Scientist	Sweden	Germany
2013.10.1- 2017.7.15	Ph.D Student, Doctoral Course in Genetics, Faculty of Biotechnology, University of Ljubljana	Slovania	LEK d.d、Researcher	Slovania	N/A	N/A	Slovania
2015.10.16- 2017.10.15	Ph. D. student, John Curtin School of Medical Research, Immunology Department, Australian National University	Australia	N/A	N/A	N/A	N/A	Australia
2017.11.1- 2018.2.28	N/A	N/A	N/A	N/A	N/A	N/A	Russia
2017.5.1- 2018.6.30	Researcher, JSPS Postdoctoral Fellowships for Research in Japan	Japan	N/A	N/A	Chemtastic (A science education promotoin firm), Representative	Australia	Australia
2014.12.1- 2019.4.8	Specially Appointed Researcher(Full-Time), Immunology Frontier Research Center, Osaka University	Japan	N/A	N/A	N/A	N/A	China
2014.5.1- 2019.4.30	Specially Appointed Researcher(Full-Time), Research Institute for Microbial Deseases, Osaka University	Japan	Specially Appointed Researcher(Full-Time), Research Institute for Microbial Deseases, Osaka University	Japan	Specially Appointed Researcher(full-time), Immunology Frontier Research Center, Osaka University	Japan	China
2016.4.1- 2019.10.31	PhD Student, Autoimmunity and Immune Regulation, Department of Clinical and Experimental Medicine, Linköping University	Sweden	City of Hope、Researcher	USA	Immunology Frontier Research Center, Osaka University, Researcher	Japan	Nepal
2019.4.16- 2020.3.31	University of Lübeck, Germany, Department for Psychiatry and Psychosomatics Resident Physician	Germany	University of Hamburg、 Physician	Germany	University of Hamburg、 Physician	Germany	Germany

Osaka University - 1

Immunology Frontier Research Center

	nditures FY2016	Operational subsidies to National Un	iniversity Corporations/Incorporated Administrative Agency	Euodi	ng by WPI Academy	Government Subsidio	sexcept Funding from WPI Academy		Donations		Indirect funding		int research projects		Competitive funding		(Th Others
	Amount Details		Details (no. of persons)	Total costs	Details	Total costs	Details	Total costs	Details	Total costs	Details	Total costs	Details	Total costs	Details	Total costs	Dthers
Personnel	<ul> <li>Operational subsidies to National University Corporations/Incorporated Administrative Agency</li> </ul>				Dotailo		Center director	1	Dotails		Dotailo		Dotailo		Dotails		
	- Funding by WPI Academy						Administrative director	1									
	701,963 Government Subsidies except Funding from WPI Academy	-	(	0 -			Principal investigator	9 -		0 -		0 -		0 -		0 -	
	- Donations						•Full-time/Japanese	6									
	- Indirect funding						Concurrent / Japanese	2									
	<ul> <li>Joint research projects</li> <li>Competitive funding</li> </ul>						•Full-time / Overseas     •Concurrent / Overseas	1									
	- Others	-	(	0 -			Other researchers 32	2 -		0 -		0 -		0 -		0 -	
						226,647	Associate professor     Assistant professor     32	2									
							•Others										
						92,394	Postdocs 68	3									
							Research support staffs 58	В									
							Administrative staffs	6									
Subtotal	701,963 16,506 Operational subsidies to National University Corporations/Incorporated Administrative Agency	- 16,506	(			0 701,963	175 Cost of consumables	-		0 - 2,010		- 0		- 0		- 0	
Project activities	Funding by WPI Academy	10,500					Cost of utilities			2,010							
	440,623 Government Subsidies except Funding from WPI Academy						Other costs										
	- Donations																
	2,010 Indirect funding																
	- Joint research projects																
	- Competitive funding																
	- Others																
Subtotal	459,139	16,506		-		440,623		-		2,010		-		-		-	
Travel	Operational subsidies to National University Corporations/Incorporated Administrative Agency					1,842	Domestic travel costs										
	- Funding by WPI Academy						Overseas travel costs										
	7,018 Government Subsidies except Funding from WPI Academy					1,066	Travel cost for scientists on secondment										
	- Donations																
	- Indirect funding																
	- Joint research projects - Competitive funding																
	- Others																
	- Others																
Subtotal	7,018	-		-		7,018		-		-		-		-		-	
Equipment	<ul> <li>Operational subsidies to National University Corporations/Incorporated Administrative Agency</li> </ul>					15,984	C1 Single-Cell Auto Prep system										
	- Funding by WPI Academy					9,374	Seahorse XFp Analyzer										
	69,380 Government Subsidies except Funding from WPI Academy						405nm laser kit										
	- Donations						Amersham Imager 600 UV system										
	- Indirect funding						GloMax Discover System										
	- Joint research projects					26,947	Others										
	Competitive funding     Others																
	- Others																
Subtotal	69,380	-		-		69,380		-		-		-		-		-	
Research projects	<ul> <li>Operational subsidies to National University Corporations/Incorporated Administrative Agency</li> </ul>							197,758				62,868		317,841	Grants-in-Aid for Scientific Research, etc.	44,239	
	- Funding by WPI Academy													214,551	Commissioned research projects, etc.		
	- Government Subsidies except Funding from WPI Academy																
	197,758 Donations																
	- Indirect funding																
	62,868 Joint research projects																
	532,392 Competitive funding 44,239 Others																
Subtotal	837,257	-		-		-		197,758		-		62,868		532,392		44,239	
Others	45,331 Operational subsidies to National University Corporations/Incorporated Administrative Agency	45,331	Debt repayment			5,574	Labor insurance fee	-		101,356	Debt repayment						Debt repaymen
	- Funding by WPI Academy																
	5,574 Government Subsidies except Funding from WPI Academy																
	- Donations																
	101,356 Indirect funding																
	- Joint research projects																
	Competitive funding 12,585 Others																
Subtotal	164,846	45,331				5,574		-		101,356		-		-		12,585	
Total	2,239,603	61,837		-		1,224,558		197,758		103,366		62,868		532,392		56,824	
		5.,507			1	., 1,000		,			i	02,000	1	302/072		00,021	

## Project Expenditures EV2014

Operational subsidies to National University Corporations/Incorporated Administrative Agency	運営費交付金
Funding by WPI Academy	WPIアカデミー国際頭脳循環の加速・拡大事業
Government Subsidies except Funding from WPI Academy	機関補助金(WPIアカデミー国際頭脳循環の加速・拡大事業を除く
Donations	寄付金
Indirect funding	間接経費
Joint research projects	共同研究費
Competitive funding	競争的資金
Others	その他

Thousand	yens)
Details	
	0
	0
	0
nent	

Note     Under team     Under team   <	Project Expe	nditures F	Y2017																(TI
And       A		Amount	Details									-						Tatal seats	Others
Image: problem       Image	Personnel	1.440	Operational subsidies to National University Corporations/Incorporated Administrative Agency		·	I OTAL COSTS	Details	I OTAI COSTS	Details		Details	I OTAL COSTS	Details	I OTAL COSTS	Details	I OTAI COSTS	Details	I OTAL COSTS	<u> </u>
No.       N				.,				10,043	Administrative director	1				4,980	Administrative director				1
Image: Participant sector s		45,621	Government Subsidies except Funding from WPI Academy	-	0	-		0 -		0 -		0 -	0	39,491	Principal investigator	7 -		0 -	
Act       A																4			1
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			-											2,048		3			1
Arr																D			1
Mark				-	0	-		0 -		0 -		0 -	C	150,423		4 -		0 -	
Appendix														150,423	/Assistant professor	4			1
Matrix						0.0/5								50 707		0			<b> </b>
Note         No						2,265	Postdocs	2	Research support staffs	4						9			1
MM       MO       MO </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>6</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>8</td> <td></td> <td></td> <td>1</td>										6						8			1
1.000       1.0000       1.000 <t< td=""><td>Subtotal</td><td>486,416</td><td></td><td>1,440</td><td>1</td><td>2,265</td><td></td><td></td><td></td><td>- 11</td><td></td><td>0 -</td><td>C</td><td></td><td>15</td><td>8 -</td><td></td><td>0 -</td><td></td></t<>	Subtotal	486,416		1,440	1	2,265				- 11		0 -	C		15	8 -		0 -	
Note:       Note: <td< td=""><td>Project activities</td><td></td><td></td><td>24,556</td><td></td><td>22,623</td><td></td><td>240</td><td></td><td></td><td></td><td>65,514</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	Project activities			24,556		22,623		240				65,514							
101000       10100       1010																			1
$ \frac{1}{12} $														168,278	Other costs				1
1.100       1.0000       1.0000       <																			1
Add       A																			1
Link       3.60       100       3.00		-	Competitive funding																1
Fod		-	Others																1
Open																			1
Open																			1
Mail																			1
Mail																			1
Type         And and the standard and and and and and and and and and an																			
9.00       100		384,421		24,556			<b>*</b>			-		65,514				-		-	
$ \begin{bmatrix} 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1$	Travel	- 4 540																	1
Name       Nam       Name       Name						3,900	Overseas traver costs	4,061	Overseas traver costs										1
Mathematical problem       Mathematical problem <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td></t<>																			1
SAME       umplex warp       umplex warp       umplex       umple		-	Indirect funding																1
Accord         Accord<																			1
2.000 $1.000$ $1.0000$ $1.0000$ $1.0000$ <td></td> <td>1</td>																			1
All Cell       All Call Call Call Call Call Call Call C		-	Others																1
WHW																			1
Summ       Funding Vold Register		13,012		-		4,549		4,139		-		-				-		-	<b>_</b>
About       About: Maximum and Maximum and Maximum       About Maximum and Maximum       About Maximum and Maximum       About Maximum       Ab	Equipment	-																	1
Landed       Unicode Distribution Distribut																			1
Image: alree houring in the starting weights in the start weights in the																			1
Later         Computer         Computer <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td></t<>																			1
Satural       Integration		185,723	Joint research projects																1
Same																			1
Rescards projects       and answersensensensensensensensensensensensensens		-	Others																1
Light of projects       and approprint       and approprint       and approprint       and approprint       and approprint       and approprint       appropri																			1
Rescripting/site       Image in the interview and measurements in the interview and measurement interview and measurement interview and	Subtotal	185,723		-		-		-		-		-		185,723		-		-	
Subtrol       Operative control       Approx       Subtrol       Subtro       Subtro       Subtrol		-	Operational subsidies to National University Corporations/Incorporated Administrative Agency				1			244,747						322,918	Grants-in-Aid for Scientific Research, etc	3,337	ſ
244,77       Journal during indirect during 3,337       Indirect during indirect during 3,337       Indirect during indirect during 3,337       Indirect during indirect during indirect during by WP Addemy indirect during by Addemy indirect																187,022	Commissioned research projects, etc.		1
Image: space of the space																			1
1/14.06       Joint research projects       Subtrained       Subtraine       Subtraine       Subtr																			1
509.940       Competitive funding 9 (chrs       Competitive fu			_																1
3.37       Others       Image: Subtral in 100 pp VMP / Academy (Simple Subtra																			1
Others       20,545       Normal addition that the latence layers       20,545       Debl repayment       35,155       Consumption tax         1,067       Funding by WPI Academy - Covernment Subsidies except Funding from WPI Academy - Donations       Subtraine																			1
Others       20,545       Neuroscience interactive (spressed																			1
Others       20,545       Neuroscience interactive (spressed	Cubatal	000,400								244 747				74.440		500.040		0.007	1
10.67       Funding by WPI Academy         Coverment Subsidies scorept Funding from WPI Academy         Docations         42.220         Indirect funding         Observert         Observert <t< td=""><td></td><td></td><td>Operational subsidies to National University Corporations/Incorporated Administrative Agency</td><td>- 20 545</td><td>Deht renavment</td><td>- 1 067</td><td>Consumption tay</td><td>-</td><td></td><td>244,/4/</td><td></td><td>-</td><td>Deht renavment</td><td></td><td></td><td>509,940</td><td></td><td>3,337</td><td><u> </u></td></t<>			Operational subsidies to National University Corporations/Incorporated Administrative Agency	- 20 545	Deht renavment	- 1 067	Consumption tay	-		244,/4/		-	Deht renavment			509,940		3,337	<u> </u>
Subtola       10.89       0.0410mg       20.545       1.067	Guidia			20,040	Sourrepayment	1,007	σοισαπριιστιταλ					42,220	2000 ropayment						1
Subtol       101.699       20.545       10.677				1										_,,					1
33,067       Joint research projects       Competitive funding         Others       Others             Subtotal       101.89             101.89       20.545             101.89       20.545		-	Donations																1
Subtolal       101.899       101.899       20.545       1.067		42,220	Indirect funding																1
Subtotal     101,899     20,545     1,067     42,220     38,067     -																			1
Subtotal 101,899 20,545 - 42,220 -																			1
Subtotal         101,899         20,545         1,067         6         6         42,220         38,667         509,940         6         6         33,337           Total         2,003,963         46,541         30,504         50,000         244,747         107,734         1,011,60         509,940         3,337		-	outors																1
Subtoal       101,899       20,545       20,545       1,067       46,541       1,067       46,541       50,900																			1
Total       2,003,963       1,011,160       509,940       3,337						1,067		-		-						-		-	1
	Total	2,003,963		46,541		30,504		50,000		244,747		107,734		1,011,160		509,940		3,337	

## Draiaat Evpandituras EV2017

Operational subsidies to National University Corporations/Incorporated Administrative Agency	運営費交付金
Funding by WPI Academy	WPIアカデミー国際頭脳循環の加速・拡大事業
Government Subsidies except Funding from WPI Academy	機関補助金(WPIアカデミー国際頭脳循環の加速・拡大事業を除く
Donations	寄付金
Indirect funding	間接経費
Joint research projects	共同研究費
Competitive funding	競争的資金
Others	その他

Thousand	yens)
Details	
Details	
	0
	0
	0

Personnel	Amount     Details       18,134     Operational subsidies to National University Corporations/Incorporated Administrative Agency       14,037     Funding by WPI Academy       41,975     Government Subsidies except Funding from WPI Academy       Donations	Operational subsidies to National University Corporations/Incorpora           Total costs         Details (no. of 18,134           Center director         18,134	of persons) Total costs	ing by WPI Academy Details	Government Subsidie Total costs	s except Funding from WPI Academy Details	Total costs	Donations Details	Total costs	Indirect funding Details	Total costs	pint research projects Details	Total costs	Competitive funding Details	Total costs	Others [
Personnel	14,037         Funding by WPI Academy           41,975         Government Subsidies except Funding from WPI Academy					Details		Details	Total Costs	Details		Details		Details		L
	14,037         Funding by WPI Academy           41,975         Government Subsidies except Funding from WPI Academy															
											15,282	Administrative director 1				
	- Donations	-	0 -		0 -		0 -		0 -			Principal investigator 7	-		0 -	
	Indirect funding										38,194					
	- Indirect funding 482,740 Joint research projects										2,005	·Concurrent/Japanese 3     ·Full-time/Overseas ()				
	- Competitive funding											•Concurrent/Overseas	)			
	- Others	-	0 -		0 -		0 -		0 -		0 168,818	Other researchers 25	-		0 -	
۹ I											168,818	Associate professor 25     /Assistant professor 25				
1	-		14.027	Postdocs	2						47.210	•Others	)			
			14,037	POSIDOCS	2 31.609	Research support staffs	5					Postdocs63Research support staffs40				
						Administrative staffs	2					Administrative staffs 18	8			
Subtotal	556,886	18,134	1 14,037	•	2 41,975		7 -		0 -	(	0 482,740		-		0 -	
Project activities	46,718 Operational subsidies to National University Corporations/Incorporated Administrative Agency	46,718	10,888		1,156				130,946			Cost of consumables				
	10,888 Funding by WPI Academy											Cost of utilities				
	1,156 Government Subsidies except Funding from WPI Academy - Donations										165,651	Other costs				
	130,946 Indirect funding															
	322,932 Joint research projects															
	- Competitive funding															
	- Others															
Subtotal	512,640	46,718	10,888		1,156	Domostia traval ageta	-		130,946		322,932		-		-	
Travel	Operational subsidies to National University Corporations/Incorporated Administrative Agency     5,301 Funding by WPI Academy			Domestic travel costs Overseas travel costs		Domestic travel costs Overseas travel costs					2,760	Travel cost for scientists on secondment				
	1,869 Government Subsidies except Funding from WPI Academy		5,017		1,023											
	- Donations															
	- Indirect funding															
	2,760 Joint research projects															
	- Competitive funding															
	- Others															
Subtotal	9,930	-	5,301		1,869		-		-		2,760		-		-	
Equipment	Operational subsidies to National University Corporations/Incorporated Administrative Agency											Mass spectrometry system				
	- Funding by WPI Academy											Rhapsody Basic System				
	- Government Subsidies except Funding from WPI Academy											Attune Nxt Cytometer FLUOVIEW FV3000				
	- Donations - Indirect funding											nano UHPLC system				
	209,855 Joint research projects											Cell Sorter SH800SAP				
	- Competitive funding											Others				
	- Others															
Subtotal	209,855										209,855					
Research projects	Operational subsidies to National University Corporations/Incorporated Administrative Agency						233,648				184,748		274,662	Grants-in-Aid for Scientific Research, etc.	44,623	
	- Funding by WPI Academy													Commissioned research projects, etc.		
	- Government Subsidies except Funding from WPI Academy															
	233,648 Donations															
	- Indirect funding															
	184,748Joint research projects655,378Competitive funding															
	44,623 Others															
í L																
Subtotal	1,118,397	-	-		-		233,648		-		184,748		655,378		44,623	
Others	Operational subsidies to National University Corporations/Incorporated Administrative Agency I EO4 Eugending by WDL Accodomy		1,594	Consumption tax							38,606	Consumption tax				
1	1,594 Funding by WPI Academy - Government Subsidies except Funding from WPI Academy															
	- Donations															
1	- Indirect funding															
1	38,606 Joint research projects															
( L	- Competitive funding															
1	- Others															
۹ I																
۱		I		-					·							
Subtotal	40,200	-	1,594		-		-		-		38,606		-		-	

## Draiaat Evpandituras EV2010

Operational subsidies to National University Corporations/Incorporated Administrative Agency	運営費交付金
Funding by WPI Academy	WPIアカデミー国際頭脳循環の加速・拡大事業
Government Subsidies except Funding from WPI Academy	機関補助金(WPIアカデミー国際頭脳循環の加速・拡大事業を除く
Donations	寄付金
Indirect funding	間接経費
Joint research projects	共同研究費
Competitive funding	競争的資金
Others	その他

Thousand	yens)
Details	
Details	
	0
	0
	0

Project Expe	naitures F	12019														IT)
	Amount	Details	Operational subsidies to National University Corporations/Incorporated Administrative Agency           Total costs         Details (no. of persons)	Fund Total costs	ing by WPI Academy Details	Government Subsidie Total costs	es except Funding from WPI Academy Details	Total costs	Donations Details	Total costs	Indirect funding Details	Joint research projects Total costs Details	Total costs	Competitive funding Details	Total costs	Others [
Personnel	4.536	Operational subsidies to National University Corporations/Incorporated Administrative Agency	Total costs         Details (no. of persons)           4,536         Center director	Total costs	Details	Total costs	Details	Total costs	Details	Total costs	Details	2,471 Center director	Total costs	Details		L
		Funding by WPI Academy										3,875 Administrative director				1
		Government Subsidies except Funding from WPI Academy	- 0	-		0 -		0 -		0 -	(	0 61,238 Principal investigator 10	- )	C	) _	
		Donations										47,829 ·Full-time / Japanese	6			
		Indirect funding										2,271 •Concurrent/Japanese	2			1
		Joint research projects										11,138 ·Full-time / Overseas	2			1
		Competitive funding Others				0		0		0		•Concurrent∕Overseas O 185,767 Other researchers 8	7	0		
	_		- 0			-				-		122 205 ·Associate professor 20	)		-	
												133,273/Assistant professor2052,472•Others6	7			1
				14,216	Postdocs	2						61,886 Postdocs 14	1			
						33,424	Research support staffs	4				100,223 Research support staffs 36	5			1
												85,137 Administrative staffs 24	1			1
Subtotal	552,773		4,536 0	) 14,216	<b>.</b>	2 33,424		4 -		0 -	(	0 500,597 173	-	0	-	
Project activities		Operational subsidies to National University Corporations/Incorporated Administrative Agency Funding by WPI Academy	42,454	12,937		734				150,051		177,811 Cost of consumables 51,453 Cost of utilities				1
		Government Subsidies except Funding from WPI Academy										264,862 Other costs				1
		Donations														1
		Indirect funding														1
	494,126	Joint research projects														1
		Competitive funding														1
	-	Others														1
																1
	1															1
																1
																1
																1
Subtotal	700,302		42,454	12,937		734		-		150,051		494,126	-		-	,
Travel	-	Operational subsidies to National University Corporations/Incorporated Administrative Agency			Domestic travel costs		Domestic travel costs					3,232 Travel cost for scientists on secondment				1
		Funding by WPI Academy Government Subsidies except Funding from WPI Academy		2,140	Overseas travel costs	2,744	Overseas travel costs									1
		Donations														1
		Indirect funding														1
		Joint research projects														1
		Competitive funding														1
	-	Others														1
																1
																1
Subtotal	8,347	Operational subsidies to National University Corporations/Incorporated Administrative Agency		2,201		2,914		-		-		3,232 181,346 NovaSeq 6000	-		-	
Equipment	-	Funding by WPI Academy										39,209 Intermolecular interaction analysis system				1
		Government Subsidies except Funding from WPI Academy										2,236 ECFG21 Super Electro- Cell Fusion System				1
		Donations														1
	-	Indirect funding														1
		Joint research projects														1
		Competitive funding														1
	-	Others														1
	1															1
Subtotal	222,791			-		-		-		-		222,791	-		_	1
Research projects		Operational subsidies to National University Corporations/Incorporated Administrative Agency						256,131				182,471	208,387	Grants-in-Aid for Scientific Research, etc.	28,891	
	-	Funding by WPI Academy												Commissioned research projects, etc.		1
	-	Government Subsidies except Funding from WPI Academy														1
		Donations														1
		Indirect funding														1
		Joint research projects														1
	608,079 28,891	Competitive funding														1
	28,891															1
																1
Subtotal	1,075,572	l	-	-		-		256,131		-		182,471	608,079		28,891	L
Others	-	Operational subsidies to National University Corporations/Incorporated Administrative Agency	T	1,926	Consumption tax							39,233 Consumption tax				
		Funding by WPI Academy														1
		Government Subsidies except Funding from WPI Academy														1
		Donations														1
		Indirect funding														1
		Joint research projects Competitive funding														1
		Others														1
	-															1
																1
Subtotal	41,159		-	1,926		-		-		-		39,233	-		-	1
Total	2,600,944		46,990	31,280		37,072		256,131		150,051		1,442,450	608,079		28,891	·

## Project Expanditures EV2010

Operational subsidies to National University Corporations/Incorporated Administrative Agency	運営費交付金
Funding by WPI Academy	WPIアカデミー国際頭脳循環の加速・拡大事業
Government Subsidies except Funding from WPI Academy	機関補助金(WPIアカデミー国際頭脳循環の加速・拡大事業を除く
Donations	寄付金
Indirect funding	間接経費
Joint research projects	共同研究費
Competitive funding	競争的資金
Others	その他

Thousand	yens)
Details	
	0
	0
	0

### **Appendix 4 Outreach Activities and Their Results**

List up to three of the Center's outreach activities carried out during the period between FY 2017 and 2019 that have contributed to enhancing the brand or recognition of your Center and/or the brand of the overall WPI program, and describe its concrete contents and effect in narrative style. (Where possible, indicate the results in concrete numbers.)

#### Examples:

- As a result of using a new OO press-release method, a OO% increase in media coverage was obtained over the previous year.
- By holding seminars for the public that include people from industry, requests for joint research were received from companies.
   We changed our public relations media. As a resulting of using OO to disseminate information, a OO% increase in inquiries from researchers was obtained over the previous year.
- As a result of vigorously carrying out OO outreach activity, ¥OO in external funding was acquired.

Enter a list of your outreach activities in Attachment 4a.

# Outcome 1: 78 applications for Advanced Postdoc program (FY2017) $\rightarrow$ 166 applications (FY 2019), a 2.1-fold increase

The increase in the number of international applications for postdoc positions is solid evidence of the improved international visibility of IFReC. In addition to posting job recruitment ads on academic journal websites, we exhibited booths at influential international events, such as Nature Careers Live and the AAAS Annual Meeting, to attract outstanding young researchers from abroad through increased exposure to our complete research support system and our Advanced Postdoc system including our original support program for research budgets. In particular, we were able to respond to a wide range of questions from our visitors by staffing our booths with some of our researchers and members from our administrative office, who were able to introduce our latest research results and hold academic discussions as well as provide information on the procedures for residency in Japan and on living in Japan. These efforts have led to increases in the number of applicants for the Advanced Postdoc position and the number of Kishimoto Fellows. We saw a significant increase of 2.1 times in the number of applications for the Advanced Postdoc position, from 78 applications in FY2017 to 166 applications in FY2019. These international public relations activities have been effective not only for recruitment but also for the WPI and IFReC activities targeting international researchers and we will continue to conduct these activities in the next fiscal year.

## Outcome 2: Energizing the outreach events by gaining repeat visitors through regular outreach activities

In order to gain the continued support of the general public for IFReC's activities over the long term, we consider it important to increase the number of outreach events and to regularly

conduct outreach activities at the same venue, which were held only infrequently in the past. We increased the number of outreach events from 17 events in FY2017 to 34 events in FY2019. In particular, we increased the number of Science Cafés to 11 in FY2019. As a result, our Science Cafés attracted 540 visitors in FY2019. Furthermore, by regularly holding workshops at a large commercial complex, we increased the number of repeat visitors residing near IFReC and many of them quickly signed up and filled up the seats soon after an event was announced. Because of repeat visitors, our staff has started to recognize their faces and names and we have begun to receive much feedback on our outreach activities. Moreover, due to the active participation in our various outreach activities by the repeaters who have a strong interest in IFReC, we expect our exposure in the community to greatly increase.

## Outcome 3: Joint events with other departments and a WPI center to reach new outreach audiences

IFReC, together with other departments in Osaka University (Graduate Schools of Medicine and Science), exhibited a booth at AAAS 2020 in Seattle in FY2019 for the first time. This resulted in a significant increase in the number of applicants from North America for Osaka University's entrance examination for foreign students. IFReC and the Graduate School of Medicine jointly participated in "Science Agora 2018 & 2019" (300 visitors each) and jointly held the outreach event "Knowledge Capital Super School 2019" (total of 200 visitors in four sessions). Furthermore, IFReC and RIMD jointly participated in "Science Agora 2017" (200 visitors) and held the "Science Cafe" (total of 120 participants in two sessions). Moreover, the "Knowledge Capital WPI Series 2019" was jointly held with Kyoto University WPI-iCeMS (total of 150 participants in three sessions). Through these joint events, we were able to arouse interest in the community among those who would not otherwise be interested in IFReC alone.

### Appendix 4a State of Outreach Activities from FY2017 to FY2019

FY2017 FY2018 FY2019 Activities (number of activities, (number of activities, (number of activities, times held) times held) times held) PR brochure, pamphlet 3 3 3 Lectures, seminars for general 9 6 10 public Teaching, experiments, training for 2 elementary, secondary and high school 1 3 students 2 Science café 2 11 4 10 Participating, exhibiting in events 6 Press releases 12 18 11 Media appearances (Newspaper, 89 134 116 Netnews, SNS)

\* For each activity, enter the number of times that the activity was held each fiscal year.

\*If there are activities that the center hasn't implemented, delete those lines. If you have other activities, list them in the space between parentheses after "Others" and state the number of times they were held in the spaces on the right. Another line under "Others" can be added, if needed.

<Notes>

Osaka University - 1

Immunology Frontier Research Center

### **WPI Academy**

### Submittal of List of Center's Research Results

#### 1. Refereed Papers published from 2017 to 2019 (Free format)

List only the Center's refereed papers published during the period from 2017 to 2019. (Note: The list should be for the calendar year, not the fiscal year.)

#### A. WPI papers

No	Article
1	Maeda, Y; Takeda, K. Host-microbiota interactions in rheumatoid arthritis. Experimental and Molecular Medicine 51, 150 (2019).
2	Sasai, M; Yamamoto, M. Innate, adaptive, and cell-autonomous immunity against Toxoplasma gondii infection. Experimental and Molecular Medicine 51, 156 (2019).
3	Nyati, KK; Agarwal, RG; Sharma, P; Kishimoto, T. Arid5a Regulation and the Roles of Arid5a in the Inflammatory Response and Disease. Frontiers in Immunology 10, 2790 (2019).
4	Romanov, V; Isohashi, K; Alobthani, G; Beshr, R; Horitsugi, G; Kanai, Y; Naka, S; Watabe, T; Shimosegawa, E; Hatazawa, J. Evaluation of the total distribution volume of F-18-FBPA in normal tissues of healthy volunteers by non-compartmental kinetic modeling. Annals of Nuclear Medicine 34, 155-162 (2020).
5	Hochsmann, B; Murakami, Y; Osato, M; Knaus, A; Kawamoto, M; Inoue, N; Hirata, T; Murata, S; Anliker, M; Eggermann, T; Jager, M; Floettmann, R; Hollein, A; Murase, S; Ueda, Y; Nishimura, JI; Kanakura, Y; Kohara, N; Schrezenmeier, H; Krawitz, PM; Kinoshita, T. Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation. Journal of Clinical investigation 129, 5123-5136 (2019).
6	Leach, S; Shinnakasu, R; Adachi, Y; Momota, M; Makino-Okamura, C; Yamamoto, T; Ishii, KJ; Fukuyama, H; Takahashi, Y; Kurosaki, T. Requirement for memory B-cell activation in protection from heterologous influenza virus reinfection. International Immunology 31, 771-779 (2019).
7	Osada-Oka, M; Goda, N; Saiga, H; Yamamoto, M; Takeda, K; Ozeki, Y; Yamaguchi, T; Soga, T; Tateishi, Y; Miura, K; Okuzaki, D; Kobayashi, K; Matsumoto, S. Metabolic adaptation to glycolysis is a basic defense mechanism of macrophages for Mycobacterium tuberculosis infection. International Immunology 31, 781-793 (2019).
8	Endo, T; Mikedis, MM; Nicholls, PK; Page, DC; de Rooij, DG. Retinoic Acid and Germ Cell Development in the Ovary and Testis. Biomolecules 9, 775 (2019).
9	Fujimoto, K; Kawaguchi, Y; Shimohigoshi, M; Gotoh, Y; Nakano, Y; Usui, Y; Hayashi, T; Kimura, Y; Uematsu, M; Yamamoto, T; Akeda, Y; Rhee, JH; Yuki, Y; Ishii, KJ; Crowe, SE; Ernst, PB; Kiyono, H; Uematsu, S. Antigen-Specific Mucosal Immunity Regulates Development of Intestinal Bacteria-Mediated Diseases. Gastroenterology 157, 1530 (2019).
10	Hasegawa, T; Kikuta, J; Sudo, T; Matsuura, Y; Matsui, T; Simmons, S; Ebina, K; Hirao, M; Okuzaki, D; Yoshida, Y; Hirao, A; Kalinichenko, VV; Yamaoka, K; Takeuchi, T; Ishii, M. Identification of a novel arthritis- associated osteoclast precursor macrophage regulated by FoxM1. Nature Immunology 20, 1631 (2019).
11	Pavillon, N; Smith, NI. Immune cell type, cell activation, and single cell heterogeneity revealed by label-free optical methods. Scientific Reports 9, 17054 (2019).
12	Suematsu, R; Miyamoto, T; Saijo, S; Yamasaki, S; Tada, Y; Yoshida, H; Miyake, Y. Identification of lipophilic ligands of Siglec5 and-14 that modulate innate immune responses. Journal of Biological Chemistry 294, 16776-16788 (2019).
13	Gao, JC; Hori, Y; Shimomura, T; Bordy, M; Hasserodt, J; Kikuchi, K. Development of Fluorogenic Probes for Rapid High-Contrast Imaging of Transient Nuclear Localization of Sirtuin 3. Chembiochem, (2019).

14	Yamaguchi, T; Teraguchi, S; Furusawa, C; Machiyama, H; Watanabe, TM; Fujita, H; Sakaguchi, S; Yanagida, T. Theoretical modeling reveals that regulatory T cells increase T-cell interaction with antigen- presenting cells for stable immune tolerance. International Immunology 31, 743-753 (2019).
15	Leu, C; Stevelink, R; Smith, AW; Goleva, SB; Kanai, M; Ferguson, L; Campbell, C; Kamatani, Y; Okada, Y; Sisodiya, SM; Cavalleri, GL; Koeleman, BPC; Lerche, H; Jehi, L; Davis, LK; Najm, IM; Palotie, A; Daly, MJ; Busch, RM; Lal, D. Polygenic burden in focal and generalized epilepsies. Brain 142, 3473-3481 (2019).
16	Noguchi, E; Akiyama, M; Yagami, A; Hirota, T; Okada, Y; Kato, Z; Kishikawa, R; Fukutomi, Y; Hide, M; Morita, E; Aihara, M; Hiragun, M; Chinuki, Y; Okabe, T; Ito, A; Adachi, A; Fukunaga, A; Kubota, Y; Aoki, T; Aoki, Y; Nishioka, K; Adachi, T; Kanazawa, N; Miyazawa, H; Sakai, H; Kozuka, T; Kitamura, H; Hashizume, H; Kanegane, C; Masuda, K; Sugiyama, K; Tokuda, R; Furuta, J; Higashimoto, I; Kato, A; Seishima, M; Tajiri, A; Tomura, A; Taniguchi, H; Kojima, H; Tanaka, H; Sakai, A; Morii, W; Nakamura, M; Kamatani, Y; Takahashi, A; Kubo, M; Tamari, M; Saito, H; Matsunaga, K. HLA-DQ and RBFOX1 as susceptibility genes for an outbreak of hydrolyzed wheat allergy. Journal of Allergy and Clinical Immunology 144, 1354-1363 (2019).
17	Kumar, A; Kumar, H. Long noncoding RNA: TRIMming the viral load. Cellular & Molecular Immunology 16, 843-845 (2019).
18	Nakai, A; Suzuki, K. Adrenergic control of lymphocyte trafficking and adaptive immune responses. Neurochemistry international 130, 104320 (2019).
19	Mastellos, DC; Blom, AM; Connolly, ES; Daha, MR; Geisbrecht, BV; Ghebrehiwet, B; Gros, P; Hajishengallis, G; Holers, VM; Huber-Lang, M; Kinoshita, T; Mollnes, TE; Montgomery, RA; Morgan, BP; Nilsson, B; Pio, R; Ricklin, D; Risitano, AM; Taylor, RP; Mantovani, A; Ioannidis, JPA; Lambris, JD. 'Stealth' corporate innovation: an emerging threat for therapeutic drug development. Nature Immunology 20, 1409-1413 (2019).
20	Mizuno, A; Okada, Y. Biological characterization of expression quantitative trait loci (eQTLs) showing tissue- specific opposite directional effects. European Journal of Human Genetics 27, 1745-1756 (2019).
21	Clark, DW; Okada, Y; Moore, KHS; Mason, D; Pirastu, N; Gandin, I et al. Associations of autozygosity with a broad range of human phenotypes. Nature Communications 10, 4957 (2019).
22	Usui, R; Yabe, D; Fauzi, M; Goto, H; Botagarova, A; Tokumoto, S; Tatsuoka, H; Tahara, Y; Kobayashi, S; Manabe, T; Baba, Y; Kurosaki, T; Herrera, PL; Nagashima, K; Ogura, M; Nagashima, K; Inagaki, N. GPR40 activation initiates store-operated Ca2+ entry and potentiates insulin secretion via the IP3R1/STIM1/Orai1 pathway in pancreatic beta-cells. Scientific Reports 9, 15562 (2019).
23	Braganza, CD; Shibata, K; Fujiwara, A; Motozono, C; Sonoda, KH; Yamasaki, S; Stocker, BL; Timmer, MSM. The effect of MR1 ligand glyco-analogues on mucosal-associated invariant T (MAIT) cell activation. Organic & Biomolecular Chemistry 17, 8992-9000 (2019).
24	Motomura, Y; Kobayashi, T; Moro, K. The Neuropeptide CGRP Induces Bipolar Syndrome in Group 2 Innate Lymphoid Cells. Immunity 51, 598-600 (2019).
25	Herppich, S; Toker, A; Pietzsch, B; Kitagawa, Y; Ohkura, N; Miyao, T; Floess, S; Hori, S; Sakaguchi, S; Huehn, J. Dynamic Imprinting of the Treg Cell-Specific Epigenetic Signature in Developing Thymic Regulatory T Cells. Frontiers in Immunology 10, 2382 (2019).
26	Sakaue, S; Okada, Y. GREP: genome for REPositioning drugs. Bioinformatics 35, 3821-3823 (2019).
27	Cossarizza, A; Chang, HD; Radbruch, A; Acs, A; Adam, D; Adam-Klages, S et al Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology 49, 1457-1973 (2019).
28	Akamatsu, M; Mikami, N; Ohkura, N; Kawakami, R; Kitagawa, Y; Sugimoto, A; Hirota, K; Nakamura, N; Ujihara, S; Kurosaki, T; Hamaguchi, H; Harada, H; Xia, GL; Morita, Y; Aramori, I; Narumiya, S; Sakaguchi, S. Conversion of antigen-specific effector/memory T cells into Foxp3-expressing T-reg cells by inhibition of CDK8/19. Science Immunology 4, eaaw2707 (2019).
29	Hori, Y; Kikuchi, K. Chemical Tools with Fluorescence Switches for Verifying Epigenetic Modifications. Accounts of Chemical Research 52, 2849-2857 (2019).
30	Kawamura, Y; Nakaoka, H; Nakayama, A; Okada, Y; Yamamoto, K; Higashino, Tet al. Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout. Annals of the Rheumatic Diseases 78, 1430-1437 (2019).
31	Simmons, S; Sasaki, N; Umemoto, E; Uchida, Y; Fukuhara, S; Kitazawa, Y; Okudaira, M; Inoue, A; Tohya, K; Aoi, K; Aoki, J; Mochizuki, N; Matsuno, K; Takeda, K; Miyasaka, M; Ishii, M. High-endothelial cell-derived S1P regulates dendritic cell localization and vascular integrity in the lymph node. Elife 8, e41239 (2019).

32	Orimo, T; Sasaki, I; Hemmi, H; Ozasa, T; Fukuda-Ohta, Y; Ohta, T; Morinaka, M; Kitauchi, M; Yamaguchi, T; Sato, Y; Tanaka, T; Hoshino, K; Katayama, K; Fukuda, S; Miyake, K; Yamamoto, M; Satoh, T; Furukawa, K; Kuroda, E; Ishii, KJ; Takeda, K; Kaisho, T. Cholera toxin B induces interleukin-1 beta production from resident peritoneal macrophages through the pyrin inflammasome as well as the NLRP3 inflammasome. International Immunology 31, 657-668 (2019).
33	Imoto, T; Muramatsu, M; Miyasaka, H; Mizukami, S; Kikuchi, K. Improvement in Photostability of Fluorescein by Lanthanide Ions Based on Energy Transfer-based Triplet State Quenching. Chemistry Letters 48, 1181- 1184 (2019).
34	Akiyama, M; Ishigaki, K; Sakaue, S; Momozawa, Y; Horikoshi, M; Hirata, M; Matsuda, K; Ikegawa, S; Takahashi, A; Kanai, M; Suzuki, S; Matsui, D; Naito, M; Yamaji, T; Iwasaki, M; Sawada, N; Tanno, K; Sasaki M; Hozawa, A; Minegishi, N; Wakai, K; Tsugane, S; Shimizu, A; Yamamoto, M; Okada, Y; Murakami, Y; Kubo, M; Kamatani, Y. Characterizing rare and low-frequency height-associated variants in the Japanese population. Nature Communications 10, 4393 (2019).
35	Ozasa, K; Temizoz, B; Kusakabe, T; Kobari, S; Momota, M; Coban, C; Ito, S; Kobiyama, K; Kuroda, E; Ishii, KJ. Cyclic GMP-AMP Triggers Asthma in an IL-33-Dependent Manner That Is Blocked by Amlexanox, a TBK1 Inhibitor. Frontiers in Immunology 10, 2212 (2019).
36	Yamada, M; Fujita, Y; Hayano, Y; Hayakawa, H; Baba, K; Mochizuki, H; Yamashita, T. Increased Expression of Fibronectin Leucine-Rich Transmembrane Protein 3 in the Dorsal Root Ganglion Induces Neuropathic Pain in Rats. Journal of Neuroscience 39, 7615-7627 (2019).
37	Nakanishi, T; Fujita, Y; Tanaka, T; Yamashita, T. Anti-repulsive guidance molecule-a antibody treatment and repetitive transcranial magnetic stimulation have synergistic effects on motor recovery after spinal cord injury Neuroscience Letters 709, 134329 (2019).
38	Osa, A; Uenami, T; Naito, Y; Hirata, H; Koyama, S; Takimoto, T; Shiroyama, T; Futami, S; Nakatsubo, S; Sawa, N; Yano, Y; Nagatomo, I; Takeda, Y; Mori, M; Kida, H; Kumanogoh, A. Monitoring antibody binding to T cells in a pembrolizumab-treated patient with lung adenocarcinoma on hemodialysis. Thoracic Cancer 10, 2183-2187 (2019).
39	Maekawa, A; Arase, N; Tamai, K; Nomura, T; Kiyohara, E; Wataya-Kaneda, M; Arase, H; Katayama, I; Fujimoto, M. Case of epidermolytic ichthyosis with impairment of pulmonary function and exacerbated skin manifestations in a late middle-aged adult. Journal of Dermatology 46, e480-e482 (2019).
40	Lee, MSJ; Natsume-Kitatani, Y; Temizoz, B; Fujita, Y; Konishi, A; Matsuda, K; Igari, Y; Tsukui, T; Kobiyama, K; Kuroda, E; Onishi, M; Marichal, T; Ise, W; Inoue, T; Kurosaki, T; Mizuguchi, K; Akira, S; Ishii, KJ; Coban, C. B cell-intrinsic MyD88 signaling controls IFN-gamma-mediated early IgG2c class switching in mice in response to a particulate adjuvant. European Journal of Immunology 49, 1433-1440 (2019).
41	Nagatake, T; Hirata, S; Koga, T; Kuroda, E; Kobari, S; Suzuki, H; Hosomi, K; Matsumoto, N; Yanrismet, Y; Shimojou, M; Morimoto, S; Sasaki, F; Ishii, KJ; Yokomizo, T; Kunisawa, J. BLT1 mediates commensal bacteria-dependent innate immune signals to enhance antigen-specific intestinal IgA responses. Mucosal Immunology 12, 1082-1091 (2019).
42	Adachi, Y; Tonouchi, K; Nithichanon, A; Kuraoka, M; Watanabe, A; Shinnakasu, R; Asanuma, H; Ainai, A; Ohmi, Y; Yamamoto, T; Ishii, KJ; Hasegawa, H; Takeyama, H; Lertmemongkolchai, G; Kurosaki, T; Ato, M; Kelsoe, G; Takahashi, Y. Exposure of an occluded hemagglutinin epitope drives selection of a class of cross protective influenza antibodies. Nature Communications 10, 3883 (2019).
43	Hashimoto, S; Furukawa, S; Hashimoto, A; Tsutaho, A; Fukao, A; Sakamura, Y; Parajuli, G; Onodera, Y; Otsuka, Y; Handa, H; Oikawa, T; Hata, S; Nishikawa, Y; Mizukami, Y; Kodama, Y; Murakami, M; Fujiwara, T Hirano, S; Sabe, H. ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America 116, 17450-17459 (2019).
44	Takeuchi, Y; Hirota, K; Sakaguchi, S. Synovial Tissue Inflammation Mediated by Autoimmune T Cells. Frontiers in Immunology 10, 1989 (2019).
45	Hossain, MM; Tsuzuki, T; Sakakibara, K; Imaizumi, F; Ikegaya, A; Inagaki, M; Takahashi, I; Ito, T; Takamatsu, H; Kumanogoh, A; Negishi, T; Yukawa, K. PlexinA1 is crucial for the midline crossing of callosal axons during corpus callosum development in BALB/cAJ mice. Plos One 14, e0221440 (2019).
46	Sanjo, H; Nakayama, J; Yoshizawa, T; Fehling, HJ; Akira, S; Taki, S. Cutting Edge: TAK1 Safeguards Macrophages against Proinflammatory Cell Death. Journal of Immunology 203, 783-788 (2019).
47	Fujita, Y; Yamashita, T. The Effects of Leptin on Glial Cells in Neurological Diseases. Frontiers in Neuroscience 13, 828 (2019).

48	Ogawa, K; Okuno, T; Hosomichi, K; Hosokawa, A; Hirata, J; Suzuki, K; Sakaue, S; Kinoshita, M; Asano, Y; Miyamoto, K; Inoue, I; Kusunoki, S; Okada, Y; Mochizuki, H. Next-generation sequencing identifies contribution of both class I and II HLA genes on susceptibility of multiple sclerosis in Japanese. Journal of Neuroinflammation 16, 162 (2019).
49	Lu, YG; Oura, S; Matsumura, T; Oji, A; Sakurai, N; Fujihara, Y; Shimada, K; Miyata, H; Tobita, T; Noda, T; Castaneda, JM; Kiyozumi, D; Zhang, Q; Larasati, T; Young, SAM; Kodani, M; Huddleston, CA; Robertson, MJ; Coarfa, C; Isotani, A; Aitken, RJ; Okabe, M; Matzuk, MM; Garcia, TX; Ikawa, M. CRISPR/Cas9-mediated genome editing reveals 30 testis-enriched genes dispensable for male fertility in mice. Biology of Reproduction 101, 501-511 (2019).
50	Arase, N; Tanemura, A; Jin, H; Nishioka, M; Aoyama, Y; Oiso, N; Matsunaga, K; Suzuki, T; Nishigori, C; Kawamura, T; Shimizu, T; Ito, A; Fukai, K; Abe, Y; Yang, LL; Tsuruta, D; Takeoka, K; Iwatani, Y; Hidaka, Y; Nishida, M; Yamauchi-Takihara, K; Arase, H; Fujimoto, M; Katayama, I. Autoantibodies detected in patients with vitiligo vulgaris but not in those with rhododendrol-induced leukoderma. Journal of Dermatological Science 95, 80-83 (2019).
51	Schritt, D; Li, SL; Rozewicki, J; Katoh, K; Yamashita, K; Volkmuth, W; Cavet, G; Standley, DM. Repertoire Builder: high-throughput structural modeling of B and T cell receptors. Molecular Systems Design & Engineering 4, 761-768 (2019).
52	Xu, ZC; Li, SL; Rozewicki, J; Yamashita, K; Teraguchi, S; Inoue, T; Shinnakasu, R; Leach, S; Kurosaki, T; Standley, DM. Functional clustering of B cell receptors using sequence and structural features. Molecular Systems Design & Engineering 4, 769-778 (2019).
53	Nishida, S; Tsuboi, A; Tanemura, A; Ito, T; Nakajima, H; Shirakata, T; Morimoto, S; Fujiki, F; Hosen, N; Oji, Y; Kumanogoh, A; Kawase, I; Oka, Y; Azuma, I; Morita, S; Sugiyama, H. Immune adjuvant therapy using Bacillus Calmette-Guerin cell wall skeleton (BCG-CWS) in advanced malignancies A phase 1 study of safety and immunogenicity assessments. Medicine 98, e16771 (2019).
54	Spiliopoulou, A; Colombo, M; Plant, D; Nair, N; Cui, J; Coenen, MJH; Ikari, K; Yamanaka, H; Saevarsdottir, S; Padyukov, L; Bridges, SL; Kimberly, RP; Okada, Y; van Riel, PLCM; Wolbink, G; van der Horst-Bruinsma, IE; de Vries, N; Tak, PP; Ohmura, K; Canhao, H; Guchelaar, HJ; Huizinga, TWJ; Criswell, LA; Raychaudhuri, S; Weinblatt, ME; Wilson, AG; Mariette, X; Isaacs, JD; Morgan, AW; Pitzalis, C; Barton, A; McKeigue, P. Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39. Annals of the Rheumatic Diseases 78, 1055-1061 (2019).
55	Kumar, N; Hori, Y; Kikuchi, K. Photoactive yellow protein and its chemical probes: an approach to protein labelling in living cells. Journal of Biochemistry 166, 121-127 (2019).
56	Bando, H; Pradipta, A; Iwanaga, S; Okamoto, T; Okuzaki, D; Tanaka, S; Vega-Rodriguez, J; Lee, Y; Ma, JS; Sakaguchi, N; Soga, A; Fukumoto, S; Sasai, M; Matsuura, Y; Yuda, M; Jacobs-Lorena, M; Yamamoto, M. CXCR4 regulates Plasmodium development in mouse and human hepatocytes. Journal of Experimental Medicine 216, 1733-1748 (2019).
57	Canete, PF; Sweet, RA; Gonzalez-Figueroa, P; Papa, I; Ohkura, N; Bolton, H; Roco, JA; Cuenca, M; Bassett, KJ; Sayin, I; Barry, E; Lopez, A; Canaday, DH; Meyer-Hermann, M; Doglioni, C; de St Groth, BF; Sakaguchi, S; Cook, MC; Vinuesa, CG. Regulatory roles of IL-10-producing human follicular T cells. Journal of Experimental Medicine 216, 1843-1856 (2019).
58	Kashiyama, N; Miyagawa, S; Fukushima, S; Kawamura, T; Kawamura, A; Yoshida, S; Eiraku, S; Harada, A; Matsunaga, K; Watabe, T; Toda, K; Hatazawa, J; Sawa, Y. MHC-mismatched Allotransplantation of Induced Pluripotent Stem Cell-derived Cardiomyocyte Sheets to Improve Cardiac Function in a Primate Ischemic Cardiomyopathy Model. Transplantation 103, 1582-1590 (2019).
59	Knaus, A; Kortrum, F; Kleefstra, T; Stray-Pedersen, A; Dukic, D; Murakami, Y; Gerstner, T; van Bokhoven, H; Iqbal, Z; Horn, D; Kinoshita, T; Hempe, MA; Krawitz, PM. Mutations in PIGU Impair the Function of the GPI Transamidase Complex, Causing Severe Intellectual Disability, Epilepsy, and Brain Anomalies. American Journal of Human Genetics 105, 395-402 (2019).
60	Tanaka, A; Sakaguchi, S. Targeting Treg cells in cancer immunotherapy. European Journal of Immunology 49, 1140-1146 (2019).
61	Tsujioka, H; Yamashita, T. Comparison of gene expression profile of the spinal cord of sprouting-capable neonatal and sprouting-incapable adult mice. Bmc Genomics 20, 619 (2019).
62	Kitazume-Taneike, R; Taneike, M; Omiya, S; Misaka, T; Nishida, K; Yamaguchi, O; Akira, S; Shattock, MJ; Sakata, Y; Otsu, K. Ablation of Toll-like receptor 9 attenuates myocardial ischemia/reperfusion injury in mice. Biochemical and Biophysical Research Communications 515, 442-447 (2019).

63	Chalise, JP; Hashimoto, S; Parajuli, G; Kang, SJ; Singh, SK; Gemechu, Y; Metwally, H; Nyati, KK; Dubey, PK; Zaman, MMU; Nagahama, Y; Hamza, H; Masuda, K; Kishimoto, T. Feedback regulation of Arid5a and Ppar-gamma 2 maintains adipose tissue homeostasis. Proceedings of the National Academy of Sciences of the United States of America 116, 15128-15133 (2019).
64	Oh, JE; Iijima, N; Song, E; Lu, PW; Klein, J; Jiang, RY; Kleinstein, SH; Iwasaki, A. Migrant memory B cells secrete luminal antibody in the vagina. Nature 571, 122 (2019).
65	Rozewicki, J; Li, SL; Amada, KM; Standley, DM; Katoh, K. MAFFT-DASH: integrated protein sequence and structural alignment. Nucleic Acids Research 47, W5-W10 (2019).
66	Tsuji, T; Cheng, J; Tatematsu, T; Ebata, A; Kamikawa, H; Fujita, A; Gyobu, S; Segawa, K; Arai, H; Taguchi, T; Nagata, S; Fujimoto, T. Predominant localization of phosphatidylserine at the cytoplasmic leaflet of the ER, and its TMEM16K-dependent redistribution. Proceedings of the National Academy of Sciences of the United States of America 116, 13368-13373 (2019).
67	Lim, EL; Okkenhaug, K. Phosphoinositide 3-kinase delta is a regulatory T-cell target in cancer immunotherapy. Immunology 157, 210-218 (2019).
68	Fisch, D; Bando, H; Clough, B; Hornung, V; Yamamoto, M; Shenoy, AR; Frickel, EM. Human GBP1 is a microbe-specific gatekeeper of macrophage apoptosis and pyroptosis. Embo Journal 38, e100926 (2019).
69	Nakai, A; Fujimoto, J; Miyata, H; Stumm, R; Narazaki, M; Schulz, S; Baba, Y; Kumanogoh, A; Suzuki, K. The COMMD3/8 complex determines GRK6 specificity for chemoattractant receptors. Journal of Experimental Medicine 216, 1630-1647 (2019).
70	Minoshima, M; Kikuta, J; Omori, Y; Seno, S; Suehara, R; Maeda, H; Matsuda, H; Ishii, M; Kikuchi, K. In Vivo Multicolor Imaging with Fluorescent Probes Revealed the Dynamics and Function of Osteoclast Proton Pumps. Acs Central Science 5, 1059-1066 (2019).
71	van der Peet, PL; Gunawan, C; Watanabe, M; Yamasaki, S; Williams, SJ. Synthetic beta-1,2- Mannosyloxymannitol Glycolipid from the Fungus Malassezia pachydermatis Signals through Human Mincle. Journal of Organic Chemistry 84, 6788-6797 (2019).
72	Reja, SI; Minoshima, M; Hori, Y; Kikuchi, K. Development of an effective protein-labeling system based on smart fluorogenic probes. Journal of Biological inorganic Chemistry 24, 443-455 (2019).
73	Tobita, T; Kiyozumi, D; Muto, M; Noda, T; Ikawa, M. Lvrn expression is not critical for mouse placentation. Journal of Reproduction and Development 65, 239-244 (2019).
74	Argilaguet, J; Pedragosa, M; Esteve-Codina, A; Riera, G; Vidal, E; Peligero-Cruz, C; Casella, V; Andreu, D; Kaisho, T; Bocharov, G; Ludewig, B; Heath, S; Meyerhans, A. Systems analysis reveals complex biological processes during virus infection fate decisions. Genome Research 29, 907-919 (2019).
75	Aoki, M; Watabe, T; Nagamori, S; Naka, S; Ikeda, H; Kongpracha, P; Horitsugi, G; Kanai, Y; Shimosegawa, E; Kanai, Y; Hatazawa, J. Distribution of LAT1-targeting PET tracer was independent of the tumor blood flow in rat xenograft models of C6 glioma and MIA PaCa-2. Annals of Nuclear Medicine 33, 394-403 (2019).
76	Kayama, H; Tani, H; Kitada, S; Opasawatchai, A; Okumura, R; Motooka, D; Nakamura, S; Takeda, K. BATF2 prevents T-cell-mediated intestinal inflammation through regulation of the IL-23/IL-17 pathway. International Immunology 31, 371-383 (2019).
77	Ikumi, K; Odanaka, M; Shime, H; Imai, M; Osaga, S; Taguchi, O; Nishida, E; Hemmi, H; Kaisho, T; Morita, A; Yamazaki, S. Hyperglycemia Is Associated with Psoriatic Inflammation in Both Humans and Mice. Journal of investigative Dermatology 139, 1329 (2019).
78	Ogawa, K; Stuart, PE; Tsoi, LC; Suzuki, K; Nair, RP; Mochizuki, H; Elder, JT; Okada, Y. A Transethnic Mendelian Randomization Study Identifies Causality of Obesity on Risk of Psoriasis. Journal of Investigative Dermatology 139, 1397-1400 (2019).
79	Matsuo, T; Hashimoto, M; Sakaguchi, S; Sakaguchi, N; Ito, Y; Hikida, M; Tsuruyama, T; Sakai, K; Yokoi, H; Shirakashi, M; Tanaka, M; Ito, H; Yoshifuji, H; Ohmura, K; Fujii, T; Mimori, T. Strain-Specific Manifestation of Lupus-like Systemic Autoimmunity Caused by Zap70 Mutation. Journal of Immunology 202, 3161-3172 (2019).
80	Matoba, T; Imai, M; Ohkura, N; Kawakita, D; Ijichi, K; Toyama, T; Morita, A; Murakami, S; Sakaguchi, S; Yamazaki, S. Regulatory T cells expressing abundant CTLA-4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer. International Journal of Cancer 144, 2811-2822 (2019).
81	Schmidleithner, L; Thabet, Y; Schonfeld, E; Kohne, M; Sommer, D et al. Enzymatic Activity of HPGD in Treg Cells Suppresses Tconv Cells to Maintain Adipose Tissue Homeostasis and Prevent Metabolic Dysfunction. Immunity 50, 1232 (2019).

82	Kamada, T; Togashi, Y; Tay, C; Ha, D; Sasaki, A; Nakamura, Y; Sato, E; Fukuoka, S; Tada, Y; Tanaka, A; Morikawa, H; Kawazoe, A; Kinoshita, T; Shitara, K; Sakaguchi, S; Nishikawa, H. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proceedings of the National Academy of Sciences of the United States of America 116, 9999-10008 (2019).
83	Hamaguchi, M; Muramatsu, R; Fujimura, H; Mochizuki, H; Kataoka, H; Yamashita, T. Circulating transforming grow factor-beta 1 facilitates remyelination in the adult central nervous system. Elife 8, e41869 (2019).
84	Nishi, C; Yanagihashi, Y; Segawa, K; Nagata, S. MERTK tyrosine kinase receptor together with TIM4 phosphatidylserine receptor mediates distinct signal transduction pathways for efferocytosis and cell proliferation. Journal of Biological Chemistry 294, 7221-7230 (2019).
85	Kubagawa, H; Honjo, K; Ohkura, N; Sakaguchi, S; Radbruch, A; Melchers, F; Jani, PK. Functional Roles of the IgM Fc Receptor in the Immune System. Frontiers in Immunology 10, 945 (2019).
86	Amariuta, T; Luo, Y; Gazal, S; Davenport, EE; van de Geijn, B; Ishigaki, K; Westra, HJ; Teslovich, N; Okada, Y; Yamamoto, K; Price, AL; Raychaudhuri, S. IMPACT: Genomic Annotation of Cell-State-Specific Regulatory Elements Inferred from the Epigenome of Bound Transcription Factors. American Journal of Human Genetics 104, 879-895 (2019).
87	Shimizu, Y; Kohyama, M; Yorifuji, H; Jin, H; Arase, N; Suenaga, T; Arase, H. Fc gamma RIIIA-mediated activation of NK cells by IgG heavy chain complexed with MHC class II molecules. International Immunology 31, 303-314 (2019).
88	Nakatsukasa, H; Oda, M; Yin, J; Chikuma, S; Ito, M; Koga-Iizuka, M; Someya, K; Kitagawa, Y; Ohkura, N; Sakaguchi, S; Koya, I; Sanosaka, T; Kohyama, J; Tsukadar, Y; Yamanaka, S; Takamura-Enya, T; Lu, QJ; Yoshimura, A. Loss of TET proteins in regulatory T cells promotes abnormal proliferation, Foxp3 destabilization and IL-17 expression. International Immunology 31, 335-347 (2019).
89	Lelliott, PM; Momota, M; Lee, MSJ; Kuroda, E; Iijima, N; Ishii, KJ; Coban, C. Rapid Quantification of NETs In Vitro and in Whole Blood Samples by Imaging Flow Cytometry. Cytometry Part A 95A, 565-578 (2019).
90	Ishifune, C; Tsukumo, S; Maekawa, Y; Hozumi, K; Chung, DH; Motozono, C; Yamasaki, S; Nakano, H; Yasutomo, K. Regulation of membrane phospholipid asymmetry by Notch-mediated flippase expression controls the number of intraepithelial TCR(+)CD8(+) T cells. Plos Biology 17, e3000262 (2019).
91	Matoba, N; Akiyama, M; Ishigaki, K; Kanai, M; Takahashi, A; Momozawa, Y; Ikegawa, S; Ikeda, M; Iwata, N; Hirata, M; Matsuda, K; Kubo, M; Okada, Y; Kamatani, Y. GWAS of smoking behaviour in 165,436 Japanese people reveals seven new loci and shared genetic architecture. Nature Human Behaviour 3, 471-477 (2019).
92	Bando, H; Lee, Y; Sakaguchi, N; Pradipta, A; Sakamoto, R; Tanaka, S; Ma, JS; Sasai, M; Yamamoto, M. Toxoplasma Effector GRA15-Dependent Suppression of IFN-gamma-Induced Antiparasitic Response in Human Neurons. Frontiers in Cellular and infection Microbiology 9, 140 (2019).
93	Oh-hora, M; Lu, XY; Shiokawa, M; Takayanagi, H; Yamasaki, S. Stromal Interaction Molecule Deficiency in T Cells Promotes Spontaneous Follicular Helper T Cell Development and Causes Type 2 Immune Disorders. Journal of Immunology 202, 2616-2627 (2019).
94	Kang, SJ; Tanaka, T; Narazaki, M; Kishimoto, T. Targeting Interleukin-6 Signaling in Clinic. Immunity 50, 1007-1023 (2019).
95	Yorifuji, H; Arase, N; Kohyama, M; Hirano, T; Suenaga, T; Kumanogoh, A; Arase, H. Transport of cellular misfolded proteins to the cell surface by HLA-B27 free heavy chain. Biochemical and Biophysical Research Communications 511, 862-868 (2019).
96	Yamamoto, T; Kanuma, T; Takahama, S; Okamura, T; Moriishi, E; Ishii, KJ; Terahara, K; Yasutomi, Y. STING agonists activate latently infected cells and enhance SIV-specific responses ex vivo in naturally SIV controlled cynomolgus macaques. Scientific Reports 9, 5917 (2019).
97	DeVorkin, L; Pavey, N; Carleton, G; Comber, A; Ho, C; Lim, J; McNamara, E; Huang, HC; Kim, P; Zacharias, LG; Mizushima, N; Saitoh, T; Akira, S; Beckham, W; Lorzadeh, A; Moksa, M; Cao, Q; Murthy, A; Hirst, M; DeBerardinis, RJ; Lum, JJ. Autophagy Regulation of Metabolism Is Required for CD8(+) T Cell Anti-tumor Immunity. Cell Reports 27, 502 (2019).
98	Matsumura, T; Ikebe, T; Arikawa, K; Hosokawa, M; Aiko, M; Iguchi, A; Togashi, I; Kai, S; Ohara, S; Ohara, N; Ohnishi, M; Watanabe, H; Kobayashi, K; Takeyama, H; Yamasaki, S; Takahashi, Y; Ato, M. Sequential Sensing by TLR2 and Mincle Directs Immature Myeloid Cells to Protect against Invasive Group A Streptococcal Infection in Mice. Cell Reports 27, 561 (2019).

99	Nakatochi, M; Kanai, M; Nakayama, A; Hishida, A; Kawamura, Y; Ichihara, S; Akiyama, M; Ikezaki, H; Furusyo, N; Shimizu, S; Yamamoto, K; Hirata, M; Okada, R; Kawai, S; Kawaguchi, M; Nishida, Y; Shimanoe, C; Ibusuki, R; Takezaki, T; Nakajima, M; Takao, M; Ozaki, E; Matsui, D; Nishiyama, T; Suzuki, S; Takashima, N; Kita, Y; Endoh, K; Kuriki, K; Uemura, H; Arisawa, K; Oze, I; Matsuo, K; Nakamura, Y; Mikami, H; Tamura, T; Nakashima, H; Nakamura, T; Kato, N; Matsuda, K; Murakami, Y; Matsubara, T; Naito, M; Kubo, M; Kamatani, Y; Shinomiya, N; Yokota, M; Wakai, K; Okada, Y; Matsuo, H. Genome-wide meta-analysis identifies multiple novel loci associated with serum uric acid levels in Japanese individuals. Communications Biology 2, 115 (2019).
100	Akizuki, S; Ishigaki, K; Kochi, Y; Law, SM; Matsuo, K; Ohmura, K; Suzuki, A; Nakayama, M; Iizuka, Y; Koseki, H; Ohara, O; Hirata, J; Kamatani, Y; Matsuda, F; Sumida, T; Yamamoto, K; Okada, Y; Mimori, T; Terao, C. PLD4 is a genetic determinant to systemic lupus erythematosus and involved in murine autoimmune phenotypes. Annals of the Rheumatic Diseases 78, 509-518 (2019).
101	Molineros, JE; Looger, LL; Kim, K; Okada, Y; Terao, C; Sun, CL; Zhou, XJ; Raj, P; Kochi, Y; Suzuki, A; Akizuki, S; Nakabo, S; Bang, SY; Lee, HS; Kang, YM; Suh, CH; Chung, WT; Park, YB; Choe, JY; Shim, SC; Lee, SS; Zuo, XX; Yamamoto, K; Li, QZ; Shen, N; Porter, LL; Harley, JB; Chua, KH; Zhang, H; Wakeland, EK; Tsao, BP; Bae, SC; Nath, SK. Amino acid signatures of HLA Class-I and II molecules are strongly associated with SLE susceptibility and autoantibody production in Eastern Asians. Plos Genetics 15, e1008092 (2019).
102	Matsumura, T; Endo, T; Isotani, A; Ogawa, M; Ikawa, M. An azoospermic factor gene, Ddx3y and its paralog, Ddx3x are dispensable in germ cells for male fertility. Journal of Reproduction and Development 65, 121-128 (2019).
103	Hayashi, Y; Jia, WZ; Kidoya, H; Muramatsu, F; Tsukada, Y; Takakura, N. Galectin-3 Inhibits Cancer Metastasis by Negatively Regulating Integrin beta 3 Expression. American Journal of Pathology 189, 900- 910 (2019).
104	Matsuda, A; Asada, Y; Suita, N; Iwamoto, S; Hirakata, T; Yokoi, N; Ohkawa, Y; Okada, Y; Yokomizo, T; Ebihara, N. Transcriptome profiling of refractory atopic keratoconjunctivitis by RNA sequencing. Journal of Allergy and Clinical Immunology 143, 1610 (2019).
105	Maeda, Y; Tsuda, T; Takeda, Y; Koyama, S; Hayama, Y; Nojima, S; Kimura, T; Ito, D; Takamatsu, H; Kang, SJ; Nishide, M; Morimoto, K; Hosokawa, T; Kinehara, Y; Kato, Y; Nakatani, T; Takeda, K; Hayama, M; Obata, S; Akazawa, H; Shikina, T; Inohara, H; Kumanogoh, A. SEMA4A promotes eosinophil survival and contributes to eosinophil-mediated allergic diseases. Allergology International 68, 274-276 (2019).
106	Reinink, P; Buter, J; Mishra, VK; Ishikawa, E; Cheng, TY; Willemsen, PTJ; Porwollik, S; Brennan, PJ; Heinz, E; Mayfield, JA; Dougan, G; van Els, CA; Cerundolo, V; Napolitani, G; Yamasaki, S; Minnaard, AJ; McCeland, M; Moody, DB; Van Rhijn, I. Discovery of Salmonella trehalose phospholipids reveals functional convergence with mycobacteria. Journal of Experimental Medicine 216, 757-771 (2019).
107	Martin, AR; Kanai, M; Kamatani, Y; Okada, Y; Neale, BM; Daly, MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nature Genetics 51, 584-591 (2019).
108	Ikeda-Matsuo, Y; Miyata, H; Mizoguchi, T; Ohama, E; Naito, Y; Uematsu, S; Akira, S; Sasaki, Y; Tanabe, M. Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson's disease. Neurobiology of Disease 124, 81-92 (2019).
109	Wang, YC; Hirata, T; Maeda, Y; Murakami, Y; Fujita, M; Kinoshita, T. Free, unlinked glycosylphosphatidylinositols on mammalian cell surfaces revisited. Journal of Biological Chemistry 294, 5038-5049 (2019).
110	Hasegawa, T; Kikuta, J; Ishii, M. Imaging the Bone-Immune Cell Interaction in Bone Destruction. Frontiers in Immunology 10, 596 (2019).
111	Kayama, H; Takeda, K. Recasting the Tissue-Resident Lymphocyte in Celiac Disease. Immunity 50, 549-551 (2019).
112	Kidoya, H; Muramatsu, F; Shimamura, T; Jia, WZ; Satoh, T; Hayashi, Y; Naito, H; Kunisaki, Y; Arai, F; Seki, M; Suzuki, Y; Osawa, T; Akira, S; Takakura, N. Regnase-1-mediated post-transcriptional regulation is essential for hematopoietic stem and progenitor cell homeostasis. Nature Communications 10, 1072 (2019).
113	Fang, CY; Cai, XB; Hayashi, S; Hao, SM; Sakiyama, H; Wang, XJ; Yang, Q; Akira, S; Nishiguchi, S; Fujiwara, N; Tsutsui, H; Sheng, J. Caffeine-stimulated muscle IL-6 mediates alleviation of non-alcoholic fatty liver disease. Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids 1864, 271-280 (2019).
114	Mazaki, Y; Higashi, T; Onodera, Y; Nam, JM; Hashimoto, A; Hashimoto, S; Horinouchi, T; Miwa, S. Endothelin type B receptor interacts with the 78-kDa glucose-regulated protein. Febs Letters 593, 644-651 (2019).

115	Ise, W; Kurosaki, T. Plasma cell differentiation during the germinal center reaction. Immunological Reviews 288, 64-74 (2019).
116	Takeda, K; Sakakibara, S; Yamashita, K; Motooka, D; Nakamura, S; El Hussien, MA; Katayama, J; Maeda, Y; Nakata, M; Hamada, S; Standley, DM; Hayama, M; Shikina, T; Inohara, H; Kikutani, H. Allergic conversion of protective mucosal immunity against nasal bacteria in patients with chronic rhinosinusitis with nasal polyposis. Journal of Allergy and Clinical Immunology 143, 1163 (2019).
117	Svensson, MND; Doody, KM; Schmiedel, BJ; Bhattacharyya, S; Panwar, B; Wiede, F; Yang, S; Santelli, E; Wu, DJ; Sacchetti, C; Gujar, R; Seumois, G; Kiosses, WB; Aubry, I; Kim, G; Mydel, P; Sakaguchi, S; Kronenberg, M; Tiganis, T; Tremblay, ML; Ay, F; Vijayanand, P; Bottini, N. Reduced expression of phosphatase PTPN2 promotes pathogenic conversion of Tregs in autoimmunity. Journal of Clinical investigation 129, 1193-1210 (2019).
118	Suzuki, K; Akiyama, M; Ishigaki, K; Kanai, M; Hosoe, J; Shojima, N; Hozawa, A; Kadota, A; Kuriki, K; Naito, M; Tanno, K; Ishigaki, Y; Hirata, M; Matsuda, K; Iwata, N; Ikeda, M; Sawada, N; Yamaji, T; Iwasaki, M; Ikegawa, S; Maeda, S; Murakami, Y; Wakai, K; Tsugane, S; Sasaki, M; Yamamoto, M; Okada, Y; Kubo, M; Kamatani, Y; Horikoshi, M; Yamauchi, T; Kadowaki, T. Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population. Nature Genetics 51, 379 (2019).
119	Hirata, J; Hosomichi, K; Sakaue, S; Kanai, M; Nakaoka, H; Ishigaki, K; Suzukil, K; Akiyama, M; Kishikawa, T Ogawa, K; Masuda, T; Yamamoto, K; Hirata, M; Matsuda, K; Momozawa, Y; Inoue, I; Kubo, M; Kamatani, Y; Okada, Y. Genetic and phenotypic landscape of the major histocompatibility complex region in the Japanese population. Nature Genetics 51, 470 (2019).
120	Shiroyama, T; Nagatomo, I; Koyama, S; Hirata, H; Nishida, S; Miyake, K; Fukushima, K; Shirai, Y; Mitsui, Y; Takata, S; Masuhiro, K; Yaga, M; Iwahori, K; Takeda, Y; Kida, H; Kumanogoh, A. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. Scientific Reports 9, 2447 (2019).
121	Nonaka, H; Nakanishi, Y; Kuno, S; Ota, T; Mochidome, K; Saito, Y; Sugihara, F; Takakusagif, Y; Aoki, I; Nagatoishi, S; Tsum, K; Sando, S. Design strategy for serine hydroxymethyltransferase probes based on retro-aldol-type reaction. Nature Communications 10, 876 (2019).
122	Wing, JB; Tanaka, A; Sakaguchi, S. Human FOXP3(+) Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer. Immunity 50, 302-316 (2019).
123	Sakuragi, T; Kosako, H; Nagata, S. Phosphorylation-mediated activation of mouse Xkr8 scramblase for phosphatidylserine exposure. Proceedings of the National Academy of Sciences of the United States of America 116, 2907-2912 (2019).
124	Kishikawa, T; Momozawa, Y; Ozeki, T; Mushiroda, T; Inohara, H; Kamatani, Y; Kubo, M; Okada, Y. Empirica evaluation of variant calling accuracy using ultra-deep whole-genome sequencing data. Scientific Reports 9, 1784 (2019).
125	Morita, N; Umemoto, E; Fujita, S; Hayashi, A; Kikuta, J; Kimura, I; Haneda, T; Imai, T; Inoue, A; Mimuro, H; Maeda, Y; Kayama, H; Okumura, R; Aoki, J; Okada, N; Kida, T; Ishii, M; Nabeshima, R; Takeda, K. GPR31-dependent dendrite protrusion of intestinal CX3CR1(+) cells by bacterial metabolites. Nature 566, 110 (2019).
126	Kong, MS; Hashimoto-Tane, A; Kawashima, Y; Sakuma, M; Yokosuka, T; Kometani, K; Onishi, R; Carpino, N; Ohara, O; Kurosaki, T; Phua, KK; Saito, T. Inhibition of T cell activation and function by the adaptor protein CIN85. Science Signaling 12, eaav4373 (2019).
127	Kuwabara, R; Hamaguchi, M; Fukuda, T; Sakaguchi, S; Iwata, H. Preparation of Immunotolerant Space Under the Skin and Transplantation of Islets in the Space. Tissue Engineering Part A 25, 183-192 (2019).
128	Yamamoto, T; Masuta, Y; Momota, M; Kanekiyo, M; Kanuma, T; Takahama, S; Moriishi, E; Yasutomi, Y; Saito, T; Graham, BS; Takahashi, Y; Ishii, KJ. A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer Fc gamma R-mediated protection against heterologous lethal influenza virus infection. International Immunology 31, 81-90 (2019).
129	Tsuboi, A; Hashimoto, N; Fujiki, F; Morimoto, S; Kagawa, N; Nakajima, H; Hosen, N; Nishida, S; Nakata, J; Morita, S; Sakamoto, J; Oji, Y; Oka, Y; Sugiyama, H. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Cancer Immunology Immunotherapy 68, 331-340 (2019).
130	Tanabe, S; Yamashita, T. B lymphocytes: Crucial contributors to brain development and neurological diseases. Neuroscience Research 139, 37-41 (2019).
131	Stocker, BL; Kodar, K; Wahi, K; Foster, AJ; Harper, JL; Mori, D; Yamasaki, S; Timmer, MSM. The effects of trehalose glycolipid presentation on cytokine production by GM-CSF macrophages. Glycoconjugate Journal 36, 69-78 (2019).

132	Imanishi, T; Unno, M; Kobayashi, W; Yoneda, N; Matsuda, S; Ikeda, K; Hoshii, T; Hirao, A; Miyake, K; Barber, GN; Arita, M; Ishii, KJ; Akira, S; Saito, T. Reciprocal regulation of STING and TCR signaling by mTORC1 for T-cell activation and function. Life Science Alliance 2, e201800282 (2019).
133	Yasuda, K; Kitagawa, Y; Kawakami, R; Isaka, Y; Watanabe, H; Kondoh, G; Kohwi-Shigematsu, T; Sakaguchi, S; Hirota, K. Satb1 regulates the effector program of encephalitogenic tissue Th17 cells in chronic inflammation. Nature Communications 10, 549 (2019).
134	Briard, B; Karki, R; Malireddi, RKS; Bhattacharya, A; Place, DE; Mavuluri, J; Peters, JL; Vogel, P; Yamamoto, M; Kanneganti, TD. Fungal ligands released by innate immune effectors promote inflammasome activation during Aspergillus fumigatus infection. Nature Microbiology 4, 316-327 (2019).
135	Shishido, T; Kohyama, M; Nakai, W; Matsumoto, M; Miyata, H; Suenaga, T; Arase, H. Invariant chain p41 mediates production of soluble MHC class II molecules. Biochemical and Biophysical Research Communications 509, 216-221 (2019).
136	Noguchi, S; Honda, S; Saitoh, T; Matsumura, H; Nishimura, E; Akira, S; Shimizu, S. Beclin 1 regulates recycling endosome and is required for skin development in mice. Communications Biology 2, 37 (2019).
137	Nakanishi, T; Fujita, Y; Yamashita, T. Neuropilin-1-mediated pruning of corticospinal tract fibers is required for motor recovery after spinal cord injury. Cell Death & Disease 10, 67 (2019).
138	Ha, D; Tanaka, A; Kibayashi, T; Tanemura, A; Sugiyama, D; Wing, JB; Lim, EL; Teng, KWW; Adeegbe, D; Newell, EW; Katayama, I; Nishikawa, H; Sakaguchi, S. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. Proceedings of the National Academy of Sciences of the United States of America 116, 609-618 (2019).
139	Yoshino, T; Miyazaki, J; Kojima, T; Kandori, S; Shiga, M; Kawahara, T; Kimura, T; Naka, T; Kiyohara, H; Watanabe, M; Yamasaki, S; Akaza, H; Yano, I; Nishiyama, H. Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guerin induce antitumor immunity in a syngeneic murine bladder cancer model. Plos One 14, e0209196 (2019).
140	Kitadate, Y; Jorg, DJ; Tokue, M; Maruyama, A; Ichikawa, R; Tsuchiya, S; Segi-Nishida, E; Nakagawa, T; Uchida, A; Kimura-Yoshida, C; Mizuno, S; Sugiyama, F; Azami, T; Ema, M; Noda, C; Kobayashi, S; Matsuo, I; Kanai, Y; Nagasawa, T; Sugimoto, Y; Takahashi, S; Simons, BD; Yoshida, S. Competition for Mitogens Regulates Spermatogenic Stem Cell Homeostasis in an Open Niche. Cell Stem Cell 24, 79 (2019).
141	Wing, JB; Tay, C; Sakaguchi, S. Control of Regulatory T Cells by Co-signal Molecules. Co-Signal Molecules in T Cell Activation: Immune Regulation in Health and Disease 1189, 179-210 (2019).
142	Fujita, Y; Yamashita, T. Roles of Effector T Cells in Neurological Autoimmunity. Neuroimmune Diseases: From Cells To the Living Brain , 63-81 (2019).
143	Naito, H; Takakura, N. TAK1 safeguards endothelial cells from gut microbes and inflammation. Molecular & Cellular Oncology 6, e1588657 (2019).
144	Sekido, Y; Yasumizu, Y; Nishimura, J; Kayama, H; Matsuno, H; Ogino, T; Miyoshi, N; Takahashi, H; Haraguchi, N; Hata, T; Matsuda, C; Doki, Y; Mori, M; Takeda, K; Ohkura, N; Sakaguchi, S; Mizushima, T. Innate Myeloid Cell Subset-Specific Gene Expression Patterns in the Human Colon are Altered in Crohn's Disease Patients. Digestion 99, 194-204 (2019).
145	Sugiyama, T; Omatsu, Y; Nagasawa, T. Niches for hematopoietic stem cells and immune cell progenitors. International Immunology 31, 5-11 (2019).
146	Ichiyama, K; Dong, C. The role of miR-183 cluster in immunity. Cancer Letters 443, 108-114 (2019).
147	Huy, LV; Tanaka, C; Imai, T; Yamasaki, S; Miyamoto, T. Synthesis of 12-O-Mono- and Diglycosyl- oxystearates, a New Class of Agonists for the C-type Lectin Receptor Mincle. Acs Medicinal Chemistry Letters 10, 44-49 (2019).
148	Adachi, T; Nakae, A; Maruo, T; Shi, K; Maeda, L; Saitoh, Y; Shibata, M; Sasaki, J. The Relationships Between Pain-Catastrophizing Subcomponents and Multiple Pain-Related Outcomes in Japanese Outpatients with Chronic Pain: A Cross-Sectional Study. Pain Practice 19, 27-36 (2019).
149	Kinehara, Y; Nagatomo, I; Koyama, S; Ito, D; Nojima, S; Kurebayashi, R; Nakanishi, Y; Suga, Y; Nishijima- Futami, Y; Osa, A; Nakatani, T; Kato, Y; Nishide, M; Hayama, Y; Higashiguchi, M; Morimura, O; Miyake, K; Kang, SJ; Minami, T; Hirata, H; Iwahori, K; Takimoto, T; Takamatsu, H; Takeda, Y; Hosen, N; Hoshino, S; Shintani, Y; Okumura, M; Kumagai, T; Nishino, K; Imamura, F; Nakatsuka, S; Kijima, T; Kida, H; Kumanogoh, A. Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells. Jci insight 3, e123093 (2018).

150	Terao, C; Yoshifuji, H; Matsumura, T; Naruse, TK; Ishii, T; Nakaoka, Y; Kirino, Y; Matsuo, K; Origuchi, T; Shimizu, M; Maejima, Y; Amiya, E; Tamura, N; Kawaguchi, T; Takahashi, M; Setoh, K; Ohmura, K; Watanabe, R; Horita, T; Atsumi, T; Matsukura, M; Miyata, T; Kochi, Y; Suda, T; Tanemoto, K; Meguro, A; Okada, Y; Ogimoto, A; Yamamoto, M; Takahashi, H; Nakayamada, S; Saito, K; Kuwana, M; Mizuki, N; Tabara, Y; Ueda, A; Komuro, I; Kimura, A; Isobe, M; Mimori, T; Matsuda, F. Genetic determinants and an epistasis of LILRA3 and HLA-B(star)52 in Takayasu arteritis. Proceedings of the National Academy of Sciences of the United States of America 115, 13045-13050 (2018).
151	Akazawa, K; Sugihara, F; Nakamura, T; Matsushita, H; Mukai, H; Akimoto, R; Minoshima, M; Mizukami, S; Kikuchi, K. Perfluorocarbon-Based F-19 MRI Nanoprobes for In Vivo Multicolor Imaging. Angewandte Chemie-International Edition 57, 16742-16747 (2018).
152	Sakaue, S; Hirata, J; Maeda, Y; Kawakami, E; Nii, T; Kishikawa, T; Ishigaki, K; Terao, C; Suzuki, K; Akiyama M; Suita, N; Masuda, T; Ogawa, K; Yamamoto, K; Saeki, Y; Matsushita, M; Yoshimura, M; Matsuoka, H; Ikari, K; Taniguchi, A; Yamanaka, H; Kawaji, H; Lassmann, T; Itoh, M; Yoshitomi, H; Ito, H; Ohmura, K; Forrest, ARR; Hayashizaki, Y; Carninci, P; Kumanogoh, A; Kamatani, Y; de Hoon, M; Yamamoto, K; Okada, Y. Integration of genetics and miRNA-target gene network identified disease biology implicated in tissue specificity. Nucleic Acids Research 46, 11898-11909 (2018).
153	Kawano, M; Nagata, S. Efferocytosis and autoimmune disease. International Immunology 30, 551-558 (2018).
154	Tsai, CY; Sakakibara, S; Yasui, T; Minamitani, T; Okuzaki, D; Kikutani, H. Bystander inhibition of humoral immune responses by Epstein-Barr virus LMP1. International Immunology 30, 579-590 (2018).
155	Naito, Y; Hamaoka, S; Kinoshita, M; Kainuma, A; Shimizu, M; Katoh, H; Moriyama, K; Ishii, KJ; Sawa, T. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia. Microbiology and Immunology 62, 774-785 (2018).
156	Komine, O; Yamashita, H; Fujimori-Tonou, N; Koike, M; Jin, SJ; Moriwaki, Y; Endo, F; Watanabe, S; Uematsu, S; Akira, S; Uchiyama, Y; Takahashi, R; Misawa, H; Yamanaka, K. Innate immune adaptor TRIF deficiency accelerates disease progression of ALS mice with accumulation of aberrantly activated astrocytes Cell Death and Differentiation 25, 2130-2146 (2018).
157	Hashimoto, T; Takahashi, H; Sakaguchi, S. Regulatory T-cell deficiency and autoimmune skin disease: Beyond the scurfy mouse and immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Journal of Allergy and Clinical Immunology 142, 1754-1756 (2018).
158	Shigeta, N; Nakamura, H; Kumasawa, K; Imai, K; Saito, S; Sakaguchi, S; Kimura, T. Are naive T cells and class-switched memory (IgD(-) CD27(+)) B cells not essential for establishment and maintenance of pregnancy? Insights from a case of common variable immunodeficiency with pregnancy. Medical Hypotheses 121, 36-41 (2018).
159	Beshr, R; Isohashi, K; Watabe, T; Naka, S; Horitsugi, G; Romanov, V; Kato, H; Miyatake, SI; Shimosegawa, E; Hatazawa, J. Preliminary feasibility study on differential diagnosis between radiation-induced cerebral necrosis and recurrent brain tumor by means of [F-18]fluoro-borono-phenylalanine PET/CT. Annals of Nuclear Medicine 32, 702-708 (2018).
160	Segawa, K; Yanagihashi, Y; Yamada, K; Suzuki, C; Uchiyama, Y; Nagata, S. Phospholipid flippases enable precursor B cells to flee engulfment by macrophages. Proceedings of the National Academy of Sciences of the United States of America 115, 12212-12217 (2018).
161	Hayashi, T; Momota, M; Kuroda, E; Kusakabe, T; Kobari, S; Makisaka, K; Ohno, Y; Suzuki, Y; Nakagawa, F; Lee, MSJ; Coban, C; Onodera, R; Higashi, T; Motoyama, K; Ishii, KJ; Arima, H. DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Spli Vaccination. Frontiers in Immunology 9, 2619 (2018).
162	Kenai, M; Maeda, Y; Okada, Y. Grimon: graphical interface to visualize multi-omics networks. Bioinformatics 34, 3934-3936 (2018).
163	Gemechu, Y; Millrine, D; Hashimoto, S; Prakash, J; Sanchenkova, K; Metwally, H; Gyanu, P; Kang, SJ; Kishimoto, T. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs. Proceedings of the National Academy of Sciences of the United States of America 115, 11802-11807 (2018).
164	Imai, T; Matsumura, T; Mayer-Lambertz, S; Wells, CA; Ishikawa, E; Butcher, SK; Barnett, TC; Walker, MJ; Imamura, A; Ishida, H; Ikebe, T; Miyamoto, T; Ato, M; Ohga, S; Lepenies, B; van Sorge, NM; Yamasaki, S. Lipoteichoic acid anchor triggers Mincle to drive protective immunity against invasive group A Streptococcus infection. Proceedings of the National Academy of Sciences of the United States of America 115, E10662- E10671 (2018).

165	Edwards, CL; de Oca, MM; Rivera, FD; Kumar, R; Ng, SS; Wang, YL; Amante, FH; Kometani, K; Kurosaki, T; Sidwell, T; Kallies, A; Engwerda, CR. The Role of BACH2 in T Cells in Experimental Malaria Caused by Plasmodium chabaudi chabaudi AS. Frontiers in Immunology 9, 2578 (2018).
166	Fukunaga, T; Fujita, Y; Kishima, H; Yamashita, T. Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma. Plos One 13, e0206552 (2018).
167	Han, B; Akiyama, M; Kim, KK; Oh, H; Choi, H; Lee, CH; Jung, S; Lee, HS; Kim, EE; Cook, S; Haritunians, T; Yamazaki, K; Park, SH; Ye, BD; McGovern, DPB; Esaki, M; Kawaguchi, T; Khor, SS; Taylor, KD; Rotter, JI; Suzuki, Y; Matsui, T; Motoya, S; Bang, SY; Kim, TH; Momozawa, Y; Kamatani, Y; Tokunaga, K; Kubo, M; Okada, Y; Yang, SK; Song, K. Amino acid position 37 of HLA-DR beta 1 affects susceptibility to Crohn's disease in Asians. Human Molecular Genetics 27, 3901-3910 (2018).
168	Uenaka, T; Satake, W; Cha, PC; Hayakawa, H; Baba, K; Jiang, SY; Kobayashi, K; Kanagawa, M; Okada, Y; Mochizuki, H; Toda, T. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson's disease. Human Molecular Genetics 27, 3974-3985 (2018).
169	Narazaki, M; Kishimoto, T. The Two-Faced Cytokine IL-6 in Host Defense and Diseases. International Journal of Molecular Sciences 19, 3528 (2018).
170	Fujita, Y; Yamashita, T. Sirtuins in Neuroendocrine Regulation and Neurological Diseases. Frontiers in Neuroscience 12, 778 (2018).
171	Teumer, A; Chaker, L; Groeneweg, S; Li, Y; Di Munno, C; Barbieri, C et al. Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation. Nature Communications 9, 4455 (2018).
172	Deng, M; Gui, X; Kim, J; Xie, L; Chen, WN; Li, ZL; He, LC; Chen, YZ; Chen, HY; Luo, WG; Lu, ZG; Xie, JJ; Churchill, H; Xu, YX; Zhou, Z; Wu, GJ; Yu, CY; John, S; Hirayasu, K; Nguyen, N; Liu, XY; Huang, FF; Li, LK; Deng, H; Tang, HD; Sadek, AH; Zhang, LB; Huang, T; Zou, YZ; Chen, B; Zhu, H; Arase, H; Xia, NS; Jiang, YX; Collins, R; You, MJ; Homsi, J; Unni, N; Lewis, C; Chen, GQ; Fu, YX; Liao, XC; An, ZQ; Zheng, JK; Zhang, NY; Zhang, CC. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature 562, 605 (2018).
173	Akazawa, K; Sugihara, F; Minoshima, M; Mizukami, S; Kikuchi, K. Sensing caspase-1 activity using activatable F-19 MRI nanoprobes with improved turn-on kinetics. Chemical Communications 54, 11785-11788 (2018).
174	Nagahama, Y; Shimoda, M; Mao, GL; Singh, SK; Kozakai, Y; Sun, X; Motooka, D; Nakamura, S; Tanaka, H; Satoh, T; Maeda, K; Akira, S. Regnase-1 controls colon epithelial regeneration via regulation of mTOR and purine metabolism. Proceedings of the National Academy of Sciences of the United States of America 115, 11036-11041 (2018).
175	Tanabe, S; Fujita, Y; Ikuma, K; Yamashita, T. Inhibiting repulsive guidance molecule-a suppresses secondary progression in mouse models of multiple sclerosis. Cell Death & Disease 9, 1061 (2018).
176	Flores-Langarica, A; Cook, C; Luda, KM; Persson, EK; Marshall, JL; Beristain-Covarrubias, N; Yam-Puc, JC; Dahlgren, M; Persson, JJ; Uematsu, S; Akira, S; Henderson, IR; Lindbom, BJ; Agace, W; Cunningham, AF. Intestinal CD103(+) CD11b(+) cDC2 Conventional Dendritic Cells Are Required for Primary CD4(+) T and B Cell Responses to Soluble Flagellin. Frontiers in Immunology 9, 2409 (2018).
177	Okuyama, Y; Tanaka, Y; Jiang, JJ; Kamimura, D; Nakamura, A; Ota, M; Ohki, T; Higo, D; Ogura, H; Ishii, N; Atsumi, T; Murakami, M. Bmi1 Regulates I kappa B alpha Degradation via Association with the SCF Complex. Journal of Immunology 201, 2264-2272 (2018).
178	Sugawa, M; Masaike, T; Mikami, N; Yamaguchi, S; Shibata, K; Saito, K; Fujii, F; Toyoshima, YY; Nishizaka, T; Yajima, J. Circular orientation fluorescence emitter imaging (COFEI) of rotational motion of motor proteins. Biochemical and Biophysical Research Communications 504, 709-714 (2018).
179	Ekemen, S; Uzay, A; Bassullu, N; Dikicioglu-Cetin, E; Matsuda, K; Ince, U; Coban, C. Does it take three to tango? An unsuspected multimorbidity of CD8(+) T cell lymphoproliferative disorder, malaria, and EBV infection. Malaria Journal 17, 349 (2018).
180	Osa, A; Uenami, T; Koyama, S; Fujimoto, K; Okuzaki, D; Takimoto, T; Hirata, H; Yano, Y; Yokota, S; Kinehara, Y; Naito, Y; Otsuka, T; Kanazu, M; Kuroyama, M; Hamaguchi, M; Koba, T; Futami, Y; Ishijima, M; Suga, Y; Akazawa, Y; Machiyama, H; Iwahori, K; Takamatsu, H; Nagatomo, I; Takeda, Y; Kida, H; Akbay, EA; Hammerman, PS; Wong, KK; Dranoff, G; Mori, M; Kijima, T; Kumanogoh, A. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. Jci insight 3, e59125 (2018).

<ul> <li><sup>101</sup>Subset of Fibroblastic Stromal Cells Constitutes the Cortex-Medulla Boundary Subcompartment of the Lymph Node. Frontiers in Immunology 9, 2196 (2018).</li> <li>Kiyozumi, D; Taniguchi, Y; Nakano, I; Toga, J; Yagi, E; Hasuwa, H; Ikawa, M; Sekiguchi, K. Laminin ge 1 C-terminal Glu to Gln mutation induces early postimplantation lethality. Life Science Alliance 1, e201800064 (2018).</li> <li>Baba, M; Endoh, M; Ma, WJ; Toyama, H; Hirayama, A; Nishikawa, K; Takubo, K; Hano, H; Hasumi, H; Umemoto, T; Hashimoto, M; Irie, N; Esumi, C; Kataoka, M; Nakagata, N; Soga, T; Yao, N; Kamba, T; Minami, T; Ishii, M; Suda, T. Follculin Regulates Osteoclastogenesis Through Metabolic Regulation. J of Bone and Mineral Research 33, 1785-1798 (2018).</li> <li>Diaz-Gallo, LM, Ramskold, D; Shchetynsky, K; Folkersen, L; Chemin, K; Brynedal, B; Uebe, S; Okada, Afredsson, L; Klareskog, L; Padyukov, L. Systematic approach demonstrates enrichnet of multiple interactions between non-HLA risk variants and HLA-DRB1 risk alleles in rheumatoid arthritis. Annals or Rheumatic Diseases 77, 1454-1462 (2018).</li> <li>Kato, Y; Park, J; Takamatsu, H; Konaka, H; Aoki, W; Aburaya, S; Ueda, M; Nishide, M; Koyama, S; Ha Y; Kinehara, Y; Hirano, T; Isbini, Y; Narazaki, M; Kumanogoh, A, Apoptosis-derived membrane vesicle drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus. <i>A</i> of the Rneumatic Diseases 77, 1507-1515 (2018).</li> <li>Tanabe, S; Yamashita, T. The role of immune cells in brain development and neurodevelopmental dise International Immunology 30, 437-444 (2018).</li> <li>Nagatake, T; Suzuki, H; Hirata, SI; Matsumoto, N; Wada, Y; Morimoto, S; Nasu, A; Shimojou, M; Kawa Ogami, K; Tsujimura, Y; Kuroda, E; Iijima, N; Hosomi, K; Ishii, KJ; Nosaka, T; Yasutomi, Y; Kuriaswa, Immunological association of inducible bronchus-associated lymphoid tissue organogenesis in Ag85B-rtHPIV2 vaccine-induced anti-tuberculosis muccosal immune responese in mice. International Immunolog 47</li></ul>		
<ul> <li>12 C-terminal Glu to Gln mutation induces early postimplantation lethality. Life Science Alliance 1, e201800064 (2018).</li> <li>Baba, M.; Endoh, M.; Ma, WJ; Toyama, H; Hirayama, A; Nishikawa, K; Takubo, K; Hano, H; Hasumi, H; Umemoto, T; Hashimoto, M: Irie, N; Esumi, C; Kataoka, M; Nakagata, N; Soga, T; Yao, M; Kamba, T; Minami, T; Ishii, M; Suda, T. Foliculin Regulates Osteoclastogenesis Through Metabolic Regulation. Jd of Bone and Mineral Research 33, 1785-1739 (2018).</li> <li>Diaz-Gallo, LM; Ramskold, D; Shchetynsky, K; Folkersen, L; Chemin, K; Brynedal, B; Uebe, S; Okada, Alfredsson, L; Klareskog, L; Padyukov, L. Systematic approach demonstrates enrichment of multiple interactions between non-HL risk variants and HLA-DRB1 risk alieles in rheumatoid arthritis. Annals c Rheumatic Diseases 77, 1454-1462 (2018).</li> <li>Kato, Y; Park, J; Takamatsu, H; Konaka, H; Aoki, W; Aburaya, S; Ueda, M; Nishide, M; Koyama, S; Ha Y; Kinehara, Y; Hirano, T; Shima, Y, Narzakai, M; Kumanogoh, A. Apotosis-derived membrane vesicl drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus. <i>J</i> of the Rheumatic Diseases 77, 1507-1515 (2018).</li> <li>Tanabe, S; Yamashita, T. The role of immune cells in brain development and neurodevelopmental dise International Immunology 30, 437-444 (2018).</li> <li>Nagatake, T; Suzuki, H; Hirata, SI; Matsumoto, N; Wada, Y; Morimoto, S; Nasu, A; Shimojou, M; Kawa Ogami, K; Taujimura, Y; Kuroda, E; Iijima, N; Hosomi, K; Ishii, KJ; Nosaka, T; Yasutoni, Y; Kunisawa, J; Kunisawa, J; Jin, MJ; Suzuki, Y; Nakai, K. Waves of chromatin modifications in mouse dendritic cells in response to LPS stimulation. Genome Biology 19, 138 (2018).</li> <li>Bando, H; Sakaguchi, N; Lee, Y; Pradipta, A; Ma, JS; Tanaka, S; Lai, DH; Liu, JF; Lun, ZR; Nishikawa, Sasai, M; Yamamoto, M. Toxoplasma Effector TgIST Tanaka, S; Lai, DH; Liu, JF; Lun, ZR; Nishikawa, Sasai, M; Yamamoto, M; Nyadaki, Y; Maki, Y, Nakai, K. Waves of chromatin modifications in m</li></ul>	81 S	Shichida, Y; Umemoto, E; Miyasaka, M; Ludewig, B; Takahama, Y; Nagasawa, T; Katakai, T. A Distinct Subset of Fibroblastic Stromal Cells Constitutes the Cortex-Medulla Boundary Subcompartment of the
<ul> <li>Umemoto, T; Hashimoto, M; Irie, N; Esumi, C; Kataoka, M; Nakagata, N; Soga, T; Yao, M; Kamba, T; Minami, T; Ishii, M; Suda, T. Folliculin Regulates Osteoclastogenesis Through Metabolic Regulation. J of Bone and Mineral Research 33, 1785-1798 (2018).</li> <li>Diaz-Gallo, LM; Ramskold, D; Shchetynsky, K; Folkersen, L; Chemin, K; Brynedal, B; Uebe, S; Okada, Alfredsson, L; Klareskog, L; Padyukov, L Systematic approach demonstrates enrichment of multiple treatcrions between non-HLA risk variants and HLA-DRB1 risk alleles in rheumatoid arthritis. Annals of Rheumatic Diseases 77, 1454-1462 (2018).</li> <li>Kato, Y; Park, J; Takamatsu, H; Konaka, H; Aoki, W; Aburaya, S; Ueda, M; Nishide, M; Koyama, S; Ha Y; Kinehara, Y; Hirano, T; Shima, Y; Narazaki, M; Kumanogoh, A. Apoptosis-derived membrane vesich drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus. <i>J</i> of the Rheumatic Diseases 77, 1507-1515 (2018).</li> <li>Tanabe, S; Yamashita, T. The role of immune cells in brain development and neurodevelopmental dise International Immunology 30, 437-444 (2018).</li> <li>Nagatake, T; Suzuki, H; Hirata, SI; Matsumoto, N; Wada, Y; Morimoto, S; Nasu, A; Shimojou, M; Kawa Ogami, K; Tsujimura, Y; Kuroda, E; Ijjima, N; Hosomi, K; Ishii, KJ; Nosaka, T; Yasutomi, Y; Kunisawa.</li> <li>Fujita, Y; Yamashita, T. Spatial organization of genome architecture in neuronal development and dise Neurochemistry international 119, 49-56 (2018).</li> <li>Vandenbon, A; Kumagai, Y; Lin, MJ; Suzuki, Y; Nakai, K. Waves of chromatin modifications in mouse dendritic cells in response to LPS stimulation. Genome Biology 19, 138 (2018).</li> <li>Bando, H; Sakaguchi, N; Lee, Y; Pradipta, A; Ma, JS; Tanaka, S; Lai, DH; Liu, JF; Lun, ZR; Nishikawa, Sasai, M; Yamamoto, M. Toxoplasma Effector TgIST Targets Host IDO1 to Antagonize the IFN-gamma Induced Anti-parasitic Response in Human Cells. Frontiers in Immunology 2073 (2018).</li> <li>Fukata, T; Mizushima, T; Nisbimura, J; O</li></ul>	82   1	
<ul> <li>Alfredsson, L; Klareskog, L; Padyuko', L Systematic approach demonstrates enrichment of multiple interactions between non-HLA risk variants and HLA-DRB1 risk alleles in rheumatic Diseases 77, 1454-1462 (2018).</li> <li>Kato, Y; Park, J; Takamatsu, H; Konaka, H; Aoki, W; Aburaya, S; Ueda, M; Nishide, M; Koyama, S; Ha Y; Kinehara, Y; Hirano, T; Shima, Y; Narazaki, M; Kumanogoh, A. Apoptosis-derived membrane vesicl drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus. <i>A</i> of the Rheumatic Diseases 77, 1507-1515 (2018).</li> <li>Tanabe, S; Yamashita, T. The role of immune cells in brain development and neurodevelopmental dise International Immunology 30, 437-444 (2018).</li> <li>Nagatake, T; Suzuki, H; Hirata, SI; Matsumoto, N; Wada, Y; Morimoto, S; Nasu, A; Shimojou, M; Kawa Ogami, K; Tsujimura, Y; Kuroda, E; Iijima, N; Hosomi, K; Ishii, KJ; Nosaka, T; Yasutomi, Y; Kunisawa, Immunological association of inducible bronchus-associated lymphoid tissue organogenesis in Ag85B-rHPIV2 vaccine-induced anti-tuberculosis mucosal immune responses in mice. International Immunolog 471-481 (2018).</li> <li>Fujita, Y; Yamashita, T. Spatial organization of genome architecture in neuronal development and dise Neurochemistry international 119, 49-56 (2018).</li> <li>Vandenbon, A; Kumagai, Y; Lin, MJ; Suzuki, Y; Nakai, K. Waves of chromatin modifications in mouse dendritic cells in response to LPS stimulation. Genome Biology 19, 138 (2018).</li> <li>Bando, H; Sakaguchi, N; Lee, Y; Pradipta, A; Ma, JS; Tanaka, S; Lai, DH; Liu, JF; Lun, ZR; Nishikawa, Ssai, M; Yamamoto, M. Toxoplasma Effector TgIST Targets Host IDO1 to Antagonize the IFN-gamme Induced Anti-parasitic Response in Human Cells. Frontiers in Immunology 9, 2073 (2018).</li> <li>Fukata, T; Mizushima, T; Nishimura, J; Okuzaki, D; Wu, X; Hirose, H; Yokoyama, Y; Kubota, Y; Nagata Tsujimura, N; Inoue, A; Miyoshi, N; Haraguchi, N; Takahashi, H; Hata, T; Matsuda, C; Kayama, H; Taki, Soaki, M; Yamamo</li></ul>	83 L M	Umemoto, T; Hashimoto, M; Irie, N; Esumi, C; Kataoka, M; Nakagata, N; Soga, T; Yao, M; Kamba, T; Minami, T; Ishii, M; Suda, T. Folliculin Regulates Osteoclastogenesis Through Metabolic Regulation. Journal
<ul> <li>Y; Kinehara, Y; Hirano, T; Shima, Y; Narazaki, M; Kumanogoh, A. Apoptosis-derived membrane vesicle drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus. <i>A</i> of the Rheumatic Diseases 77, 1507-1515 (2018).</li> <li>Tanabe, S; Yamashita, T. The role of immune cells in brain development and neurodevelopmental dise International Immunology 30, 437-444 (2018).</li> <li>Nagatake, T; Suzuki, H; Hirata, SI; Matsumoto, N; Wada, Y; Morimoto, S; Nasu, A; Shimojou, M; Kawa Ogami, K; Tsujimura, Y; Kuroda, E; Iijima, N; Hosomi, K; Ishii, KJ; Nosaka, T; Yasutomi, Y; Kunisawa, Immunological association of inducible bronchus-associated lympholissue organogenesis in Ag85B-rHPIV2 vaccine-induced anti-tuberculosis mucosal immune responses in mice. International Immunolog 471-481 (2018).</li> <li>Fujita, Y; Yamashita, T. Spatial organization of genome architecture in neuronal development and dise Neurochemistry international 119, 49-56 (2018).</li> <li>Vandenbon, A; Kumagai, Y; Lin, MJ; Suzuki, Y; Nakai, K. Waves of chromatin modifications in mouse dendritic cells in response to LPS stimulation. Genome Biology 19, 138 (2018).</li> <li>Bando, H; Sakaguchi, N; Lee, Y; Pradipta, A; Ma, JS; Tanaka, S; Lai, DH; Liu, JF; Lun, ZR; Nishikawa, Sasai, M; Yamamoto, M. Toxoplasma Effector TgIST Targets Host IDO1 to Antagonize the IFN-gamma Induced Anti-parasitic Response in Human Cells. Frontiers in Immunology 9, 2073 (2018).</li> <li>Fukata, T; Mizushima, T; Nishimura, J; Okuzaki, D; Wu, X; Hirose, H; Yokoyama, Y; Kubota, Y; Nagata Tsujimura, N; Inoue, A; Miyoshi, N; Haraguchi, N; Takahashi, H; Hata, T; Matsuda, C; Kayama, H; Tak K; Doki, Y; Mori, M; Yamamoto, H. The Supercarbonate Apatite-MicroRNA Complex Inhibits Dextran S Sulfate-Induced Colitis. Molecular therapy-Nucleic Acids 12, 658-671 (2018).</li> <li>Bando, H; Lee, Y; Sakaguchi, N; Pradipta, A; Ma, JS; Tanaka, S; Cai, YH; Liu, JF; Shen, JL; Nishikawa Sasai, M; Yamamoto, M. Inducible Nitric Zovide Synth</li></ul>	84 <sup> </sup> 4	interactions between non-HLA risk variants and HLA-DRB1 risk alleles in rheumatoid arthritis. Annals of the
<ul> <li>International Immunology 30, 437-444 (2018).</li> <li>Nagatake, T; Suzuki, H; Hirata, SI; Matsumoto, N; Wada, Y; Morimoto, S; Nasu, A; Shimojou, M; Kawa Ogami, K; Tsujimura, Y; Kuroda, E; Iijima, N; Hosomi, K; Ishii, KJ; Nosaka, T; Yasutomi, Y; Kunisawa, Immunological association of inducible bronchus-associated lymphoid tissue organogenesis in Ag85B-rHPIV2 vaccine-induced anti-tuberculosis mucosal immune responses in mice. International Immunolog 471-481 (2018).</li> <li>Fujita, Y; Yamashita, T. Spatial organization of genome architecture in neuronal development and dise Neurochemistry international 119, 49-56 (2018).</li> <li>Vandenbon, A; Kumagai, Y; Lin, MJ; Suzuki, Y; Nakai, K. Waves of chromatin modifications in mouse dendritic cells in response to LPS stimulation. Genome Biology 19, 138 (2018).</li> <li>Bando, H; Sakaguchi, N; Lee, Y; Pradipta, A; Ma, JS; Tanaka, S; Lai, DH; Liu, JF; Lun, ZR; Nishikawa, Sasai, M; Yamamoto, M. Toxoplasma Effector TgIST Targets Host IDO1 to Antagonize the IFN-gamma Induced Anti-parasitic Response in Human Cells. Frontiers in Immunology 9, 2073 (2018).</li> <li>Fukata, T; Mizushima, T; Nishimura, J; Okuzaki, D; Wu, X; Hirose, H; Yokoyama, Y; Kubota, Y; Nagata Tsujimura, N; Inoue, A; Miyoshi, N; Haraguchi, N; Takahashi, H; Hata, T; Matsuda, C; Kayama, H; Takk K; Doki, Y; Mori, M; Yamamoto, H. The Supercarbonate Apatite-MicroRNA Complex Inhibits Dextran S Sulfate-Induced Colitis. Molecular therapy-Nucleic Acids 12, 658-671 (2018).</li> <li>Bando, H; Lee, Y; Sakaguchi, N; Pradipta, A; Ma, JS; Tanaka, S; Cai, YH; Liu, JF; Shen, JL; Nishikawa Sasai, M; Yamamoto, M. Inducible Nitric Oxide Synthase Is a Key Host Factor for Toxoplasma GRA15-Dependent Disruption of the Gamma Interferon-Induced Antiparasitic Human Response. Mbio 9, e0177 (2018).</li> <li>Hiradate, Y; Sasaki, E; Momose, H; Asanuma, H; Furuhata, K; Takai, M; Aoshi, T; Yamada, H; Ishii, K. Tanemura, K; Mizukami, T; Hamaguchi, I. Development of screening method for intranasal infl</li></ul>	85 S	Kato, Y; Park, J; Takamatsu, H; Konaka, H; Aoki, W; Aburaya, S; Ueda, M; Nishide, M; Koyama, S; Hayama, Y; Kinehara, Y; Hirano, T; Shima, Y; Narazaki, M; Kumanogoh, A. Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus. Annals of the Rheumatic Diseases 77, 1507-1515 (2018).
<ul> <li>Ogami, K; Tsujimura, Y; Kuroda, E; Iijima, N; Hosomi, K; Ishii, KJ; Nosaka, T; Yasutomi, Y; Kunisawa, Immunological association of inducible bronchus-associated lymphoid tissue organogenesis in Ag85B-rHPIV2 vaccine-induced anti-tuberculosis mucosal immune responses in mice. International Immunolog 471-481 (2018).</li> <li>Fujita, Y; Yamashita, T. Spatial organization of genome architecture in neuronal development and dise Neurochemistry international 119, 49-56 (2018).</li> <li>Vandenbon, A; Kumagai, Y; Lin, MJ; Suzuki, Y; Nakai, K. Waves of chromatin modifications in mouse dendritic cells in response to LPS stimulation. Genome Biology 19, 138 (2018).</li> <li>Bando, H; Sakaguchi, N; Lee, Y; Pradipta, A; Ma, JS; Tanaka, S; Lai, DH; Liu, JF; Lun, ZR; Nishikawa, Sasai, M; Yamamoto, M. Toxoplasma Effector TgIST Targets Host IDO1 to Antagonize the IFN-gamma Induced Anti-parasitic Response in Human Cells. Frontiers in Immunology 9, 2073 (2018).</li> <li>Fukata, T; Mizushima, T; Nishimura, J; Okuzaki, D; Wu, X; Hirose, H; Yokoyama, Y; Kubota, Y; Nagata Tsujimura, N; Inoue, A; Miyoshi, N; Haraguchi, N; Takahashi, H; Hata, T; Matsuda, C; Kayama, H; Tak K; Doki, Y; Mori, M; Yamamoto, H. The Supercarbonate Apatite-MicroRNA Complex Inhibits Dextran S Sulfate-Induced Colitis. Molecular therapy-Nucleic Acids 12, 658-671 (2018).</li> <li>Bando, H; Lee, Y; Sakaguchi, N; Pradipta, A; Ma, JS; Tanaka, S; Cai, YH; Liu, JF; Shen, JL; Nishikawa Sasai, M; Yamamoto, M. Inducible Nitric Oxide Synthase Is a Key Host Factor for Toxoplasma GRA15-Dependent Disruption of the Gamma Interferon-Induced Antiparasitic Human Response. Mbio 9, e0173 (2018).</li> <li>Hiradate, Y; Sasaki, E; Momose, H; Asanuma, H; Furuhata, K; Takai, M; Aoshi, T; Yamada, H; Ishii, K. Tanemura, K; Mizukami, T; Hamaguchi, I. Development of screening method for intranasal influenza va and adjuvant safety in preclinical study. Biologicals 55, 43-52 (2018).</li> <li>Nakagawa, S; Serada, S; Kakubari, R; Hiramatsu, K; Sugase, T; Ma</li></ul>		Tanabe, S; Yamashita, T. The role of immune cells in brain development and neurodevelopmental diseases. International Immunology 30, 437-444 (2018).
<ul> <li>Neurochemistry international 119, 49-56 (2018).</li> <li>Vandenbon, A; Kumagai, Y; Lin, MJ; Suzuki, Y; Nakai, K. Waves of chromatin modifications in mouse dendritic cells in response to LPS stimulation. Genome Biology 19, 138 (2018).</li> <li>Bando, H; Sakaguchi, N; Lee, Y; Pradipta, A; Ma, JS; Tanaka, S; Lai, DH; Liu, JF; Lun, ZR; Nishikawa, Sasai, M; Yamamoto, M. Toxoplasma Effector TgIST Targets Host IDO1 to Antagonize the IFN-gamma Induced Anti-parasitic Response in Human Cells. Frontiers in Immunology 9, 2073 (2018).</li> <li>Fukata, T; Mizushima, T; Nishimura, J; Okuzaki, D; Wu, X; Hirose, H; Yokoyama, Y; Kubota, Y; Nagata Tsujimura, N; Inoue, A; Miyoshi, N; Haraguchi, N; Takahashi, H; Hata, T; Matsuda, C; Kayama, H; Takk K; Doki, Y; Mori, M; Yamamoto, H. The Supercarbonate Apatite-MicroRNA Complex Inhibits Dextran S Sulfate-Induced Colitis. Molecular therapy-Nucleic Acids 12, 658-671 (2018).</li> <li>Bando, H; Lee, Y; Sakaguchi, N; Pradipta, A; Ma, JS; Tanaka, S; Cai, YH; Liu, JF; Shen, JL; Nishikawa Sasai, M; Yamamoto, M. Inducible Nitric Oxide Synthase Is a Key Host Factor for Toxoplasma GRA15-Dependent Disruption of the Gamma Interferon-Induced Antiparasitic Human Response. Mbio 9, e0173 (2018).</li> <li>Hiradate, Y; Sasaki, E; Momose, H; Asanuma, H; Furuhata, K; Takai, M; Aoshi, T; Yamada, H; Ishii, K. Tanemura, K; Mizukami, T; Hamaguchi, I. Development of screening method for intranasal influenza va and adjuvant safety in preclinical study. Biologicals 55, 43-52 (2018).</li> <li>Nakagawa, S; Serada, S; Kakubari, R; Hiramatsu, K; Sugase, T; Matsuzaki, S; Matsuzaki, S; Ueda, Y;</li> </ul>	87 li r	rHPIV2 vaccine-induced anti-tuberculosis mucosal immune responses in mice. International Immunology 30,
<ul> <li>dendritic cells in response to LPS stimulation. Genome Biology 19, 138 (2018).</li> <li>Bando, H; Sakaguchi, N; Lee, Y; Pradipta, A; Ma, JS; Tanaka, S; Lai, DH; Liu, JF; Lun, ZR; Nishikawa, Sasai, M; Yamamoto, M. Toxoplasma Effector TgIST Targets Host IDO1 to Antagonize the IFN-gamma Induced Anti-parasitic Response in Human Cells. Frontiers in Immunology 9, 2073 (2018).</li> <li>Fukata, T; Mizushima, T; Nishimura, J; Okuzaki, D; Wu, X; Hirose, H; Yokoyama, Y; Kubota, Y; Nagata Tsujimura, N; Inoue, A; Miyoshi, N; Haraguchi, N; Takahashi, H; Hata, T; Matsuda, C; Kayama, H; Tak K; Doki, Y; Mori, M; Yamamoto, H. The Supercarbonate Apatite-MicroRNA Complex Inhibits Dextran S Sulfate-Induced Colitis. Molecular therapy-Nucleic Acids 12, 658-671 (2018).</li> <li>Bando, H; Lee, Y; Sakaguchi, N; Pradipta, A; Ma, JS; Tanaka, S; Cai, YH; Liu, JF; Shen, JL; Nishikawa Sasai, M; Yamamoto, M. Inducible Nitric Oxide Synthase Is a Key Host Factor for Toxoplasma GRA15-Dependent Disruption of the Gamma Interferon-Induced Antiparasitic Human Response. Mbio 9, e0173 (2018).</li> <li>Hiradate, Y; Sasaki, E; Momose, H; Asanuma, H; Furuhata, K; Takai, M; Aoshi, T; Yamada, H; Ishii, K. Tanemura, K; Mizukami, T; Hamaguchi, I. Development of screening method for intranasal influenza va and adjuvant safety in preclinical study. Biologicals 55, 43-52 (2018).</li> <li>Nakagawa, S; Serada, S; Kakubari, R; Hiramatsu, K; Sugase, T; Matsuzaki, S; Matsuzaki, S; Ueda, Y;</li> </ul>		Fujita, Y; Yamashita, T. Spatial organization of genome architecture in neuronal development and disease. Neurochemistry international 119, 49-56 (2018).
<ul> <li>Sasai, M; Yamamoto, M. Toxoplasma Effector TgIST Targets Host IDO1 to Antagonize the IFN-gamma Induced Anti-parasitic Response in Human Cells. Frontiers in Immunology 9, 2073 (2018).</li> <li>Fukata, T; Mizushima, T; Nishimura, J; Okuzaki, D; Wu, X; Hirose, H; Yokoyama, Y; Kubota, Y; Nagata Tsujimura, N; Inoue, A; Miyoshi, N; Haraguchi, N; Takahashi, H; Hata, T; Matsuda, C; Kayama, H; Take K; Doki, Y; Mori, M; Yamamoto, H. The Supercarbonate Apatite-MicroRNA Complex Inhibits Dextran S Sulfate-Induced Colitis. Molecular therapy-Nucleic Acids 12, 658-671 (2018).</li> <li>Bando, H; Lee, Y; Sakaguchi, N; Pradipta, A; Ma, JS; Tanaka, S; Cai, YH; Liu, JF; Shen, JL; Nishikawa Sasai, M; Yamamoto, M. Inducible Nitric Oxide Synthase Is a Key Host Factor for Toxoplasma GRA15- Dependent Disruption of the Gamma Interferon-Induced Antiparasitic Human Response. Mbio 9, e0173 (2018).</li> <li>Hiradate, Y; Sasaki, E; Momose, H; Asanuma, H; Furuhata, K; Takai, M; Aoshi, T; Yamada, H; Ishii, K, Tanemura, K; Mizukami, T; Hamaguchi, I. Development of screening method for intranasal influenza va and adjuvant safety in preclinical study. Biologicals 55, 43-52 (2018).</li> <li>Nakagawa, S; Serada, S; Kakubari, R; Hiramatsu, K; Sugase, T; Matsuzaki, S; Matsuzaki, S; Ueda, Y;</li> </ul>		
<ul> <li>191 Tsujimura, N; Inoue, A; Miyoshi, N; Haraguchi, N; Takahashi, H; Hata, T; Matsuda, C; Kayama, H; Taka K; Doki, Y; Mori, M; Yamamoto, H. The Supercarbonate Apatite-MicroRNA Complex Inhibits Dextran S Sulfate-Induced Colitis. Molecular therapy-Nucleic Acids 12, 658-671 (2018).</li> <li>192 Bando, H; Lee, Y; Sakaguchi, N; Pradipta, A; Ma, JS; Tanaka, S; Cai, YH; Liu, JF; Shen, JL; Nishikawa Sasai, M; Yamamoto, M. Inducible Nitric Oxide Synthase Is a Key Host Factor for Toxoplasma GRA15- Dependent Disruption of the Gamma Interferon-Induced Antiparasitic Human Response. Mbio 9, e0173 (2018).</li> <li>193 Hiradate, Y; Sasaki, E; Momose, H; Asanuma, H; Furuhata, K; Takai, M; Aoshi, T; Yamada, H; Ishii, K. Tanemura, K; Mizukami, T; Hamaguchi, I. Development of screening method for intranasal influenza va and adjuvant safety in preclinical study. Biologicals 55, 43-52 (2018).</li> <li>Nakagawa, S; Serada, S; Kakubari, R; Hiramatsu, K; Sugase, T; Matsuzaki, S; Matsuzaki, S; Ueda, Y;</li> </ul>	90 5	Bando, H; Sakaguchi, N; Lee, Y; Pradipta, A; Ma, JS; Tanaka, S; Lai, DH; Liu, JF; Lun, ZR; Nishikawa, Y; Sasai, M; Yamamoto, M. Toxoplasma Effector TgIST Targets Host IDO1 to Antagonize the IFN-gamma- Induced Anti-parasitic Response in Human Cells. Frontiers in Immunology 9, 2073 (2018).
192       Sasai, M; Yamamoto, M. Inducible Nitric Oxide Synthase Is a Key Host Factor for Toxoplasma GRA15- Dependent Disruption of the Gamma Interferon-Induced Antiparasitic Human Response. Mbio 9, e0173 (2018).         193       Hiradate, Y; Sasaki, E; Momose, H; Asanuma, H; Furuhata, K; Takai, M; Aoshi, T; Yamada, H; Ishii, K. Tanemura, K; Mizukami, T; Hamaguchi, I. Development of screening method for intranasal influenza va and adjuvant safety in preclinical study. Biologicals 55, 43-52 (2018).         Nakagawa, S; Serada, S; Kakubari, R; Hiramatsu, K; Sugase, T; Matsuzaki, S; Matsuzaki, S; Ueda, Y;	91   1   k	Fukata, T; Mizushima, T; Nishimura, J; Okuzaki, D; Wu, X; Hirose, H; Yokoyama, Y; Kubota, Y; Nagata, K; Tsujimura, N; Inoue, A; Miyoshi, N; Haraguchi, N; Takahashi, H; Hata, T; Matsuda, C; Kayama, H; Takeda, K; Doki, Y; Mori, M; Yamamoto, H. The Supercarbonate Apatite-MicroRNA Complex Inhibits Dextran Sodium Sulfate-Induced Colitis. Molecular therapy-Nucleic Acids 12, 658-671 (2018).
<ul> <li>193 Tanemura, K; Mizukami, T; Hamaguchi, I. Development of screening method for intranasal influenza va and adjuvant safety in preclinical study. Biologicals 55, 43-52 (2018).</li> <li>Nakagawa, S; Serada, S; Kakubari, R; Hiramatsu, K; Sugase, T; Matsuzaki, S; Matsuzaki, S; Ueda, Y;</li> </ul>	92 S	Bando, H; Lee, Y; Sakaguchi, N; Pradipta, A; Ma, JS; Tanaka, S; Cai, YH; Liu, JF; Shen, JL; Nishikawa, Y; Sasai, M; Yamamoto, M. Inducible Nitric Oxide Synthase Is a Key Host Factor for Toxoplasma GRA15- Dependent Disruption of the Gamma Interferon-Induced Antiparasitic Human Response. Mbio 9, e01738-18 (2018).
	93   T	Hiradate, Y; Sasaki, E; Momose, H; Asanuma, H; Furuhata, K; Takai, M; Aoshi, T; Yamada, H; Ishii, KJ; Tanemura, K; Mizukami, T; Hamaguchi, I. Development of screening method for intranasal influenza vaccine and adjuvant safety in preclinical study. Biologicals 55, 43-52 (2018).
194 Yoshino, K; Onkawara, T; Fujimoto, M; Kishimoto, T; Kimura, T; Naka, T. Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell-Mediated Antitumor Immunity By Suppressing PD-L1. Molecular Cancer therapeutics 17, 1941-1950 (2018).	94 A	Yoshino, K; Ohkawara, T; Fujimoto, M; Kishimoto, T; Kimura, T; Naka, T. Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell-Mediated Antitumor Immunity By
	95 E	Ikeda, H; Hayashi, Y; Takahashi, N; Watabe, T; Kanai, Y; Shinohara, A; Kato, H; Watabe, H; Shimosegawa, E; Hatazawa, J. Application of astatine-210: Evaluation of astatine distribution and effect of pre-injected iodide in whole body of normal rats. Applied Radiation and Isotopes 139, 251-255 (2018).
196 Chu, SW; Fujita, K; Kemper, B; Pavillon, N; Smith, NI. Trends in Label-Free Imaging. Optics Communic 422, 1-2 (2018).		Chu, SW; Fujita, K; Kemper, B; Pavillon, N; Smith, NI. Trends in Label-Free Imaging. Optics Communications 422, 1-2 (2018).
197 Hobro, AJ; Smith, NI. Vibrational spectroscopic imaging of pathogens, microorganisms, and their intera- with host systems. Optics Communications 422, 75-84 (2018).		Hobro, AJ; Smith, NI. Vibrational spectroscopic imaging of pathogens, microorganisms, and their interactions with host systems. Optics Communications 422, 75-84 (2018).

198	Maruyama, K; Takayama, Y; Sugisawa, E; Yamanoi, Y; Yokawa, T; Kondo, T; Ishibashi, K; Sahoo, BR; Takemura, N; Mori, Y; Kanemaru, H; Kumagai, Y; Martino, MM; Yoshioka, Y; Nishijo, H; Tanaka, H; Sasaki, A; Ohno, N; Iwakura, Y; Moriyama, Y; Nomura, M; Akira, S; Tominaga, M. The ATP Transporter VNUT Mediates Induction of Dectin-1-Triggered Candida Nociception. Iscience 6, 306 (2018).
199	Wing, JB; Tekguc, M; Sakaguchi, S. Control of Germinal Center Responses by T-Follicular Regulatory Cells. Frontiers in Immunology 9, 1910 (2018).
200	Kayama, H; Kohyama, M; Okuzaki, D; Motooka, D; Barman, S; Okumura, R; Muneta, M; Hoshino, K; Sasaki, I; Ise, W; Matsuno, H; Nishimura, J; Kurosaki, T; Nakamura, S; Arase, H; Kaisho, T; Takeda, K. Heme ameliorates dextran sodium sulfate-induced colitis through providing intestinal macrophages with noninflammatory profiles. Proceedings of the National Academy of Sciences of the United States of America 115, 8418-8423 (2018).
201	Okamoto, K; Germond, A; Fujita, H; Furusawa, C; Okada, Y; Watanabe, TM. Single cell analysis reveals a biophysical aspect of collective cell-state transition in embryonic stem cell differentiation. Scientific Reports 8, 11965 (2018).
202	Matsumoto, R; Dainichi, T; Tsuchiya, S; Nomura, T; Kitoh, A; Hayden, MS; Ishii, KJ; Tanaka, M; Honda, T; Egawa, G; Otsuka, A; Nakajima, S; Sakurai, K; Nakano, Y; Kobayashi, T; Sugimoto, Y; Kabashima, K. Epithelial TRAF6 drives IL-17-mediated psoriatic inflammation. Jci insight 3, e121175 (2018).
203	Tanaka, T; Narazaki, M; Kishimoto, T. Interleukin (IL-6) Immunotherapy. Cold Spring Harbor Perspectives in Biology 10, a028456 (2018).
204	Temizoz, B; Kuroda, E; Ishii, KJ. Combination and inducible adjuvants targeting nucleic acid sensors. Current Opinion in Pharmacology 41, 104-113 (2018).
205	Nawa, Y; Yonemaru, Y; Kasai, A; Oketani, R; Hashimoto, H; Smith, NI; Fujita, K. Saturated excitation microscopy using differential excitation for efficient detection of nonlinear fluorescence signals. Apl Photonics 3, 80805 (2018).
206	Li, G; Martinez-Bonet, M; Wu, D; Yang, Y; Cui, J; Nguyen, HN; Cunin, P; Levescot, A; Bai, M; Westra, HJ; Okada, Y; Brenner, MB; Raychaudhuri, S; Hendrickson, EA; Maas, RL; Nigrovic, PA. High-throughput identification of noncoding functional SNPs via type IIS enzyme restriction. Nature Genetics 50, 1180 (2018).
207	Matsuura, Y; Kikuta, J; Kishi, Y; Hasegawa, T; Okuzaki, D; Hirano, T; Minoshima, M; Kikuchi, K; Kumanogoh, A; Ishii, M. In vivo visualisation of different modes of action of biological DMARDs inhibiting osteoclastic bone resorption. Annals of the Rheumatic Diseases 77, 1220-1226 (2018).
208	Liu, BYC; Sarhan, J; Panda, A; Muendlein, HI; Ilyukha, V; Coers, J; Yamamoto, M; Isberg, RR; Poltorak, A. Constitutive Interferon Maintains GBP Expression Required for Release of Bacterial Components Upstream of Pyroptosis and Anti-DNA Responses. Cell Reports 24, 155 (2018).
209	Nishizawa, N; Ito, Y; Eshima, K; Ohkubo, H; Kojo, K; Inoue, T; Raouf, J; Jakobsson, PJ; Uematsu, S; Akira, S; Narumiya, S; Watanabe, M; Majima, M. Inhibition of microsomal prostaglandin E synthase-1 facilitates liver repair after hepatic injury in mice. Journal of Hepatology 69, 110-120 (2018).
210	Ota, F; Hirayama, T; Kizuka, Y; Yamaguchi, Y; Fujinawa, R; Nagata, M; Ismanto, HS; Lepenies, B; Aretz, J; Rademacher, C; Seeberger, PH; Angata, T; Kitazume, S; Yoshida, K; Betsuyaku, T; Kida, K; Yamasaki, S; Taniguchi, N. High affinity sugar ligands of C-type lectin receptor langerin. Biochimica Et Biophysica Acta-General Subjects 1862, 1592-1601 (2018).
211	Nishibe, M; Katsuyama, Y; Yamashita, T. Developmental abnormality contributes to cortex-dependent motor impairments and higher intracortical current requirement in the reeler homozygous mutants. Brain Structure & Function 223, 2575-2587 (2018).
212	Balakrishnan, A; Karki, R; Berwin, B; Yamamoto, M; Kanneganti, TD. Guanylate binding proteins facilitate caspase-11-dependent pyroptosis in response to type 3 secretion system-negative Pseudomonas aeruginosa. Cell Death Discovery 4, (2018).
213	Hirota, K; Hashimoto, M; Ito, Y; Matsuura, M; Ito, H; Tanaka, M; Watanabe, H; Kondoh, G; Tanaka, A; Yasuda, K; Kopf, M; Potocnik, AJ; Stockinger, B; Sakaguchi, N; Sakaguchi, S. Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis. Immunity 48, 1220 (2018).
214	Takaoka, Y; Uchinomiya, S; Kobayashi, D; Endo, M; Hayashi, T; Fukuyama, Y; Hayasaka, H; Miyasaka, M; Ueda, T; Shimada, I; Hamachi, I. Endogenous Membrane Receptor Labeling by Reactive Cytokines and Growth Factors to Chase Their Dynamics in Live Cells. Chem 4, 1451-1464 (2018).
215	Gyori, D; Lim, EL; Grant, FM; Spensberger, D; Roychoudhuri, R; Shuttleworth, SJ; Okkenhaug, K; Stephens, LR; Hawkins, PT. Compensation between CSF1R(+) macrophages and Foxp3(+) Treg cells drives resistance to tumor immunotherapy. Jci insight 3, e120631 (2018).

216	Nakasone, A; Muramatsu, R; Kato, Y; Kawahara, Y; Yamashita, T. Myotube-derived factor promotes oligodendrocyte precursor cell proliferation. Biochemical and Biophysical Research Communications 500, 609-613 (2018).
217	Saijou, E; Enomoto, Y; Matsuda, M; Kok, CYY; Akira, S; Tanaka, M; Miyajima, A. Neutrophils Alleviate Fibrosis in the CCl4-Induced Mouse Chronic Liver Injury Model. Hepatology Communications 2, 703-717 (2018).
218	Kang, SJ; Nakanishi, Y; Kioi, Y; Okuzaki, D; Kimura, T; Takamatsu, H; Koyama, S; Nojima, S; Nishide, M; Hayama, Y; Kinehara, Y; Kato, Y; Nakatani, T; Shimogori, T; Takagi, J; Toyofuku, T; Kumanogoh, A. Semaphorin 6D reverse signaling controls macrophage lipid metabolism and anti-inflammatory polarization. Nature Immunology 19, 561 (2018).
219	Hayama, Y; Kimura, T; Takeda, Y; Nada, S; Koyama, S; Takamatsu, H; Kang, S; Ito, D; Maeda, Y; Nishide, M; Nojima, S; Sarashina-Kida, H; Hosokawa, T; Kinehara, Y; Kato, Y; Nakatani, T; Nakanishi, Y; Tsuda, T; Koba, T; Okada, M; Kumanogoh, A. Lysosomal Protein Lamtor1 Controls Innate Immune Responses via Nuclear Translocation of Transcription Factor EB. Journal of Immunology 200, 3790-3800 (2018).
220	Sueyoshi, T; Kawasaki, T; Kitai, Y; Ori, D; Akira, S; Kawai, T. Hu Antigen R Regulates Antiviral Innate Immune Responses through the Stabilization of mRNA for Polo-like Kinase 2. Journal of Immunology 200, 3814-3824 (2018).
221	Koga, S; Hozumi, K; Hirano, K; Yazawa, M; Terooatea, T; Minoda, A; Nagasawa, T; Koyasu, S; Moro, K. Peripheral PDGFR alpha(+)gp38(+) mesenchymal cells support the differentiation of fetal liver-derived ILC2. Journal of Experimental Medicine 215, 1609-1626 (2018).
222	Pagnamenta, AT; Murakami, Y; Anzilotti, C; Titheradge, H; Oates, AJ; Morton, J; Kinoshita, T; Kini, U; Taylor, JC. A homozygous variant disrupting the PIGH start-codon is associated with developmental delay, epilepsy, and microcephaly. Human Mutation 39, 822-826 (2018).
223	Suzuki, K; Nakai, A. Immune modulation by neuronal electric shock waves. Journal of Allergy and Clinical Immunology 141, 2022-2023 (2018).
224	Lu, XY; Nagata, M; Yamasaki, S. Mincle: 20 years of a versatile sensor of insults. International Immunology 30, 233-239 (2018).
225	Kanemaru, H; Yamane, F; Tanaka, H; Maeda, K; Satoh, T; Akira, S. BATF2 activates DUSP2 gene expression and up-regulates NF-kappa B activity via phospho-STAT3 dephosphorylation. International Immunology 30, 255-265 (2018).
226	Mendoza, P; Martinez-Martin, N; Bovolenta, ER; Reyes-Garau, D; Hernansanz-Agustin, P; Delgado, P; Diaz- Munoz, MD; Oeste, CL; Fernandez-Pisonero, I; Castellano, E; Martinez-Ruiz, A; Alonso-Lopez, D; Santos, E; Bustelo, XR; Kurosaki, T; Alarcon, B. R-Ras2 is required for germinal center formation to aid B cells during energetically demanding processes. Science Signaling 11, eaal1506 (2018).
227	Tanaka, K; Martinez, GJ; Yan, XW; Long, WW; Ichiyama, K; Chi, XX; Kim, BS; Reynolds, JM; Chung, Y; Tanaka, S; Liao, L; Nakanishi, Y; Yoshimura, A; Zheng, P; Wang, XH; Tian, Q; Xu, JM; O'Malley, BW; Dong, C. Regulation of Pathogenic T Helper 17 Cell Differentiation by Steroid Receptor Coactivator-3. Cell Reports 23, 2318-2329 (2018).
228	Sakaguchi, Y; Nishikawa, K; Seno, S; Matsuda, H; Takayanagi, H; Ishii, M. Roles of Enhancer RNAs in RANKL-induced Osteoclast Differentiation Identified by Genome-wide Cap-analysis of Gene Expression using CRISPR/Cas9. Scientific Reports 8, 7504 (2018).
229	Inoue, T; Moran, I; Shinnakasu, R; Phan, TG; Kurosaki, T. Generation of memory B cells and their reactivation. Immunological Reviews 283, 138-149 (2018).
230	Raju, S; Kometani, K; Kurosaki, T; Shaw, AS; Egawa, T. The adaptor molecule CD2AP in CD4 T cells modulates differentiation of follicular helper T cells during chronic LCMV infection. Plos Pathogens 14, e1007053 (2018).
231	Tran, TT; Nguyen, NT; Pham, NB; Chu, HN; Nguyen, TD; Kishimoto, T; Chau, MV; Chu, HM. Hairy Root Cultures of Eurycoma longifolia and Production of Anti-inflammatory 9-Methoxycanthin-6-one. Natural Product Communications 13, 539-542 (2018).
232	Shibata, N; Kunisawa, J; Hosomi, K; Fujimoto, Y; Mizote, K; Kitayama, N; Shimoyama, A; Mimuro, H; Sato, S; Kishishita, N; Ishii, KJ; Fukase, K; Kiyono, H. Lymphoid tissue-resident Alcaligenes LPS induces IgA production without excessive inflammatory responses via weak TLR4 agonist activity. Mucosal Immunology 11, 693-702 (2018).
233	Akazawa, K; Sugihara, F; Nakamura, T; Mizukami, S; Kikuchi, K. Highly Sensitive Detection of Caspase-3/7 Activity in Living Mice Using Enzyme-Responsive F-19 MRI Nanoprobes. Bioconjugate Chemistry 29, 1720- 1728 (2018).

234	Zhang, SX; Fujita, Y; Matsuzaki, R; Yamashita, T. Class I histone deacetylase (HDAC) inhibitor CI-994 promotes functional recovery following spinal cord injury. Cell Death & Disease 9, 460 (2018). Bambouskova, M; Gorvel, L; Lampropoulou, V; Sergushichev, A; Loginicheva, E; Johnson, K; Korenfeld, D; Mathyer, ME; Kim, H; Huang, LH; Duncan, D; Bregman, H; Keskin, A; Santeford, A; Apte, RS; Sehgal, R;
235	
	Johnson, B; Amarasinghe, GK; Soares, MP; Satoh, T; Akira, S; Hai, T; Strong, CD; Auclair, K; Roddy, TP; Biller, SA; Jovanovic, M; Klechevsky, E; Stewart, KM; Randolph, GJ; Artyomov, MN. Electrophilic properties of itaconate and derivatives regulate the I kappa B zeta-ATF3 inflammatory axis. Nature 556, 501 (2018).
236	Okada, Y; Momozawa, Y; Sakaue, S; Kanai, M; Ishigaki, K; Akiyama, M; Kishikawa, T; Arai, Y; Sasaki, T; Kosaki, K; Suematsu, M; Matsuda, K; Yamamoto, K; Kubo, M; Hirose, N; Kamatani, Y. Deep whole-genome sequencing reveals recent selection signatures linked to evolution and disease risk of Japanese. Nature Communications 9, 1631 (2018).
237	Ono, E; Murota, H; Mori, Y; Yoshioka, Y; Nomura, Y; Munetsugu, T; Yokozeki, H; Katayama, I. Sweat glucose and GLUT2 expression in atopic dermatitis: Implication for clinical manifestation and treatment. Plos One 13, e0195960 (2018).
238	Takahashi, H; Misato, K; Aoshi, T; Yamamoto, Y; Kubota, Y; Wu, X; Kuroda, E; Ishii, KJ; Yamamoto, H; Yoshioka, Y. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides. Frontiers in Immunology 9, 783 (2018).
239	Herndler-Brandstetter, D; Ishigame, H; Shinnakasu, R; Plajer, V; Stecher, C; Zhao, J; Lietzenmayer, M; Kroehling, L; Takumi, A; Kometani, K; Inoue, T; Kluger, Y; Kaech, SM; Kurosaki, T; Okada, T; Flavell, RA. KLRG1(+) Effector CD8(+) T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity. Immunity 48, 716 (2018).
240	Ise, W; Fujii, K; Shiroguchi, K; Ito, A; Kometani, K; Takeda, K; Kawakami, E; Yamashita, K; Suzuki, K; Okada, T; Kurosaki, T. T Follicular Helper Cell-Germinal Center B Cell Interaction Strength Regulates Entry into Plasma Cell or Recycling Germinal Center Cell Fate. Immunity 48, 702 (2018).
241	Katayama, Y; Tachibana, M; Kurisu, N; Oya, Y; Terasawa, Y; Goda, H; Kobiyama, K; Ishii, KJ; Akira, S; Mizuguchi, H; Sakurai, F. Oncolytic Reovirus Inhibits Immunosuppressive Activity of Myeloid-Derived Suppressor Cells in a TLR3-Dependent Manner. Journal of Immunology 200, 2987-2999 (2018).
	Teraguchi, S; Kumagai, Y. Estimation of diffusion constants from single molecular measurement without explicit tracking. Bmc Systems Biology 12, 15 (2018).
243	Ikeno, Y; Seo, S; Iwaisako, K; Yoh, T; Nakamoto, Y; Fuji, H; Taura, K; Okajima, H; Kaido, T; Sakaguchi, S; Uemoto, S. Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by F-18-FDG-PET is associated with the KRAS mutation status and prognosis. Journal of Translational Medicine 16, 95 (2018).
	Okumura, R; Takeda, K. Maintenance of intestinal homeostasis by mucosal barriers. Inflammation and Regeneration 38, UNSP 5 (2018).
245	Malik, R; Chauhan, G; Traylor, M; Sargurupremraj, M; Okada, Y; Mishra, A et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nature Genetics 50, 524 (2018).
	Tanabe, S; Yamashita, T. B-1a lymphocytes promote oligodendrogenesis during brain development. Nature Neuroscience 21, 506 (2018).
	Coban, C; Lee, MSJ; Ishii, KJ. Tissue-specific immunopathology during malaria infection. Nature Reviews Immunology 18, 266-278 (2018).
248	Hanieh, H; Masuda, K; Metwally, H; Chalise, JP; Mohamed, M; Nyati, KK; Standley, DM; Li, SL; Higa, M; Zaman, MM; Kishimoto, T. Arid5a stabilizes OX40 mRNA in murine CD4(+) Tcells by recognizing a stem- loop structure in its 3 ' UTR. European Journal of Immunology 48, 593-604 (2018).
	Mizuno, H; Kikuta, J; Ishii, M. In vivo live imaging of bone cells. Histochemistry and Cell Biology 149, 417-422 (2018).
250	Murakami, Y; Wataya-Kaneda, M; Kitayama, K; Arase, N; Murota, H; Hirayasu, K; Arase, H; Katayama, I. Heightened BRAF and BRAF pseudogene expression levels in 2 Japanese patients with Erdheim-Chester disease. Journal of Cutaneous Immunology and Allergy 1, 16-22 (2018).
251	Watanabe, R; Sakuragi, T; Noji, H; Nagata, S. Single-molecule analysis of phospholipid scrambling by TMEM16F. Proceedings of the National Academy of Sciences of the United States of America 115, 3066-3071 (2018).

252	Pavillon, N; Hobro, AJ; Akira, S; Smith, NI. Noninvasive detection of macrophage activation with single-cell resolution through machine learning. Proceedings of the National Academy of Sciences of the United States of America 115, E2676-E2685 (2018).
253	Masuta, Y; Yamamoto, T; Natsume-Kitatani, Y; Kanuma, T; Moriishi, E; Kobiyama, K; Mizuguchi, K; Yasutomi, Y; Ishii, KJ. An Antigen-Free, Plasmacytoid Dendritic Cell-Targeting Immunotherapy To Bolster Memory CD8(+) T Cells in Nonhuman Primates. Journal of Immunology 200, 2067-2075 (2018).
254	Sasaki, E; Momose, H; Hiradate, Y; Ishii, KJ; Mizukami, T; Hamaguchi, I. In vitro marker gene expression analyses in human peripheral blood mononuclear cells: A tool to assess safety of influenza vaccines in humans. Journal of Immunotoxicology 15, 53-62 (2018).
255	Galluzzi, L; Vitale, I; Aaronson, SA; Abrams, JM; Adam, D; Agostinis, P et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation 25, 486-541 (2018).
256	Hirata, J; Hirota, T; Ozeki, T; Kanai, M; Sudo, T; Tanaka, T; Hizawa, N; Nakagawa, H; Sato, S; Mushiroda, T; Saeki, H; Tamari, M; Okada, Y. Variants at HLA-A, HLA-C, and HLA-DQB1 Confer Risk of Psoriasis Vulgaris in Japanese. Journal of investigative Dermatology 138, 542-548 (2018).
257	Kanai, M; Akiyama, M; Takahashi, A; Matoba, N; Momozawa, Y; Ikeda, M; Iwata, N; Ikegawa, S; Hirata, M; Matsuda, K; Kubo, M; Okada, Y; Kamatani, Y. Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. Nature Genetics 50, 390 (2018).
258	Coban, C; Yamamoto, M. Introduction: Interactions Between the Immune System and Parasites Special Issue. International Immunology 30, 91-91 (2018).
259	Sasai, M; Pradipta, A; Yamamoto, M. Host immune responses to Toxoplasma gondii. International Immunology 30, 113-119 (2018).
260	Lee, MSJ; Coban, C. Unforeseen pathologies caused by malaria. International Immunology 30, 121-129 (2018).
261	Seike, M; Omatsu, Y; Watanabe, H; Kondoh, G; Nagasawa, T. Stem cell niche-specific Ebf3 maintains the bone marrow cavity. Genes & Development 32, 359-372 (2018).
262	Nishida, S; Ishikawa, T; Egawa, S; Koido, S; Yanagimoto, H; Ishii, J; Kanno, Y; Kokura, S; Yasuda, H; Oba, MS; Sato, M; Morimoto, S; Fujiki, F; Eguchi, H; Nagano, H; Kumanogoh, A; Unno, M; Kon, M; Shimada, H; Ito, K; Homma, S; Oka, Y; Morita, S; Sugiyama, H. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study. Cancer Immunology Research 6, 320-331 (2018).
263	Kuwabara, R; Hamaguchi, M; Fukuda, T; Sakai, H; Inui, M; Sakaguchi, S; Iwata, H. Long-term Functioning of Allogeneic Islets in Subcutaneous Tissue Pretreated With a Novel Cyclic Peptide Without Immunosuppressive Medication. Transplantation 102, 417-425 (2018).
264	Inoue, N; Ogura, S; Kasai, A; Nakazawa, T; Ikeda, K; Higashi, S; Isotani, A; Baba, K; Mochizuki, H; Fujimura, H; Ago, Y; Hayata-Takano, A; Seiriki, K; Shintani, Y; Shintani, N; Hashimoto, H. Knockdown of the mitochondria-localized protein p13 protects against experimental parkinsonism. Embo Reports 19, e44860 (2018).
265	Kawano, M; Nagata, S. Lupus-like autoimmune disease caused by a lack of Xkr8, a caspase-dependent phospholipid scramblase. Proceedings of the National Academy of Sciences of the United States of America 115, 2132-2137 (2018).
266	Takemura, N; Kurashima, Y; Mori, Y; Okada, K; Ogino, T; Osawa, H; Matsuno, H; Aayam, L; Kaneto, S; Park, EJ; Sato, S; Matsunaga, K; Tamura, Y; Ouchi, Y; Kumagai, Y; Kobayashi, D; Suzuki, Y; Yoshioka, Y; Nishimura, J; Mori, M; Ishii, KJ; Rothenberg, ME; Kiyono, H; Akira, S; Uematsu, S. Eosinophil depletion suppresses radiation-induced small intestinal fibrosis. Science Translational Medicine 10, eaan0333 (2018).
267	Segawa, K; Kurata, S; Nagata, S. The CDC50A extracellular domain is required for forming a functional complex with and chaperoning phospholipid flippases to the plasma membrane. Journal of Biological Chemistry 293, 2172-2182 (2018).
268	Foster, AJ; Nagata, M; Lu, XY; Lynch, AT; Omandi, Z; Ishikawa, E; Yamasaki, S; Timmer, MSM; Stocker, BL. Lipidated Brartemicin Analogues Are Potent Th1-Stimulating Vaccine Adjuvants. Journal of Medicinal Chemistry 61, 1045-1060 (2018).
269	Hori, Y; Otomura, N; Nishida, A; Nishiura, M; Umeno, M; Suetake, I; Kikuchi, K. Synthetic-Molecule/Protein Hybrid Probe with Fluorogenic Switch for Live-Cell Imaging of DNA Methylation. Journal of the American Chemical Society 140, 1686-1690 (2018).

270	Larouche, J; Sheoran, S; Maruyama, K; Martino, MM. Immune Regulation of Skin Wound Healing: Mechanisms and Novel Therapeutic Targets. Advances in Wound Care 7, 209-231 (2018).
271	Sasaki, E; Momose, H; Hiradate, Y; Furuhata, K; Takai, M; Asanuma, H; Ishii, KJ; Mizukami, T; Hamaguchi, I. Modeling for influenza vaccines and adjuvants profile for safety prediction system using gene expression profiling and statistical tools. Plos One 13, e0191896 (2018).
272	Higa, M; Oka, M; Fujihara, Y; Masuda, K; Yoneda, Y; Kishimoto, T. Regulation of inflammatory responses by dynamic subcellular localization of RNA-binding protein Arid5a. Proceedings of the National Academy of Sciences of the United States of America 115, E1214-E1220 (2018).
273	Yokokawa, H; Higashino, A; Suzuki, S; Moriyama, M; Nakamura, N; Suzuki, T; Suzuki, R; Ishii, K; Kobiyama, K; Ishii, KJ; Wakita, T; Akari, H; Kato, T. Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model. Gut 67, 372-U254 (2018).
274	Nakagawa, K; Matsuki, T; Zhao, L; Kuniyoshi, K; Tanaka, H; Ebina, I; Yoshida, KJ; Nabeshimai, H; Fukushima, K; Kanemaru, H; Yamane, F; Kawasaki, T; Machida, T; Naito, H; Takakura, N; Satoh, T; Akira, S. Schlafen-8 is essential for lymphatic endothelial cell activation in experimental autoimmune encephalomyelitis. International Immunology 30, 69-78 (2018).
275	Liu, YS; Guo, XY; Hirata, T; Rong, Y; Motooka, D; Kitajima, T; Murakami, Y; Gao, XD; Nakamura, S; Kinoshita, T; Fujita, M. N-Glycan-dependent protein folding and endoplasmic reticulum retention regulate GPI-anchor processing. Journal of Cell Biology 217, 585-599 (2018).
276	Hirata, T; Mishra, SK; Nakamura, S; Saito, K; Motooka, D; Takada, Y; Kanzawa, N; Murakami, Y; Maeda, Y; Fujita, M; Yamaguchi, Y; Kinoshita, T. Identification of a Golgi GPI-N-acetylgalactosamine transferase with tandem transmembrane regions in the catalytic domain. Nature Communications 9, 405 (2018).
277	Furuya, M; Kikuta, J; Fujimori, S; Seno, S; Maeda, H; Shirazaki, M; Uenaka, M; Mizuno, H; Iwamoto, Y; Morimoto, A; Hashimoto, K; Ito, T; Isogai, Y; Kashii, M; Kaito, T; Ohba, S; Chung, U; Lichtler, AC; Kikuchi, K; Matsuda, H; Yoshikawa, H; Ishii, M. Direct cell-cell contact between mature osteoblasts and osteoclasts dynamically controls their functions in vivo. Nature Communications 9, 300 (2018).
278	Fuchs, A; Gliwinski, M; Grageda, N; Spiering, R; Abbas, AK; Appel, S et al. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers in Immunology 8, 1844 (2018).
279	Harada, K; Fujita, Y; Okuno, T; Tanabe, S; Koyama, Y; Mochizuki, H; Yamashita, T. Inhibition of RGMa alleviates symptoms in a rat model of neuromyelitis optica. Scientific Reports 8, 34 (2018).
280	Morita, M; Tachikawa, T; Seino, S; Tanaka, K; Majima, T. Controlled Synthesis of Gold Nanoparticles on Fluorescent Nanodiamond via Electron-Beam-Induced Reduction Method for Dual-Modal Optical and Electron Bioimaging. Acs Applied Nano Materials 1, 355-363 (2018).
281	Nagata, S. Apoptosis and Clearance of Apoptotic Cells. Annual Review of Immunology, Vol 36 36, 489-517 (2018).
282	Kimura, T; Kumanogoh, A; Okada, M. Roles of Lamtor1 in Macrophages, CD4(+) T-cells, and Regulatory T-cells. Critical Reviews in Immunology 38, 403-414 (2018).
283	Lin, HY; Muramatsu, R; Maedera, N; Tsunematsu, H; Hamaguchi, M; Koyama, Y; Kuroda, M; Ono, K; Sawada, M; Yamashita, T. Extracellular Lactate Dehydrogenase A Release From Damaged Neurons Drives Central Nervous System Angiogenesis. Ebiomedicine 27, 71-85 (2018).
284	Takahama, M; Akira, S; Saitoh, T. Autophagy limits activation of the inflammasomes. Immunological Reviews 281, 62-73 (2018).
285	Tanaka, M; Kobiyama, K; Honda, T; Uchio-Yamada, K; Natsume-Kitatani, Y; Mizuguchi, K; Kabashima, K; Ishii, KJ. Essential Role of CARD14 in Murine Experimental Psoriasis. Journal of Immunology 200, 71-81 (2018).
286	Masuda, K; Kishimoto, T. A Potential Therapeutic Target RNA-binding Protein, Arid5a for the Treatment of Inflammatory Disease Associated with Aberrant Cytokine Expression. Current Pharmaceutical Design 24, 1766-1771 (2018).
287	Kimura, T; Nakamura, N; Hashimoto, Y; Sakaguchi, S; Kimura, S; Kishida, A. Selective Cell Capture and Release Using Antibody-Immobilized Polymer-Grafted Surface. Kobunshi Ronbunshu 75, 155-163 (2018).
288	Uchida, T; Ueta, H; Xu, XD; Hirakawa, J; Tahara, K; Zhou, S; Sawanobori, Y; Simmons, S; Kitazawa, Y; Kawashima, H; Matsuno, K. Rapid immunosurveillance by recirculating lymphocytes in the rat intestine: critical role of unsulfated sialyl-Lewis X on high endothelial venules of the Peyer's patches. International Immunology 30, 23-33 (2018).
289	Nishide, M; Kumanogoh, A. The role of semaphorins in immune responses and autoimmune rheumatic diseases. Nature Reviews Rheumatology 14, 19-31 (2018).

290	Yamazaki, S; Odanaka, M; Nishioka, A; Kasuya, S; Shime, H; Hemmi, H; Imai, M; Riethmacher, D; Kaisho, T; Ohkura, N; Sakaguchi, S; Morita, A. Ultraviolet B-Induced Maturation of CD11b-Type Langerin(-) Dendritic Cells Controls the Expansion of Foxp3(+) Regulatory T Cells in the Skin. Journal of Immunology 200, 119-129 (2018).
291	Kaito, T; Morimoto, T; Mori, Y; Kanayama, S; Makino, T; Takenaka, S; Sakai, Y; Otsuru, S; Yoshioka, Y; Yoshikawa, H. BMP-2/7 heterodimer strongly induces bone regeneration in the absence of increased soft tissue inflammation. Spine Journal 18, 139-146 (2018).
292	Matsui, Y; Mizukami, S; Kikuchi, K. Ratiometric Imaging of Intracellular Mg2+ Dynamics Using a Red Fluorescent Turn-off Probe and a Green Fluorescent Turn-on Probe. Chemistry Letters 47, 23-26 (2018).
293	Furukawa, A; Kakita, K; Yamada, T; Ishizuka, M; Sakamoto, J; Hatori, N; Maeda, N; Ohsaka, F; Saitoh, T; Nomura, T; Kuroki, K; Nambu, H; Arase, H; Matsunaga, S; Anada, M; Ose, T; Hashimoto, S; Maenaka, K. Structural and thermodynamic analyses reveal critical features of glycopeptide recognition by the human PILR alpha immune cell receptor. Journal of Biological Chemistry 292, 21128-21136 (2017).
294	Lelliott, PM; Huang, HM; Dixon, MW; Namvar, A; Blanch, AJ; Rajagopal, V; Tilley, L; Coban, C; McMorran, BJ; Foote, SJ; Burgio, G. Erythrocyte beta spectrin can be genetically targeted to protect mice from malaria. Blood Advances 1, 2624-2636 (2017).
295	Saito, F; Hirayasu, K; Satoh, T; Wang, CW; Lusingu, J; Arimori, T; Shida, K; Palacpac, NMQ; Itagaki, S; Iwanaga, S; Takashima, E; Tsuboi, T; Kohyama, M; Suenaga, T; Colonna, M; Takagi, J; Lavstsen, T; Horii, T; Arase, H. Immune evasion of Plasmodium falciparum by RIFIN via inhibitory receptors. Nature 552, 101 (2017).
296	Sato, R; Kozuka, J; Ueda, M; Mishima, R; Kumagai, Y; Yoshimura, A; Minoshima, M; Mizukami, S; Kikuchi, K. Intracellular Protein-Labeling Probes for Multicolor Single-Molecule Imaging of Immune Receptor-Adaptor Molecular Dynamics. Journal of the American Chemical Society 139, 17397-17404 (2017).
297	Atsumi, T; Suzuki, H; Jiang, JJ; Okuyama, Y; Nakagawa, I; Ota, M; Tanaka, Y; Ohki, T; Katsunuma, K; Nakajima, K; Hasegawa, Y; Ohara, O; Ogura, H; Arima, Y; Kamimura, D; Murakami, M. Rbm10 regulates inflammation development via alternative splicing of Dnmt3b. International Immunology 29, 581-591 (2017).
298	Miyara, M; Chader, D; Burlion, A; Goldstein, J; Sterlin, D; Norol, F; Trebeden-Negre, H; Claer, L; Sakaguchi, S; Marodon, G; Amoura, Z; Gorochov, G. Combination of IL-2, rapamycin, DNA methyltransferase and histone deacetylase inhibitors for the expansion of human regulatory T cells. Oncotarget 8, 104733-104744 (2017).
299	Shiokawa, M; Yamasaki, S; Saijo, S. C-type lectin receptors in anti-fungal immunity. Current Opinion in Microbiology 40, 123-130 (2017).
300	Hosen, N; Matsunaga, Y; Hasegawa, K; Matsuno, H; Nakamura, Y; Makita, M; Watanabe, K; Yoshida, M; Satoh, K; Morimoto, S; Fujiki, F; Nakajima, H; Nakata, J; Nishida, S; Tsuboi, A; Oka, Y; Manabe, M; Ichihara, H; Aoyama, Y; Mugitani, A; Nakao, T; Hino, M; Uchibori, R; Ozawa, K; Baba, Y; Terakura, S; Wada, N; Morii, E; Nishimura, J; Takeda, K; Oji, Y; Sugiyama, H; Takagi, J; Kumanogoh, A. The activated conformation of integrin beta(7) is a novel multiple myeloma-specific target for CAR T cell therapy. Nature Medicine 23, 1436 (2017).
301	Ando, T; Kashiwakura, J; Itoh-Nagato, N; Yamashita, H; Baba, M; Kawakami, Y; Tsai, SH; Inagaki, N; Takeda, K; Iwata, T; Shimojo, N; Fujisawa, T; Nagao, M; Matsumoto, K; Kawakami, Y; Kawakami, T. Histamine-releasing factor enhances food allergy. Journal of Clinical investigation 127, 4541-4553 (2017).
302	Matsui, Y; Funato, Y; Imamura, H; Miki, H; Mizukami, S; Kikuchi, K. Visualization of long-term Mg2+ dynamics in apoptotic cells using a novel targetable fluorescent probe. Chemical Science 8, 8255-8264 (2017).
303	Kitagawa, Y; Sakaguchi, S. Molecular control of regulatory T cell development and function. Current Opinion in Immunology 49, 64-70 (2017).
304	Hori, Y; Hirayama, S; Kikuchi, K. Development of cyanine probes with dinitrobenzene quencher for rapid fluorogenic protein labelling. Philosophical Transactions of the Royal Society A-Mathematical Physical and Engineering Sciences 375, 20170018 (2017).
305	Sakakibara, S; Arimori, T; Yamashita, K; Jinzai, H; Motooka, D; Nakamura, S; Li, SL; Takeda, K; Katayama, J; El Hussien, MA; Narazaki, M; Tanaka, T; Standley, DM; Takagi, J; Kikutani, H. Clonal evolution and antigen recognition of anti-nuclear antibodies in acute systemic lupus erythematosus. Scientific Reports 7, 16428 (2017).
306	Endo, T; Freinkman, E; de Rooij, DG; Page, DC. Periodic production of retinoic acid by meiotic and somatic cells coordinates four transitions in mouse spermatogenesis. Proceedings of the National Academy of Sciences of the United States of America 114, E10132-E10141 (2017).
307	Kayama, H; Kitada, S; Takeda, K. Quantification of Trypanosoma cruzi in Tissue and Trypanosoma cruzi Killing Assay. Bio-Protocol 7, e2613 (2017).

308	Kuroda, E; Morimoto, Y; Ishii, KJ. Instillation of Particulate Suspensions to the Lungs. Bio-Protocol 7, e2618 (2017).
309	Ohba, T; Watanabe, H; Murakami, M; Iino, K; Adachi, T; Baba, Y; Kurosaki, T; Ono, K; Ito, H. Stromal interaction molecule 1 haploinsufficiency causes maladaptive response to pressure overload. Plos One 12, e0187950 (2017).
310	Sato, K; Omahdi, Z; Shibata, K; Sonoda, KH; Yamasaki, S; Tanaka, H. Synthesis and Biological Evaluation of O-Methylated Glycolipids Related to PGLs via Direct Stereoselective Glycosidation and Sequential Suzuki-Miyaura Coupling using Boracyclane. Chemistry-A European Journal 23, 16374-16379 (2017).
311	Ye, BQ; Liu, BY; Yang, LL; Huang, GL; Hao, L; Xia, PY; Wang, S; Du, Y; Qin, XW; Zhu, PP; Wu, JY; Sakaguchi, N; Zhang, JY; Fan, ZS. Suppression of SRCAP chromatin remodelling complex and restriction of lymphoid lineage commitment by Pcid2. Nature Communications 8, 1518 (2017).
312	Ikeda, K; Kinoshita, M; Kayama, H; Nagamori, S; Kongpracha, P; Umemoto, E; Okumura, R; Kurakawa, T; Murakami, M; Mikami, N; Shintani, Y; Ueno, S; Andou, A; Ito, M; Tsumura, H; Yasutomo, K; Ozono, K; Takashima, S; Sakaguchi, S; Kanai, Y; Takeda, K. Slc3a2 Mediates Branched-Chain Amino-Acid-Dependent Maintenance of Regulatory T Cells. Cell Reports 21, 1824-1838 (2017).
313	Hemmi, M; Tachibana, M; Fujimoto, N; Shoji, M; Sakurai, F; Kobiyama, K; Ishii, KJ; Akira, S; Mizuguchi, H. T helper 17 Promotes induction of antigen-specific gut-Mucosal cytotoxic T lymphocytes following adenovirus Vector Vaccination. Frontiers in Immunology 8, 1456 (2017).
314	Ebina-Shibuya, R; Matsumoto, M; Kuwahara, M; Jang, KJ; Sugai, M; Ito, Y; Funayama, R; Nakayama, K; Sato, Y; Ishii, N; Okamura, Y; Kinoshita, K; Kometani, K; Kurosaki, T; Muto, A; Ichinose, M; Yamashita, M; Igarashi, K. Inflammatory responses induce an identity crisis of alveolar macrophages, leading to pulmonary alveolar proteinosis. Journal of Biological Chemistry 292, 18098-18112 (2017).
315	Nguyen, CH; Nakahama, T; Dang, TT; Chu, HH; Hoang, LV; Kishimoto, T; Nguyen, NT. Expression of aryl hydrocarbon receptor, inflammatory cytokines, and incidence of rheumatoid arthritis in Vietnamese dioxin- exposed people. Journal of Immunotoxicology 14, 196-203 (2017).
316	Nguyen, TTM; Murakami, Y; Sheridan, E; Ehresmann, S; Rousseau, J; St-Denis, A; Chai, G; Ajeawung, NF; Fairbrother, L; Reimschisel, T; Bateman, A; Berry-Kravis, E; Xia, F; Tardif, J; Parry, DA; Logan, CV; Diggle, C; Bennett, CP; Hattingh, L; Rosenfeld, JA; Perry, MS; Parker, MJ; Le Deist, F; Zaki, MS; Ignatius, E; Isohanni, P; Lonnqvist, T; Carroll, CJ; Johnson, CA; Gleeson, JG; Kinoshita, T; Campeau, PM. Mutations in GPAA1, Encoding a GPI Transamidase Complex Protein, Cause Developmental Delay, Epilepsy, Cerebellar Atrophy, and Osteopenia. American Journal of Human Genetics 101, 856-865 (2017).
317	Sasaki, E; Momose, H; Hiradate, Y; Furuhata, K; Takai, M; Kamachi, K; Asanuma, H; Ishii, KJ; Mizukami, T; Hamaguchi, I. Evaluation of marker gene expression as a potential predictive marker of leukopenic toxicity for inactivated influenza vaccines. Biologicals 50, 100-108 (2017).
318	Oka, Y; Tsuboi, A; Nakata, J; Nishida, S; Hosen, N; Kumanogoh, A; Oji, Y; Sugiyama, H. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy. Oncology Research and Treatment 40, 682-690 (2017).
319	Takano, T; Motozono, C; Imai, T; Sonoda, KH; Nakanishi, Y; Yamasaki, S. Dectin-1 intracellular domain determines species-specific ligand spectrum by modulating receptor sensitivity. Journal of Biological Chemistry 292, 16933-16941 (2017).
320	Wijaya, E; Igarashi, Y; Nakatsu, N; Haseda, Y; Billaud, J; Chen, YA; Mizuguchi, K; Yamada, H; Ishii, K; Aoshi, T. Quantifying the relative immune cell activation from whole tissue/organ-derived differentially expressed gene data. Scientific Reports 7, 12847 (2017).
321	Matsui, Y; Sadhu, KK; Mizukami, S; Kikuchi, K. Highly selective tridentate fluorescent probes for visualizing intracellular Mg2+ dynamics without interference from Ca2+ fluctuation. Chemical Communications 53, 10644-10647 (2017).
322	Shiokawa, M; Lu, XY; Miyake, Y; Ishikawa, E; Pages, G; Pouyssegur, J; Ogata, M; Yamasaki, S. Spontaneous chondroma formation in CD2-Cre-driven Erk-deficient mice. International Immunology 29, 479-485 (2017).
323	Zwack, EE; Feeley, EM; Burton, AR; Hu, BF; Yamamoto, M; Kanneganti, TD; Bliska, JB; Coers, J; Brodsky, IE. Guanylate Binding Proteins Regulate Inflammasome Activation in Response to Hyperinjected Yersinia Translocon Components. Infection and Immunity 85, e00778-16 (2017).
324	Nyati, KK; Prasad, KN; Agrawal, V; Husain, N. Matrix metalloproteinases-2 and-9 in Campylobacter jejuni- induced paralytic neuropathy resembling Guillain-Barre syndrome in chickens. Microbial Pathogenesis 111, 395-401 (2017).

325	Cossarizza, A; Chang, HD; Radbruch, A; Akdis, M; Andra, I; Annunziato, F et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies. European Journal of Immunology 47, 1584-1797 (2017).
326	Akiyama, M; Okada, Y; Kanai, M; Takahashi, A; Momozawa, Y; Ikeda, M; Iwata, N; Ikegawa, S; Hirata, M; Matsuda, K; Iwasaki, M; Yamaji, T; Sawada, N; Hachiya, T; Tanno, K; Shimizu, A; Hozawa, A; Minegishi, N; Tsugane, S; Yamamoto, M; Kubo, M; Kamatani, Y. Genome-wide association study identifies 112 new loci for body mass index in the Japanese population. Nature Genetics 49, 1458 (2017).
327	Liu, Y; Ojima, Y; Horie, M; Nagamori, E; Fujita, H. Design and Fabrication of Devices for Investigating Cell- sheet Stretch. Biochip Journal 11, 173-179 (2017).
328	Fujitani, M; Sato, R; Yamashita, T. Loss of p73 in ependymal cells during the perinatal period leads to aqueductal stenosis. Scientific Reports 7, 12007 (2017).
329	Sarashina-Kida, H; Negishi, H; Nishio, J; Suda, W; Nakajima, Y; Yasui-Kato, M; Iwaisako, K; Kang, SJ; Endo, N; Yanai, H; Asagiri, M; Kida, H; Hattori, M; Kumanogoh, A; Taniguchi, T. Gallbladder-derived surfactant protein D regulates gut commensal bacteria for maintaining intestinal homeostasis. Proceedings of the National Academy of Sciences of the United States of America 114, 10178-10183 (2017).
330	Hosokawa, T; Kimura, T; Nada, S; Okuno, T; Ito, D; Kang, SJ; Nojima, S; Yamashita, K; Nakatani, T; Hayama, Y; Kato, Y; Kinehara, Y; Nishide, M; Mikami, N; Koyama, S; Takamatsu, H; Okuzaki, D; Ohkura, N; Sakaguchi, S; Okada, M; Kumanogoh, A. Lamtor1 Is Critically Required for CD4(+) T Cell Proliferation and Regulatory T Cell Suppressive Function. Journal of Immunology 199, 2008-2019 (2017).
331	Kang, HL; Nakae, A; Ito, H; Vitayaburananont, P; Minamoto, T; Ikeda, T; Osaka, M; Mashimo, T; Fujino, Y; Hagihira, S. Effects of sedation on subjective perception of pain intensity and autonomic nervous responses to pain: A preliminary study. Plos One 12, e0183635 (2017).
332	Kuroda, H; Mabuchi, S; Kozasa, K; Yokoi, E; Matsumoto, Y; Komura, N; Kawano, M; Hashimoto, K; Sawada, K; Kimura, T. PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo. Immunotherapy 9, 805-817 (2017).
333	Huang, HM; Bauer, DC; Lelliott, PM; Dixon, MWA; Tilley, L; McMorran, BJ; Foote, SJ; Burgio, G. Ankyrin-1 Gene Exhibits Allelic Heterogeneity in Conferring Protection Against Malaria. G3-Genes Genomes Genetics 7, 3133-3144 (2017).
334	Matsuno, H; Kayama, H; Nishimura, J; Sekido, Y; Osawa, H; Barman, S; Ogino, T; Takahashi, H; Haraguchi, N; Hata, T; Matsuda, C; Yamamoto, H; Uchino, M; Ikeuchi, H; Doki, Y; Mori, M; Takeda, K; Mizushima, T. CD103(+) Dendritic Cell Function Is Altered in the Colons of Patients with Ulcerative Colitis. Inflammatory Bowel Diseases 23, 1524-1534 (2017).
335	Kuroda, M; Muramatsu, R; Maedera, N; Koyama, Y; Hamaguchi, M; Fujimura, H; Yoshida, M; Konishi, M; Itoh, N; Mochizuki, H; Yamashita, T. Peripherally derived FGF21 promotes remyelination in the central nervous system. Journal of Clinical investigation 127, 3502-3515 (2017).
336	Kanemaru, H; Yamane, F; Fukushima, K; Matsuki, T; Kawasaki, T; Ebina, I; Kuniyoshi, K; Tanaka, H; Maruyama, K; Maeda, K; Satoh, T; Akira, S. Antitumor effect of Batf2 through IL-12 p40 up-regulation in tumor-associated macrophages. Proceedings of the National Academy of Sciences of the United States of America 114, E7331-E7340 (2017).
337	Noguchi, S; Arakawa, T; Fukuda, S; Furuno, M; Hasegawa, A; Hori, F et al. Data Descriptor: FANTOM5 CAGE profiles of human and mouse samples. Scientific Data 4, 170112 (2017).
338	Geng, JF; Ito, Y; Shi, LY; Amin, P; Chu, JC; Ouchida, AT; Mookhtiar, AK; Zhao, H; Xu, DC; Shan, B; Najafov, A; Gao, GP; Akira, S; Yuan, JY. Regulation of RIPK1 activation by TAK1-mediated phosphorylation dictates apoptosis and necroptosis. Nature Communications 8, 359 (2017).
339	Nojima, S; Susaki, EA; Yoshida, K; Takemoto, H; Tsujimura, N; Iijima, S; Takachi, K; Nakahara, Y; Tahara, S; Ohshima, K; Kurashige, M; Hori, Y; Wada, N; Ikeda, J; Kumanogoh, A; Morii, E; Ueda, HR. CUBIC pathology: three-dimensional imaging for pathological diagnosis. Scientific Reports 7, 9269 (2017).
340	Saito, S; Tanoue, M; Masuda, K; Mori, Y; Nakatani, S; Yoshioka, Y; Murase, K. Longitudinal observations of progressive cardiac dysfunction in a cardiomyopathic animal model by self-gated cine imaging based on 11.7-T magnetic resonance imaging. Scientific Reports 7, 9106 (2017).
341	Kobayashi, D; Endo, M; Ochi, H; Hojo, H; Miyasaka, M; Hayasaka, H. Regulation of CCR7-dependent cell migration through CCR7 homodimer formation. Scientific Reports 7, 8536 (2017).

342	Arima, Y; Ohki, T; Nishikawa, N; Higuchi, K; Ota, M; Tanaka, Y; Nio-Kobayashi, J; Elfeky, M; Sakai, R; Mori, Y; Kawamoto, T; Stofkova, A; Sakashita, Y; Morimoto, Y; Kuwatani, M; Iwanaga, T; Yoshioka, Y; Sakamoto, N; Yoshimura, A; Takiguchi, M; Sakoda, S; Prinz, M; Kamimura, D; Murakami, M. Brain micro-inflammation at specific vessels dysregulates organ-homeostasis via the activation of a new neural circuit. Elife 6, e25517 (2017).
343	Yanagihashi, Y; Segawa, K; Maeda, R; Nabeshima, Y; Nagata, S. Mouse macrophages show different requirements for phosphatidylserine receptor Tim4 in efferocytosis. Proceedings of the National Academy of Sciences of the United States of America 114, 8800-8805 (2017).
344	Ouji, Y; Sakagami, M; Omori, H; Higashiyama, S; Kawai, N; Kitahara, T; Wanaka, A; Yoshikawa, M. Efficient induction of inner ear hair cell-like cells from mouse ES cells using combination of Math1 transfection and conditioned medium from ST2 stromal cells. Stem Cell Research 23, 50-56 (2017).
345	Ishidome, T; Yoshida, T; Hanayama, R. Induction of Live Cell Phagocytosis by a Specific Combination of Inflammatory Stimuli. Ebiomedicine 22, 89-99 (2017).
346	Nakatsu, N; Igarashi, Y; Aoshi, T; Hamaguchi, I; Saito, M; Mizukami, T; Momose, H; Ishii, KJ; Yamada, H. Isoflurane is a suitable alternative to ether for anesthetizing rats prior to euthanasia for gene expression analysis. Journal of Toxicological Sciences 42, 491-497 (2017).
347	Maruyama, K; Takemura, N; Martino, MM; Kondo, T; Akira, S. Netrins as prophylactic targets in skeletal diseases: A double-edged sword?. Pharmacological Research 122, 46-52 (2017).
348	Uchiyama, R; Yonehara, S; Taniguchi, S; Ishido, S; Ishii, KJ; Tsutsui, H. Inflammasome and Fas-Mediated IL-1 beta Contributes to Th17/Th1 Cell Induction in Pathogenic Bacterial Infection In Vivo. Journal of Immunology 199, 1122-1130 (2017).
349	Ilkovicova, L; Trost, N; Szentpeteriova, E; Solar, P; Komel, R; Debeljak, N. Overexpression of the erythropoietin receptor in RAMA 37 breast cancer cells alters cell growth and sensitivity to tamoxifen. International Journal of Oncology 51, 737-746 (2017).
350	Sasai, M; Sakaguchi, N; Ma, JS; Nakamura, S; Kawabata, T; Bando, H; Lee, Y; Saitoh, T; Akira, S; Iwasaki, A; Standley, DM; Yoshimori, T; Yamamoto, M. Essential role for GABARAP autophagy proteins in interferon- inducible GTPase-mediated host defense. Nature Immunology 18, 899 (2017).
351	Wing, JB; Kitagawa, Y; Locci, M; Hume, H; Tay, C; Morita, T; Kidani, Y; Matsuda, K; Inoue, T; Kurosaki, T; Crotty, S; Coban, C; Ohkura, N; Sakaguchi, S. A distinct subpopulation of CD25(-) T-follicular regulatory cells localizes in the germinal centers. Proceedings of the National Academy of Sciences of the United States of America 114, E6400-E6409 (2017).
352	Dai, HS; Griffin, N; Bolyard, C; Mao, HC; Zhang, JY; Cripe, TP; Suenaga, T; Arase, H; Nakano, I; Chiocca, EA; Kaur, B; Yu, JH; Caligiuri, MA. The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. Immunity 47, 159 (2017).
353	Biering, SB; Choi, J; Halstrom, RA; Brown, HM; Beatty, WL; Lee, S; McCune, BT; Dominici, E; Williams, LE; Orchard, RC; Wilen, CB; Yamamoto, M; Coers, J; Taylor, GA; Hwang, S. Viral Replication Complexes Are Targeted by LC3-Guided Interferon-Inducible GTPases. Cell Host & Microbe 22, 74 (2017).
354	Morimura, O; Minami, T; Kijima, T; Koyama, S; Otsuka, T; Kinehara, Y; Osa, A; Higashiguchi, M; Miyake, K; Nagatomo, I; Hirata, H; Iwahori, K; Takimoto, T; Takeda, Y; Kida, H; Kumanogoh, A. Trastuzumab emtansing suppresses the growth of HER2-positive small-cell lung cancer in preclinical models. Biochemical and Biophysical Research Communications 488, 596-602 (2017).
355	Isotani, A; Matsumura, T; Ogawa, M; Tanaka, T; Yamagata, K; Ikawa, M; Okabe, M. A delayed sperm penetration of cumulus layers by disruption of acrosin gene in rats. Biology of Reproduction 97, 61-68 (2017)
356	Minoshima, M; Kikuchi, K. Photostable and photoswitching fluorescent dyes for super-resolution imaging. Journal of Biological inorganic Chemistry 22, 639-652 (2017).
357	Machiyama, H; Yamaguchi, T; Watanabe, TM; Fujita, H. A novel c-Src recruitment pathway from the cytosol to focal adhesions. Febs Letters 591, 1940-1946 (2017).
358	Hobro, AJ; Smith, NI. An evaluation of fixation methods: Spatial and compositional cellular changes observe by Raman imaging. Vibrational Spectroscopy 91, 31-45 (2017).
359	Watabe, T; Hanaoka, K; Naka, S; Kanai, Y; Ikeda, H; Aoki, M; Shimosegawa, E; Kirihata, M; Hatazawa, J. Practical calculation method to estimate the absolute boron concentration in tissues using F-18-FBPA PET. Annals of Nuclear Medicine 31, 481-485 (2017).
360	Ishigaki, K; Kochi, Y; Suzuki, A; Tsuchida, Y; Tsuchiya, H; Sumitomo, S; Yamaguchi, K; Nagafuchi, Y; Nakachi, S; Kato, R; Sakurai, K; Shoda, H; Ikari, K; Taniguchi, A; Yamanaka, H; Miya, F; Tsunoda, T; Okada Y; Momozawa, Y; Kamatani, Y; Yamada, R; Kubo, M; Fujio, K; Yamamoto, K. Polygenic burdens on cell-specific pathways underlie the risk of rheumatoid arthritis. Nature Genetics 49, 1120 (2017).

361	Igarashi, K; Kurosaki, T; Roychoudhuri, R. BACH transcription factors in innate and adaptive immunity. Nature Reviews Immunology 17, 437-450 (2017).
362	Yokota, M; Tamachi, T; Yokoyama, Y; Maezawa, Y; Takatori, H; Suto, A; Suzuki, K; Hirose, K; Takeda, K; Nakajima, H. I kappa BNS induces Muc5ac expression in epithelial cells and causes airway hyper- responsiveness in murine asthma models. Allergy 72, 1043-1053 (2017).
363	Tanaka, A; Tumkosit, U; Nakamura, S; Motooka, D; Kishishita, N; Priengprom, T; Sa-ngasang, A; Kinoshita, T; Takeda, N; Maeda, Y. Genome-Wide Screening Uncovers the Significance of N-Sulfation of Heparan Sulfate as a Host Cell Factor for Chikungunya Virus Infection. Journal of Virology 91, UNSP e00432-17 (2017).
364	Mertins, P; Przybylski, D; Yosef, N; Qiao, JN; Clauser, K; Raychowdhury, R; Eisenhaure, TM; Maritzen, T; Haucke, V; Satoh, T; Akira, S; Carr, SA; Regev, A; Hacohen, N; Chevrier, N. An Integrative Framework Reveals Signaling-to-Transcription Events in Toll-like Receptor Signaling. Cell Reports 19, 2853-2866 (2017).
365	Maruyama, K; Takayama, Y; Kondo, T; Ishibashi, K; Sahoo, BR; Kanemaru, H; Kumagai, Y; Martino, MM; Tanaka, H; Ohno, N; Iwakura, Y; Takemura, N; Tominaga, M; Akira, S. Nociceptors Boost the Resolution of Fungal Osteoinflammation via the TRP Channel-CGRP-Jdp2 Axis. Cell Reports 19, 2730-2742 (2017).
366	Andrabi, M; Hutchins, AP; Miranda-Saavedra, D; Kono, H; Nussinov, R; Mizuguchi, K; Ahmad, S. Predicting conformational ensembles and genome-wide transcription factor binding sites from DNA sequences. Scientific Reports 7, 4071 (2017).
367	Kawasaki, T; Ito, K; Miyata, H; Akira, S; Kawai, T. Deletion of PIKfyve alters alveolar macrophage populations and exacerbates allergic inflammation in mice. Embo Journal 36, 1707-1718 (2017).
368	Gyobu, S; Ishihara, K; Suzuki, J; Segawa, K; Nagata, S. Characterization of the scrambling domain of the TMEM16 family. Proceedings of the National Academy of Sciences of the United States of America 114, 6274-6279 (2017).
369	Germond, A; Kumar, V; Ichimura, T; Moreau, J; Furusawa, C; Fujita, H; Watanabe, TM. Raman spectroscopy as a tool for ecology and evolution. Journal of the Royal Society interface 14, 20170174 (2017).
370	Maeda, Y; Takeda, K. Role of Gut Microbiota in Rheumatoid Arthritis. Journal of Clinical Medicine 6, 60 (2017).
371	Kato, K; Kawase, A; Azukizawa, H; Hanafusa, T; Nakagawa, Y; Murota, H; Sakaguchi, S; Asada, H; Katayama, I. Novel interferon-gamma enzyme-linked immunoSpot assay using activated cells for identifying hypersensitivity-inducing drug culprits. Journal of Dermatological Science 86, 222-229 (2017).
372	Pagnamenta, AT; Murakami, Y; Taylor, JM; Anzilotti, C; Howard, MF; Miller, V; Johnson, DS; Tadros, S; Mansour, S; Temple, IK; Firth, R; Rosser, E; Harrison, RE; Kerr, B; Popitsch, N; Kinoshita, T; Taylor, JC; Kini, U. Analysis of exome data for 4293 trios suggests GPI-anchor biogenesis defects are a rare cause of developmental disorders. European Journal of Human Genetics 25, 669-679 (2017).
373	Pham, P; Afif, SA; Shimoda, M; Maeda, K; Sakaguchi, N; Pedersen, LC; Goodman, MF. Activation-induced deoxycytidine deaminase: Structural basis for favoring WRC hot motif specificities unique among APOBEC family members. Dna Repair 54, 8-12 (2017).
374	Marttila-Ichihara, F; Elima, K; Auvinen, K; Veres, TZ; Rantakari, P; Weston, C; Miyasaka, M; Adams, D; Jalkanen, S; Salmi, M. Amine oxidase activity regulates the development of pulmonary fibrosis. Faseb Journal 31, 2477-2491 (2017).
375	Hong, CP; Park, A; Yang, BG; Yun, CH; Kwak, MJ; Lee, GW; Kim, JH; Jang, MS; Lee, EJ; Jeun, EJ; You, G; Kim, KS; Choi, Y; Park, JH; Hwang, D; Im, SH; Kim, JF; Kim, YK; Seoh, JY; Surh, CD; Kim, YM; Jang, MH. Gut-Specific Delivery of T-Helper 17 Cells Reduces Obesity and Insulin Resistance in Mice. Gastroenterology 152, 1998-2010 (2017).
376	Lee, MSJ; Maruyama, K; Fujita, Y; Konishi, A; Lelliott, PM; Itagaki, S; Horii, T; Lin, JW; Khan, SM; Kuroda, E; Akira, S; Ishii, KJ; Coban, C. a Plasmodium products persist in the bone marrow and promote chronic bone loss. Science Immunology 2, eaam8093 (2017).
377	Garg, G; Nikolouli, E; Hardtke-Wolenski, M; Toker, A; Ohkura, N; Beckstette, M; Miyao, T; Geffers, R; Floess, S; Gerdes, N; Lutgens, E; Osterloh, A; Hori, S; Sakaguchi, S; Jaeckel, E; Huehn, J. Unique properties of thymic antigen-presenting cells promote epigenetic imprinting of alloantigen-specific regulatory T cells. Oncotarget 8, 35542-35557 (2017).
378	Lopez, Y; Vandenbon, A; Nose, A; Nakai, K. Modeling the cis-regulatory modules of genes expressed in developmental stages of Drosophila melanogaster. Peerj 5, e3389 (2017).
379	Yoshinaga, M; Nakatsuka, Y; Vandenbon, A; Ori, D; Uehata, T; Tsujimura, T; Suzuki, Y; Mino, T; Takeuchi, O. Regnase-1 Maintains Iron Homeostasis via the Degradation of Transferrin Receptor 1 and Prolyl-Hydroxylase- Domain-Containing Protein 3 mRNAs. Cell Reports 19, 1614-1630 (2017).

380	Hill, A; DeZern, AE; Kinoshita, T; Brodsky, RA. Paroxysmal nocturnal haemoglobinuria. Nature Reviews Disease Primers 3, 17028 (2017).
381	Carrascosa, LC; Klein, M; Kitagawa, Y; Luckel, C; Marini, F; Konig, A; Guralnik, A; Raifer, H; Hagner-Benes, S; Radler, D; Bock, A; Kang, C; Lohoff, M; Garn, H; Schaub, B; Berberich-Siebelt, F; Sakaguchi, S; Bopp, T; Huber, M. Reciprocal regulation of the II9 locus by counteracting activities of transcription factors IRF1 and IRF4. Nature Communications 8, 15366 (2017).
382	Kakugawa, K; Kojo, S; Tanaka, H; Seo, W; Endo, TA; Kitagawa, Y; Muroi, S; Tenno, M; Yasmin, N; Kohwi, Y; Sakaguchi, S; Kowhi-Shigematsu, T; Taniuchi, I. Essential Roles of SATB1 in Specifying T Lymphocyte Subsets. Cell Reports 19, 1176-1188 (2017).
383	Minamitani, T; Ma, YJ; Zhou, HF; Kida, H; Tsai, CY; Obana, M; Okuzaki, D; Fujio, Y; Kumanogoh, A; Zhao, B; Kikutani, H; Kieff, E; Gewurz, BE; Yasui, T. Mouse model of Epstein-Barr virus LMP1-and LMP2A-driven germinal center B-cell lymphoproliferative disease. Proceedings of the National Academy of Sciences of the United States of America 114, 4751-4756 (2017).
384	Eid, MMA; Shimoda, M; Singh, SK; Almofty, SA; Pham, P; Goodman, MF; Maeda, K; Sakaguchi, N. Integrity of immunoglobulin variable regions is supported by GANP during AID-induced somatic hypermutation in germinal center B cells. International Immunology 29, 211-220 (2017).
385	Okumura, R; Takeda, K. Roles of intestinal epithelial cells in the maintenance of gut homeostasis. Experimental and Molecular Medicine 49, e338 (2017).
386	Kitada, S; Kayama, H; Okuzaki, D; Koga, R; Kobayashi, M; Arima, Y; Kumanogoh, A; Murakami, M; Ikawa, M; Takeda, K. BATF2 inhibits immunopathological Th17 responses by suppressing Il23a expression during Trypanosoma cruzi infection. Journal of Experimental Medicine 214, 1313-1331 (2017).
387	Johnstone, DL; Nguyen, TTM; Murakami, Y; Kernohan, KD; Tetreault, M; Goldsmith, C; Doja, A; Wagner, JD; Huang, L; Hartley, T; St-Denis, A; le Deist, F; Majewski, J; Bulman, DE; Kinoshita, T; Dyment, DA; Boycott, KM; Campeau, PM. Compound heterozygous mutations in the gene PIGP are associated with early infantile epileptic encephalopathy. Human Molecular Genetics 26, 1706-1715 (2017).
388	Nagata, S; Tanaka, M. Programmed cell death and the immune system. Nature Reviews Immunology 17, 333-340 (2017).
389	Ikeda, T; Shimoda, M; Ebrahimi, D; VandeBerg, JL; Harris, RS; Koito, A; Maeda, K. Opossum APOBEC1 is a DNA mutator with retrovirus and retroelement restriction activity. Scientific Reports 7, 46719 (2017).
390	Veres, TZ; Kopcsanyi, T; Tirri, M; Braun, A; Miyasaka, M; Germain, RN; Jalkanen, S; Salmi, M. Intubation- free in vivo imaging of the tracheal mucosa using two-photon microscopy. Scientific Reports 7, 694 (2017).
391	Maeda, K; Akira, S. Regulation of mRNA stability by CCCH-type zinc-finger proteins in immune cells. International Immunology 29, 149-155 (2017).
392	Shinnakasu, R; Kurosaki, T. Regulation of memory B and plasma cell differentiation. Current Opinion in Immunology 45, 126-131 (2017).
393	Millrine, D; Kishimoto, T. A Brighter Side to Thalidomide: Its Potential Use in Immunological Disorders. Trends in Molecular Medicine 23, 348-361 (2017).
394	Kadena, M; Kumagai, Y; Vandenbon, A; Matsushima, H; Fukamachi, H; Maruta, N; Kataoka, H; Arimoto, T; Morisaki, H; Funatsu, T; Kuwata, H. Microarray and gene co expression analysis reveals that melatonin attenuates immune responses and modulates actin rearrangement in macrophages. Biochemical and Biophysical Research Communications 485, 414-420 (2017).
395	Matsushima, H; Kumagai, Y; Vandenbon, A; Kataoka, H; Kadena, M; Fukamachi, H; Arimoto, T; Morisaki, H; Fujiwara, N; Okahashi, N; Kuwata, H. Microarray analysis of macrophage response to infection with Streptococcus oralis reveals the immunosuppressive effect of hydrogen peroxide. Biochemical and Biophysical Research Communications 485, 461-467 (2017).
396	Nagae, M; Liebschner, D; Yamada, Y; Morita-Matsumoto, K; Matsugaki, N; Senda, T; Fujita, M; Kinoshita, T; Yamaguchi, Y. Crystallographic analysis of murine p24 gamma 2 Golgi dynamics domain. Proteins-Structure Function and Bioinformatics 85, 764-770 (2017).
397	Inoue, T; Shinnakasu, R; Ise, W; Kawai, C; Egawa, T; Kurosaki, T. The transcription factor Foxo1 controls germinal center B cell proliferation in response to T cell help. Journal of Experimental Medicine 214, 1181-1198 (2017).
398	Mizukami, S; Kashibe, M; Matsumoto, K; Hori, Y; Kikuchi, K. Enzyme-triggered compound release using functionalized antimicrobial peptide derivatives. Chemical Science 8, 3047-3053 (2017).
399	Sahoo, BR; Maruyama, K; Edula, JR; Tougan, T; Lin, YX; Lee, YH; Horii, T; Fujiwara, T. Mechanistic and structural basis of bioengineered bovine Cathelicidin-5 with optimized therapeutic activity. Scientific Reports 7, 44781 (2017).

400	Hubber, A; Kubori, T; Coban, C; Matsuzawa, T; Ogawa, M; Kawabata, T; Yoshimori, T; Nagai, H. Bacterial secretion system skews the fate of Legionella-containing vacuoles towards LC3-associated phagocytosis. Scientific Reports 7, 44795 (2017).
401	Nyati, KK; Masuda, K; Mahabub-Uz Zaman, M; Dubey, PK; Millrine, D; Chalise, JP; Higa, M; Li, SL; Standley, DM; Saito, K; Hanieh, H; Kishimoto, T. TLR4-induced NF-kappa B and MAPK signaling regulate the IL-6 mRNA stabilizing protein Arid5a. Nucleic Acids Research 45, 2687-2703 (2017).
402	Kim, H; Walsh, MC; Takegahara, N; Middleton, SA; Shin, HI; Kim, J; Choi, Y. The purinergic receptor P2X5 regulates inflammasome activity and hyper-multinucleation of murine osteoclasts. Scientific Reports 7, 196 (2017).
403	Chiu, LD; Ichimura, T; Sekiya, T; Machiyama, H; Watanabe, T; Fujita, H; Ozawa, T; Fujita, K. Protein expression guided chemical profiling of living cells by the simultaneous observation of Raman scattering and anti-Stokes fluorescence emission. Scientific Reports 7, 43569 (2017).
404	Kozaki, T; Komano, J; Kanbayashi, D; Takahama, M; Misawa, T; Satoh, T; Takeuchi, O; Kawai, T; Shimizu, S; Matsuura, Y; Akira, S; Saitoh, T. Mitochondrial damage elicits a TCDD-inducible poly(ADP-ribose) polymerase- mediated antiviral response. Proceedings of the National Academy of Sciences of the United States of America 114, 2681-2686 (2017).
405	Korosec, T; Tomazin, U; Horvat, S; Keber, R; Salobir, J. The diverse effects of alpha- and gamma-tocopherol on chicken liver transcriptome. Poultry Science 96, 667-680 (2017).
406	Fujimoto, K; Kinoshita, M; Tanaka, H; Okuzaki, D; Shimada, Y; Kayama, H; Okumura, R; Furuta, Y; Narazaki, M; Tamura, A; Hatakeyama, S; Ikawa, M; Tsuchiya, K; Watanabe, M; Kumanogoh, A; Tsukita, S; Takeda, K. Regulation of intestinal homeostasis by the ulcerative colitis-associated gene RNF186. Mucosal Immunology 10, 446-459 (2017).
407	Edvardson, S; Murakami, Y; Nguyen, TTM; Shahrour, M; St-Denis, A; Shaag, A; Damseh, N; Le Deist, F; Bryceson, Y; Abu-Libdeh, B; Campeau, PM; Kinoshita, T; Elpeleg, O. Mutations in the phosphatidylinositol glycan C (PIGC) gene are associated with epilepsy and intellectual disability. Journal of Medical Genetics 54, 196-201 (2017).
408	Hamano, Y; Kida, H; Ihara, S; Murakami, A; Yanagawa, M; Ueda, K; Honda, O; Tripathi, LP; Arai, T; Hirose, M; Hamasaki, T; Yano, Y; Kimura, T; Kato, Y; Takamatsu, H; Otsuka, T; Minami, T; Hirata, H; Inoue, K; Nagatomo, I; Takeda, Y; Mori, M; Nishikawa, H; Mizuguchi, K; Kijima, T; Kitaichi, M; Tomiyama, N; Inoue, Y; Kumanogoh, A. Classification of idiopathic interstitial pneumonias using anti-myxovirus resistance-protein 1 autoantibody. Scientific Reports 7, 43201 (2017).
409	Furuta, Y; Tsai, SH; Kinoshita, M; Fujimoto, K; Okumura, R; Umemoto, E; Kurashima, Y; Kiyono, H; Kayama, H; Takeda, K. E-NPP3 controls plasmacytoid dendritic cell numbers in the small intestine. Plos One 12, e0172509 (2017).
410	Zaretsky, AG; Konradt, C; Depis, F; Wing, JB; Goenka, R; Atria, DG; Silver, JS; Cho, S; Wolf, AI; Quinn, WJ; Engiles, JB; Brown, DC; Beiting, D; Erikson, J; Allman, D; Cancro, MP; Sakaguchi, S; Lu, LF; Benoist, CO; Hunter, CA. T Regulatory Cells Support Plasma Cell Populations in the Bone Marrow. Cell Reports 18, 1906-1916 (2017).
411	Brewitz, A; Eickhoff, S; Dahling, S; Quast, T; Bedoui, S; Kroczek, RA; Kurts, C; Garbi, N; Barchet, W; Iannacone, M; Klauschen, F; Kolanus, W; Kaisho, T; Colonna, M; Germain, RN; Kastenmuller, W. CD8(+) T Cells Orchestrate pDC-XCR1(+) Dendritic Cell Spatial and Functional Cooperativity to Optimize Priming. Immunity 46, 205-219 (2017).
412	Yoshioka, Y; Kuroda, E; Hirai, T; Tsutsumi, Y; Ishii, KJ. Allergic Responses induced by the immunomodulatory effects of Nanomaterials upon Skin exposure. Frontiers in Immunology 8, 169 (2017).
413	Watabe, T; Kanai, Y; Ikeda, H; Horitsugi, G; Matsunaga, K; Kato, H; Isohashi, K; Abe, K; Shimosegawa, E; Hatazawa, J. Quantitative evaluation of oxygen metabolism in the intratumoral hypoxia: F-18-fluoromisonidazole and O-15-labelled gases inhalation PET. Ejnmmi Research 7, 16 (2017).
414	Kitai, Y; Kawasaki, T; Sueyoshi, T; Kobiyama, K; Ishii, KJ; Zou, J; Akira, S; Matsuda, T; Kawai, T. DNA- Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING- Dependent Pathway and Reinforce Antitumor Immunity. Journal of Immunology 198, 1649-1659 (2017).
415	Motooka, D; Fujimoto, K; Tanaka, R; Yaguchi, T; Gotoh, K; Maeda, Y; Furuta, Y; Kurakawa, T; Goto, N; Yasunaga, T; Narazaki, M; Kumanogoh, A; Horii, T; Iida, T; Takeda, K; Nakamura, S. Fungal ITS1 Deep-Sequencing Strategies to Reconstruct the Composition of a 26-Species Community and Evaluation of the Gut Mycobiota of Healthy Japanese Individuals. Frontiers in Microbiology 8, 238 (2017).

416	Kawano, Y; Fukui, C; Shinohara, M; Wakahashi, K; Ishii, S; Suzuki, T; Sato, M; Asada, N; Kawano, H; Minagawa, K; Sada, A; Furuyashiki, T; Uematsu, S; Akira, S; Uede, T; Narumiya, S; Matsui, T; Katayama, Y. G-CSF-induced sympathetic tone provokes fever and primes antimobilizing functions of neutrophils via PGE(2). Blood 129, 587-597 (2017).
417	Yang, BG; Seoh, JY; Jang, MH. Regulatory Eosinophils in Inflammation and Metabolic Disorders. Immune Network 17, 41-47 (2017).
418	Dubey, PK; Masuda, K; Nyati, KK; Zaman, MMU; Chalise, JP; Millrine, D; Kai, W; Ripley, B; Kishimoto, T. Arid5a-deficient mice are highly resistant to bleomycin-induced lung injury. International Immunology 29, 79-85 (2017).
419	Hamaoka, S; Naito, Y; Katoh, H; Shimizu, M; Kinoshita, M; Akiyama, K; Kainuma, A; Moriyama, K; Ishii, KJ; Sawa, T. Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia. Microbiology and Immunology 61, 57-74 (2017).
420	Koba, T; Kijima, T; Takimoto, T; Hirata, H; Naito, Y; Hamaguchi, M; Otsuka, T; Kuroyama, M; Nagatomo, I; Takeda, Y; Kida, H; Kumanogoh, A. Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation Two Case Reports. Medicine 96, e6087 (2017).
421	Yanagida, T; Ishii, Y. Single molecule detection, thermal fluctuation and life. Proceedings of the Japan Academy Series B-Physical and Biological Sciences 93, 51-63 (2017).
422	Ogura, M; Inoue, T; Yamaki, J; Homma, MK; Kurosaki, T; Homma, Y. Mitochondrial reactive oxygen species suppress humoral immune response through reduction of CD19 expression in B cells in mice. European Journal of Immunology 47, 406-418 (2017).
423	Ihara, S; Nakayama, S; Murakami, Y; Suzuki, E; Asakawa, M; Kinoshita, T; Sawa, H. PIGN prevents protein aggregation in the endoplasmic reticulum independently of its function in the GPI synthesis. Journal of Cell Science 130, 602-613 (2017).
424	Hayashi, M; Aoshi, T; Haseda, Y; Kobiyama, K; Wijaya, E; Nakatsu, N; Igarashi, Y; Standley, DM; Yamada, H; Honda-Okubo, Y; Hara, H; Saito, T; Takai, T; Coban, C; Petrovsky, N; Ishii, KJ. Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines. Ebiomedicine 15, 127-136 (2017).
425	Ito, H; Ando, T; Nakamura, M; Ishida, H; Kanbe, A; Kobiyama, K; Yamamoto, T; Ishii, KJ; Hara, A; Seishima, M; Ishikawa, T. Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin-1 ligand. Journal of Viral Hepatitis 24, 155-162 (2017).
426	Saito, S; Masuda, K; Mori, Y; Nakatani, S; Yoshioka, Y; Murase, K. Mapping of left ventricle wall thickness in mice using 11.7-T magnetic resonance imaging. Magnetic Resonance Imaging 36, 128-134 (2017).
427	Oketani, R; Doi, A; Smith, NI; Nawa, Y; Kawata, S; Fujita, K. Saturated two-photon excitation fluorescence microscopy with core-ring illumination. Optics Letters 42, 571-574 (2017).
428	Watabe, T; Ikeda, H; Nagamori, S; Wiriyasermkul, P; Tanaka, Y; Naka, S; Kanai, Y; Hagiwara, K; Aoki, M; Shimosegawa, E; Kanai, Y; Hatazawa, J. F-18-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with F-18-FDG and C-11-Methionine PET. European Journal of Nuclear Medicine and Molecular Imaging 44, 321-331 (2017).
429	Yasuda, S. Monte Carlo simulation for kinetic chemotaxis model: An application to the traveling population wave. Journal of Computational Physics 330, 1022-1042 (2017).
430	Kitagawa, Y; Ohkura, N; Kidani, Y; Vandenbon, A; Hirota, K; Kawakami, R; Yasuda, K; Motooka, D; Nakamura, S; Kondo, M; Taniuchi, I; Kohwi-Shigematsu, T; Sakaguchi, S. Guidance of regulatory T cell development by Satb1-dependent super-enhancer establishment. Nature Immunology 18, 173-183 (2017).
431	Sasaki, E; Kuramitsu, M; Momose, H; Kobiyama, K; Aoshi, T; Yamada, H; Ishii, KJ; Mizukami, T; Hamaguch I. A novel vaccinological evaluation of intranasal vaccine and adjuvant safety for preclinical tests. Vaccine 35 821-830 (2017).
432	Nagase, H; Takeoka, T; Urakawa, S; Morimoto-Okazawa, A; Kawashima, A; Iwahori, K; Takiguchi, S; Nishikawa, H; Sato, E; Sakaguchi, S; Mori, M; Doki, Y; Wada, H. ICOS+ Foxp3(+) TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. International Journal of Cancer 140, 686-695 (2017).
433	Veres, TZ; Kopcsanyi, T; van Panhuys, N; Gerner, MY; Liu, ZD; Rantakari, P; Dunkel, J; Miyasaka, M; Salmi M; Jalkanen, S; Germain, RN. Allergen-Induced CD4(+) T Cell Cytokine Production within Airway Mucosal Dendritic Cell-T Cell Clusters Drives the Local Recruitment of Myeloid Effector Cells. Journal of Immunology 198, 895-907 (2017).

434	Satoh, T; Nakagawa, K; Sugihara, F; Kuwahara, R; Ashihara, M; Yamane, F; Minowa, Y; Fukushima, K; Ebina, I; Yoshioka, Y; Kumanogoh, A; Akira, S. Identification of an atypical monocyte and committed progenitor involved in fibrosis. Nature 541, 96 (2017).
435	Tanaka, A; Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Cell Research 27, 109-118 (2017).
436	Narazaki, M; Tanaka, T; Kishimoto, T. The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Review of Clinical Immunology 13, 535-551 (2017).
437	Lim, HM; Woon, H; Han, JW; Baba, Y; Kurosaki, T; Lee, MG; Kim, JY. UDP-Induced Phagocytosis and ATP- Stimulated Chemotactic Migration Are Impaired in STIM1(-/-) Microglia In Vitro and In Vivo. Mediators of inflammation , 8158514 (2017).
438	Hsu, CC; Okumura, R; Takeda, K. Human LYPD8 protein inhibits motility of flagellated bacteria. Inflammation and Regeneration 37, UNSP 23 (2017).
439	Kuroda, E; Temizoz, B; Coban, C; Ozasa, K; Ishii, KJ. Particulate-Driven Type-2 Immunity and Allergic Responses. Allergy and Immunotoxicology in Occupational Health , 63-82 (2017).
440	Sugimoto, A; Kawakami, R; Mikami, N. Transcription Factors Downstream of IL-4 and TGF-beta Signals: Analysis by Quantitative PCR, Western Blot, and Flow Cytometry. Th9 Cells: Methods and Protocols 1585, 141-153 (2017).
441	Kudo, K; Uwano, I; Hirai, T; Murakami, R; Nakamura, H; Fujima, N; Yamashita, F; Goodwin, J; Higuchi, S; Sasaki, M. Comparison of Different Post-Processing Algorithms for Dynamic Susceptibility Contrast Perfusion Imaging of Cerebral Gliomas. Magnetic Resonance in Medical Sciences 16, 129-136 (2017).
442	Chen, T; Mori, Y; Inui-Yamamoto, C; Komai, Y; Tago, Y; Yoshida, S; Takabatake, Y; Isaka, Y; Ohno, K; Yoshioka, Y. Polymer-brush-afforded SPIO Nanoparticles Show a Unique Biodistribution and MR Imaging Contrast in Mouse Organs. Magnetic Resonance in Medical Sciences 16, 275-283 (2017).
443	Koga, T; Fujimoto, S; Kawakami, A; Kawabata, H; Masaki, Y; Kishimoto, T; Yoshizaki, K. Therapeutic outlook for Castleman's disease: prospects for the next decade. Expert Opinion on Orphan Drugs 5, 633-640 (2017).
444	Nojima, S; Kumanogoh, A. Characterizing Semaphorin-Mediated Immune Responses Using an Antigen- Presentation Assay. Semaphorin Signaling: Methods and Protocols 1493, 379-391 (2017).
445	Boswell, KL; Yamamoto, T. Phenotypic and Functional Analysis of Antigen-Specific T Cell Exhaustion. T-Cell Differentiation: Methods and Protocols 1514, 83-92 (2017).
446	Nagata, S; Nakano, H. Apoptotic and Non-apoptotic Cell Death Preface. Apoptotic and Non-Apoptotic Cell Death 403, V-V (2017).
447	Ebata, T; Mitsui, Y; Sugimoto, W; Maeda, M; Araki, K; Machiyama, H; Harada, I; Sawada, Y; Fujita, H; Hirata, H; Kawauchi, K. Substrate Stiffness Influences Doxorubicin-Induced p53 Activation via ROCK2 Expression. Biomed Research international , 5158961 (2017).
448	Kolicheski, AL; Johnson, GS; Mhlanga-Mutangadura, T; Taylor, JF; Schnabel, RD; Kinoshita, T; Murakami, Y; O'Brien, DP. A homozygous PIGN missense mutation in Soft-Coated Wheaten Terriers with a canine paroxysmal dyskinesia. Neurogenetics 18, 39-47 (2017).
449	Ooi, Y; Inui-Yamamoto, C; Yoshioka, Y; Seiyama, A; Seki, J. 11.7T MR Imaging Revealed Dilatation of Virchow-Robin Spaces within Hippocampus in Maternally Lipopolysaccharide-exposed Rats. Magnetic Resonance in Medical Sciences 16, 54-60 (2017).
450	Sasaki, N; Yamashita, T; Kasahara, K; Fukunaga, A; Yamaguchi, T; Emoto, T; Yodoi, K; Matsumoto, T; Nakajima, K; Kita, T; Takeda, M; Mizoguchi, T; Hayashi, T; Sasaki, Y; Hatakeyama, M; Taguchi, K; Washio, K; Sakaguchi, S; Malissen, B; Nishigori, C; Hirata, K. UVB Exposure Prevents Atherosclerosis by Regulating Immunoinflammatory Responses. Arteriosclerosis Thrombosis and Vascular Biology 37, 66 (2017).
451	Pissuwan, D; Hattori, Y. Detection of Adhesion Molecules on Inflamed Macrophages at Early-Stage Using SERS Probe Gold Nanorods. Nano-Micro Letters 9, UNSP 8 (2017).

### B. WPI-related papers: NONE